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Abstract 
 
Colorectal cancer is primarily a disease of ageing, yet older adults are underrepresented in 
both clinical and health services cancer research. There is evidence that older patients are 
less likely to receive guideline-recommended treatment than younger patients based on 
their age alone. However, treatment decision making for this group can be complex. This 
thesis presents a series of studies that explore the barriers to the evidence-based care of 
older people with colorectal cancer in New South Wales (NSW), with a focus on the receipt 
of adjuvant chemotherapy and radiotherapy. The chapters forming the body of the thesis 
consist of peer-reviewed published, accepted or submitted publications. 
Chapter 1 provides an introduction to the role of age in cancer care and outcomes. People 
aged over 65 currently represent more than two-thirds of newly diagnosed colorectal 
cancer cases in NSW. With the ageing of the population, the number of older adults with 
colorectal cancer is expected to increase dramatically. This chapter describes the unique 
physiological, functional, social, life expectancy, quality of life, and cost-effectiveness 
considerations in treating this growing and heterogeneous group. Current evidence-based 
recommendations for colorectal cancer treatment are outlined, including the efficacy and 
potential adverse effects of surgery, chemotherapy and radiotherapy. Chapter 1 then 
summarises existing literature on the impact of age on the receipt of colorectal cancer care 
and on patient outcomes. Previously identified barriers to the implementation and 
acceptance of guideline-recommended treatment for older adults are described, as well as 
gaps and limitations of this research. Lastly, the specific aims of this thesis are outlined. 
These consist of: 1) exploring issues in the measurement of patient-reported outcomes that 
may affect patient care, 2) establishing current levels and predictors of adjuvant therapy 
receipt in NSW, 3) investigating physician and patient-based barriers to adjuvant therapy 
use, and 4) developing a risk model that could be used in chemotherapy decision making.  
ix 
Patient-reported outcomes are increasingly being recognised as integral to both research 
and clinical practice for informing decision making and monitoring treatment effects. 
Chapter 2 presents the results of two studies that explore issues in the measurement of 
patient-reported outcomes that may affect the treatment and care that older patients 
receive. This involved the use of existing prospectively collected data from participants in 
the control groups of pilot phases of a supportive care intervention following colorectal 
cancer surgery (n=57). In Study 1, the unmet supportive care needs of older and younger 
patients were compared at one month and three months after hospital discharge. Older 
age independently predicted significantly lower levels of unmet need in nearly all domains 
of the Supportive Care Needs Survey-Short Form 34. However, older patients were less 
likely than younger patients to report ‘satisfied’ needs, instead being more likely to report 
items were ‘not applicable’ at both one month (mean difference 29%, p<0.001) and three 
months (mean difference 23%, p=0.01). More than half of all older patients also had unmet 
needs at both time points. In Study 2, age differences in item non-response were explored 
in quality of life (QOL) assessments that had been completed using the Functional 
Assessment of Cancer Therapy-Colorectal at baseline, one month and three months after 
hospital discharge. Older age was significantly associated with non-response to a number 
of ‘sensitive’ questionnaire items (e.g. sex life, diarrhoea), as well as with greater levels of 
missing data overall. QOL in the social/family domain was overestimated when simple 
mean imputation was used to manage missing data. Where needs and QOL are not 
accurately captured or represented, older adults may be less likely to receive care that 
would enable them to better cope with their cancer and cancer treatment. 
Chapter 3 establishes current levels of adjuvant therapy use for colorectal cancer in NSW 
and identifies patient and hospital-level predictors of treatment receipt. Linked population-
based administrative and clinical data was used to examine the records of 580 people with 
lymph node-positive colon cancer, and 498 people with high-risk rectal cancer, who 
underwent surgery in NSW following their diagnosis in 2007/2008. Overall, 65-73% of 
eligible patients received chemotherapy and 42-53% received radiotherapy. Increasing age  
x 
was strongly associated with decreasing likelihood of receiving chemotherapy for lymph 
node-positive colon cancer (p<0.001) and receiving radiotherapy for high-risk rectal cancer 
(p=0.003), even after adjusting for confounders such as Charlson comorbidity score and 
American Society of Anesthesiologists (ASA) physical status. Other independent predictors 
of chemotherapy receipt included having an elective resection and having a current 
partner. Being discussed at a multidisciplinary team meeting also facilitated radiotherapy 
use. Adjuvant therapy rates varied widely between hospitals where surgery was 
performed. While chronological age alone continues to impact receipt of guideline-
recommended adjuvant therapy, variation by hospital and other identified predictors 
indicates the potential to improve the care of older colorectal cancer patients in NSW. 
Surgeons act as important gatekeepers to the care of patients after their cancer surgery. In 
Chapter 4, a survey of Australian and New Zealand colorectal surgeons was conducted to 
identify factors affecting their decisions to refer older patients to oncology. The self-
administered survey consisted of three sections: 1) knowledge of current research 
evidence, 2) opinions on evidence and adjuvant therapy use in older patients, and 3) self-
reported practice, or likelihood of referring a younger patient (60 years) and an older 
patient (80 years) across a range of different scenarios. Seventy percent of surgeons 
responded (n=102). Surgeons were significantly less likely to refer an older patient than a 
younger patient for adjuvant therapy in all scenarios (p<0.001), including when the patient 
had no other medical problems. The difference in referral recommendations was greatest 
when patients lived a long way from treatment, had a comorbid condition, or had little 
social support. There was larger variation in referral recommendations for older patients, 
and marked disagreement between surgeons in knowledge and opinion questions. Greater 
knowledge and more positive opinions predicted similar referral recommendations for 
older and younger patients (p=0.02, p=0.01). The lack of consensus among surgeons 
suggests that more research is needed both to predict the benefit and risks of treatment 
for older patients, and to determine how information from emerging evidence can best be 
used to assist physicians’ treatment decisions. 
xi 
Patients who decide not to undergo adjuvant therapy are typically older than those who 
accept treatment. Chapter 5 reports the findings of a survey that aimed to identify 
potential barriers to adjuvant chemotherapy use in older patients by examining the 
associations between patient age, factors influencing chemotherapy treatment decisions, 
and preferences for information and decision-making involvement. A self-administered 
survey was completed by sixty-eight patients who had undergone surgery for colorectal 
cancer in a tertiary referral hospital in NSW within the previous 24 months. Fear of dying, 
health status, age, quality of life, and understanding treatment procedures and effects 
were significantly more important to older patients (aged ≥65 years) than younger patients 
in deciding whether to accept chemotherapy (all p<0.05). Reducing the risk of the cancer 
returning and physician trust were important factors for all patients. While older patients 
preferred less information and less involvement in treatment decisions than younger 
patients, the majority of the older group wanted detailed chemotherapy information and 
rated many factors as important in their decision making. This study also revealed that 
surgeons’ and patients’ perceived barriers to adjuvant chemotherapy use may differ. 
Practical barriers such as distance to treatment were important to the colorectal surgeons 
surveyed in Chapter 4, but were not important to the older patients in this study. Through 
greater understanding and explicit assessment of patient preferences and perceived 
barriers to treatment, physicians may be better able to support older patients to make 
informed decisions about their care. 
Taken together, the results of Chapters 3 and 4 imply that surgeon knowledge and views 
are a contributing factor to the age differences in adjuvant therapy receipt in NSW.  
Chapter 6 describes the development of a mortality risk model that could be used by 
clinicians to assist the identification of patients who would benefit from discussion about 
adjuvant chemotherapy and their treatment preferences. All lymph node-positive patients 
aged ≥65 years who received surgery for colon cancer in NSW in 2007/2008 were identified 
using a linked population-based dataset (n=1,550). 12% of these patients did not survive 
the first year after surgery and therefore would not benefit from adjuvant chemotherapy.  
xii 
A mortality risk model was built using multilevel logistic regression, and risk scores based 
on model predictors were summed for each patient. The risk model consisted of fourteen 
factors, including patient comorbidities, hospital admission factors, and other markers of 
frailty or health status. Age was not an independent predictor of mortality in the adjusted 
model. People with a total risk score of 0, 1 or 2 were considered at low risk (predicted 
one-year mortality of 3.0%), those scoring 3 to 6 at medium risk (7.5% mortality), and those 
with a score of 7 or above were considered at high risk of mortality (25.8% mortality). The 
model had good discrimination (AUC=0.79, 95% CI: 0.75-0.83) and calibration (p=0.46).The 
risk model may be useful in shifting the emphasis in treatment decision making from 
chronological age to the identification of those of any age who will live to benefit from 
these resources. 
Chapter 7 provides an overview of the unique contributions of the research presented in 
this thesis. This includes the identification of a range of factors that impact the treatment 
of older colorectal cancer patients locally, and the potential of linked routinely collected 
data to monitor and generate evidence for an underresearched and at-risk patient group in 
NSW. This chapter also addresses the limitations and methodological issues that were 
encountered, and discusses implications of the work for clinical practice and for the future 
research that is needed to ensure greater understanding and improved outcomes for older 
people with colorectal cancer. 
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1 
Introduction 
 
 
This chapter provides an overview of the role of age in cancer care and outcomes. There 
are several excellent reviews and resources about cancer in the older person,1-6 each 
reflecting the authors’ own areas of interest and expertise. While a truly comprehensive 
review is beyond the scope of this thesis, the following chapter summarises the unique 
challenges faced by older people with colorectal cancer and their physicians, with a focus 
on the factors that may contribute to age differences in treatment practices. Gaps and 
limitations of the existing literature are identified, and the specific aims and approaches of 
this thesis to filling these gaps are outlined. 
1.1. Cancer and the older person 
“If you’re not a paediatric oncologist, you’re a geriatric oncologist” (Lichtman, 2007).7 
1.1.1. A growing population 
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the world, with 
over 1.2 million new cases and an estimated 608,700 deaths occurring in 2008.8 Australia 
has one of the highest incidence rates of CRC.9 It is the second most frequently diagnosed 
invasive cancer and the second most common cause of cancer death, accounting for 13% of 
the total cancer burden and 9% of cancer-related deaths in Australia.10 Five-year relative 
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survival from CRC in Australia is currently 66%.11 The majority of colorectal cancers are 
adenocarcinomas (96%),12 with approximately two thirds arising in the colon and one third 
in the rectum.13 Men have a higher lifetime risk of CRC than women, with 1 in 10 men and 1 
in 15 women being diagnosed by the age of 85.14 Cases are relatively rare in those under 45 
years, however incidence rates rise sharply with age until around 80 years (see Figure 1). 
CRC is therefore described as a disease of ageing. 
Figure 1. Age-specific colorectal cancer incidence rates by sex* 
 
*Based on Australian Institute of Health and Welfare material14 
The incidence of CRC in Australia has more than doubled in the last 30 years, from 6,970 
cases in 1982 to 14,401 cases in 2009.14 By 2020, the number of new cases is projected to 
reach 19,960,15 an annual growth of over 3%. This outstrips the expected increase in the 
Australian population of 1% per year,16 indicating that CRC will present an ever-increasing 
burden on the healthcare system. The main driver of the increasing incidence of CRC is 
population ageing.15 While the age-standardised incidence rate has remained relatively 
stable since 1982, there has been a large increase in the number of new cases in those over 
65 years (see Figure 2). People aged over 65 currently represent more than two thirds of 
newly diagnosed CRC cases,14,17 and the average age of diagnosis is nearly 70 years.10 
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Figure 2. Number and rate of new colorectal cancer cases by year and age group* 
 
*Based on Australian Institute of Health and Welfare material14 
Population ageing is generally defined as a rise in the median age of an area caused by 
increasing life expectancy and/or a decline in birth rates. Population ageing is occurring in 
nearly every country and region,18 and the speed of this ageing is likely to increase over the 
coming decades.19 In Australia, the median age of the population has risen from 28 years in 
1970 to 37 years in 2012.20,21 People aged over 65 years currently make up more than 14% 
of Australia’s population.21 With those born during the post-WWII baby boom now 
beginning to enter into old age, the percentage of people over 65 is projected to increase 
to between 20% and 22% by 2033.16 The number of people over 85 is also expected to 
more than double from 430,000 to nearly 1 million over the next 20 years.16 Given the 
expected increase in the number of older people and therefore the number of older CRC 
patients, the needs of this population require increasing attention.  
Preventing illness and promoting good health throughout life are a core part of the national 
strategy to encourage participation and reduce the potential burden of future health care 
costs.22 CRC is particularly amenable to prevention and early detection, as most cancers are 
thought to originate from previously benign adenomas.23 Improved detection through 
public awareness and screening could explain trends for increasing incidence rates of CRC 
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in older groups up to age 85,14 despite a flat age-standardised rate overall. The National 
Bowel Cancer Screening program, in operation since 2006, has been found to be effective 
in diagnosing people at earlier stages of disease,24 though it remains limited in scope.25 
Other community screening programs, such as Rotary Bowelscan, have been reported to 
have significant reach.26 While Australia has one of the highest incidence rates of CRC, it 
has fewer late stage diagnoses than many other countries and is a leader in CRC survival.13 
Mortality rates among the elderly have also improved considerably (see Figure 3). Though 
75% of the 4,047 CRC deaths in 2007 occurred in those over 65,14 improved survival means 
a growing number of older CRC survivors with unique health needs.27,28 
Figure 3. Colorectal cancer mortality rates by year and age group* 
 
*Based on Australian Institute of Health and Welfare material14 
Life expectancy should play a central role in treatment decisions.29 Most of the life 
expectancy gains in the last few decades have been driven by people living longer into old 
age. Life expectancy at age 65 has increased since 1980 from 14 to 19 years for men, and 
from 18 to 22 years for women.30 An important consideration alongside population ageing 
and cancer survivorship is the amount of remaining life spent in good health. Three major 
theories have emerged to explain how increases in life expectancy may affect health on a 
population level.31 The “compression of morbidity” theory suggests that increases in life 
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expectancy will be accompanied by a delay in the onset of disease.32 In the “expansion of 
morbidity” theory, the lives of people with chronic disease will simply be extended by life-
sustaining medical care.33,34 The “dynamic equilibrium” theory highlights a delay in the 
progression of chronic disease, with a decreasing proportion of the life span spent in 
serious illness, but an expanding proportion of the life span with less severe illness.35 A 
fourth more recent theory suggests an eventual emergence of a very old and frail 
population: an “epidemic of frailty”.31 
While people with CRC have a reduced life expectancy compared to the general population 
(see Table 1), even those aged 80 have a life expectancy of 5-7 years, and could expect 3-4 
years of self-reported good health.36 Differing definitions and a complicated and fluid 
relationship between longevity and morbidity means there is yet no consistent evidence of 
a compression or expansion of disability among older populations.37-40 However, around 
half of the gains in life expectancy at age 65 between 1998 and 2009 in Australia were 
years with disability,40 some of which were likely due to cancer sequelae. As the population 
ages, there will be a greater number of older people both with and without chronic health 
conditions. This means a growing and diverse population of older people with CRC who 
may also present with unique issues relating to the biology of ageing and cancer. 
Table 1. Population and colorectal cancer (CRC) life expectancy in years by sex and age 
 Males  Females 
Age Ausa Aus 
DFLEb 
CRC III, 
0c 
CRC III, 
1-2c 
CRC surv 
HLEd 
 Ausa Aus 
DFLEb 
CRC III, 
0c 
CRC III, 
1-2c 
CRC surv 
HLEd 
50 31.7 18.1 . . 9.5  35.4 19.7 . . 9.9 
65 18.9 8.2 . . 7.3  21.8 9.7 . . 7.9 
67 17.3 . 8.4 6.8 .  20.1 . 8.5 7.9 . 
71 14.3 . 7.4 6.1 .  16.8 . 8.3 6.6 . 
76 10.9 . 6.3 5.2 .  12.9 . 7.4 5.8 . 
80 8.5 2.1 . . 3.8  10.1 2.7 . . 4.1 
81 7.9 . 5.5 4.9 .  9.4 . 6.4 4.8 . 
85 6.0 1.0 . . .  7.1 1.4 . . . 
aAll population life expectancy (Australia)30; bAll population disability-free life expectancy (DFLE) (Australia)40; 
cCRC stage III life expectancy, 0 or 1-2 comorbidities (USA)41; dCRC survivors healthy life expectancy (HLE) (Netherlands)36 
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1.1.2. A disease of ageing 
The strongest risk factor for cancer is age. However, there is no universally accepted view 
of the cause of this increased risk.42 One view holds that time is the risk factor rather than 
age. Time is required for neoplastic changes to take place in normal tissues, and the dose 
and duration of carcinogenic exposure increases over a person’s lifetime regardless of any 
effects of ageing.43,44 Another view holds that age-related changes in physiology may 
provide a favourable environment for the initiation and growth of cancer cells.45 Increasing 
evidence suggests the rise in cancer incidence with age results from the accumulation of 
cancer-causing cellular mutations alongside age-related changes in tissue 
microenvironment, gene silencing and telomere dysfunction.46 
As ageing involves genetic events that appear similar to those occurring in early cancer 
growth, cellular senescence and telomeres are often implicated in unifying theories of 
ageing and cancer.47 Telomeres are gibberish DNA that act like shoelace tips in protecting 
chromosomes from fraying during cell division and replication. These regions progressively 
shorten with each division and therefore with age. When telomeres become critically short 
or DNA damage is sustained, cells can become inactive (“senescent”) or die to prevent 
instability and tumour growth.48 A cell that escapes from these normal controls and begins 
to become cancerous divides rapidly, and its telomeres quickly become very short. 
Shortened telomeres are thus a common feature of CRC tissue,49 and have been associated 
with other age-related diseases and characteristics such as heart failure and immuno-
senescence.50 Telomere length has also been proposed as a biomarker of ageing, as it 
appears to predict lifespan.51,52 The rate at which telomeres wear down varies between 
people and can depend on environmental stimuli (e.g. smoking).53 Accumulation of 
senescent cells with age compromises tissue function and repair, but also appears to 
promote cancer growth by triggering inflammation in nearby cells and tissues.54 Though 
still largely theoretical, increased understanding of the common pathways of cancer and 
ageing implies that older patients are not simply “adults who are old”. 
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Paradoxically, age-related biological changes may also act to suppress cancer development 
and improve prognosis. While national cancer organisations typically aggregate incidence 
data for those aged over 85, researchers have noted a deceleration and decline in all-site 
cancer incidence and prevalence from between the ages of 75 and 84, and a decline in 
cancer mortality from age 90.55,56 Changes in screening practices or differential exposures 
to environmental carcinogens are potential contributing factors. However, a strong genetic 
component to exceptional longevity (e.g. clustering of centenarians in families) suggests 
that those living to the oldest ages have a survival advantage that protects them from 
ageing-related diseases like cancer.57 Age-related declines in metabolism, rate of cell 
proliferation, and a high proportion of senescent cells may reduce the probability of 
malignant transformation and spread.56 Indeed, the lower rates of metastatic disease 
reported in older people with CRC,58 and the presence of less poorly differentiated 
tumours,59 may help to explain improved survival in the very old.57  
However, other age-associated biological features may impact on treatment success. A 
greater proportion of older people present with right-sided colon cancers.60 These are 
considerably more likely to be associated with microsatellite instability (MSI),61 the 
molecular fingerprint of a deficient DNA mismatch repair (MMR) system. Colorectal cancers 
with MSI have a better prognosis than microsatellite stable CRC,62 but their responses to 
fluorouracil-based chemotherapy regimens may be poorer.63 However, MSI is only present 
in about 15% of cancers.61 Ageing-related changes in the way drugs affect the body 
(pharmacodynamics) and the way the body affects drugs (pharmacokinetics) may cause 
enhanced chemotherapy toxicity and reduced effectiveness.64 Nonetheless, these factors 
do not prevent effective cancer treatment for the majority of older adults.65 Individualised 
assessment of ageing and its effects is therefore required to ensure the most appropriate 
treatments, and therefore the best outcomes, are achieved. 
1.1.3. Definitions of old age 
While ageing is a universal reality, definitions of “old age” vary between countries and over  
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time. In the developed world, chronological time plays an important role in the definition. 
Old age is often linked to the age at which the state offers an age pension, currently 60 to 
65 years in most countries.66 However, changes in the social, political and economic 
environment have resulted in pension ages gradually being increased, and women’s 
eligibility age brought into line with men. In many parts of the developing world, 
chronological time has little importance in the meaning of old age, and a loss of ability to 
perform roles and to actively contribute in society plays more into the definition.67 
This definition recognises that individuals with the same chronological age vary widely in 
their health and ability to function. Because of this heterogeneity, chronological age is not 
an accurate measure of the ageing process, remaining life expectancy, or how well a person 
will cope with treatment.68 Individual biomarkers (e.g. telomere length, inflammation 
markers) are not yet adequately developed to be used exclusively to determine biological 
age.69 The consequences of biological ageing are typically explained as a cumulative decline 
of physiological reserves across multiple systems.70 Concepts such as loss of entropy, 
allostatic load or loss of homeostasis have been used to describe this decreased ability to 
cope with stress, in the presence of adequate baseline functioning.65 Those with critically 
reduced reserves may be characterised as “frail”.71 Though there is no consensus on the 
definition of frailty, it is generally conceptualised in one of two ways:72 as a “frailty 
phenotype” or syndrome identified by the presence of a number of criteria (e.g. weight 
loss, exhaustion, gait speed, grip strength, low physical activity),73 or as a “deficit 
accumulation” model across a number of domains, including chronic disease, ability to 
manage daily activities, and physical signs.74 
Those that support the frailty phenotype model suggest that comorbidity, disability, and 
frailty are distinct clinical entities.75 Comorbidities may be measured based on the presence 
of a number of chronic conditions, or as a comorbidity index reflecting the severity of a set 
of predefined conditions, for example the Charlson comorbidity index.76 The prevalence of 
chronic conditions increases with age,77 and the severity of comorbidities appears to have a  
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“dose-dependent” effect on overall survival of cancer patients.78 However, there is minimal 
correlation between comorbidity and the ability to manage daily activities (functional 
status).79 Functional status is frequently assessed in oncology research as a single 
performance status score, for example, the Eastern Cooperative Oncology Group (ECOG) 
score or the Karnofsky score. 80,81 Ideally, evaluation of functional status for treatment 
decision making should be more extensive than assigning a performance status score,82 and 
may include assessment of independence in a checklist of self-care activities of daily living 
(ADLs) or activities for living independently in the community (instrumental ADLs). 83,84 
Social support can play an attenuating role on the effects of poor function.85 
However, the current gold standard in assessing physiological age is a comprehensive 
geriatric assessment (CGA), which identifies a suite of factors that better predict reduced 
life expectancy and underlying vulnerability than any single element alone.82,86-88 CGA 
commonly includes assessment of functional status, comorbidity, nutrition, mobility, 
polypharmacy, social support, mood, cognition, and the presence of geriatric syndromes 
such as falls and incontinence.89 Because of the resource intensiveness of the CGA, a two-
step approach to geriatric assessment is widely recommended.90 This involves the use of 
screening tools to identify those requiring further full evaluation. 
For practical reasons, a chronological definition of ageing is often used in research. 
Conventionally, old age has been defined as beginning at 65 years.91 The categorisation of 
“young old” (65-74), “old old” (75-84), and “oldest old” (85+) may have some usefulness in 
accounting for the diversity of this population.1 The age of 70 has also been identified as a 
commonly used cutoff in the field of geriatric oncology.92 This is based on a sharp increase 
in the clinical signs of ageing,93 though it is recognised that ageing-related bodily changes 
appear to start decades earlier. Various terms are also used to describe this population in 
research. One international media style guide suggests that “older” is preferable to 
“elderly” or “senior”.94 In this thesis, any age cutoffs are explicitly defined within the 
chapter. The population will generally be described as “older”, implying that individuals are 
“older than” but not necessarily “elderly” or “frail”. 
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1.2. Age differences in treatment and outcomes 
1.2.1. Recommended treatment: surgery 
Surgery is the mainstay of curative treatment for colorectal cancer. In a population-based 
patterns of care study of 3,095 people diagnosed with colorectal cancer in New South 
Wales (NSW) in 2000, 96.4% received surgery (n=2,984).95 Operative treatment for colon 
cancer should consist of en bloc removal of the involved bowel segment (“resection”), the 
associated lymphatic tissue to the origin of the feeding vessels (“apical nodes”), and any 
adjacent tissue or organs that are attached or adhered to the tumour.96,97 At least 12 lymph 
nodes be examined to confirm the absence of nodal involvement.98 Nodes outside the field 
of resection that are suspected of being positive for disease should be sampled.99 The type 
of bowel resection performed is determined by the tumour location. For example, a right 
hemicolectomy is the accepted treatment for tumours in the ascending colon.100 People 
with disease that has metastasised to distant organs or tissues may still benefit curatively 
from surgery.97 Following a resection, reconnection of the two healthy ends of the bowel 
(“anastomosis”) should be performed if possible. Laparoscopic-assisted colon surgery has 
been shown to have equivalent outcomes to conventional surgery when performed by 
experienced surgeons, and may also reduce morbidity.101,102 
Elective surgery for rectal cancer should be carried out by a specialist surgeon as it is more 
technically challenging and has greater potential for poor patient outcomes.97 For many 
years, abdominoperineal resection (APR) was the standard treatment for rectal cancer.103 
APE includes the removal of the anus, rectum and part of the sigmoid colon. In a procedure 
called a colostomy, the end of the remaining colon is brought out permanently through the 
abdominal wall (“stoma”) and fixed to the surface of the skin, so faecal matter can leave 
the body. Advances in treatment techniques and equipment mean that preservation of the 
anal sphincter and avoidance of a permanent colostomy is now possible. A low anterior 
resection, where the colon is attached to the remaining part of the rectum, typically 
achieves superior rates of survival and recurrence104 and is therefore the preferred 
treatment where a distal clearance margin of 1-2 cm can be achieved.97 
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For tumours in the middle or lower third of the rectum, total mesorectal excision (TME) is 
recommended.97 In this operation, the perirectal soft tissue envelope including the entire 
rectum (proctectomy) is removed to reduce local recurrence and the colon connected to 
the anus. Temporary stomas are typically created to give distal anastomoses at particular 
risk of leakage or breakdown time to heal. Local excision of some early colon or rectal 
cancers can be performed transanally i.e. using instruments inserted through the anus.97 
A note on the rectosigmoid junction 
The site where the colon ends and the rectum begins is known as the rectosigmoid 
junction. There are no consistent anatomical or histological features to distinguish this 
region; a tumour is generally classified as rectal if its lower margin lies less than 16cm from 
the anal verge.105 Because rectosigmoid junction cancers account for only 10% of cases,106 
they are typically combined with either colon or rectal cancers for research purposes. 
Similar rates of survival and recurrence suggest they may be better classified and treated 
with colon cancers,107 however there remains no consensus in the literature. In this thesis, 
the categorisation of rectosigmoid junction cancers are defined where necessary. 
1.2.2. Recommended treatment: adjuvant therapy 
Adjuvant therapy refers to treatment that is given in addition to the primary or main 
treatment. In the context of cancer care, this includes radiation therapy or systemic 
treatments (chemotherapy, immunotherapy, hormone therapy). Treatment can be given 
adjuvantly (post-surgery) or neoadjuvantly (pre-surgery). Adjuvant therapy is intended to 
eliminate any residual micrometastatic disease after potentially curative surgery, in order 
to reduce the risk of recurrence and improve survival.108 It is distinct from palliative 
chemotherapy or radiotherapy, which is typically used in advanced disease to alleviate 
symptoms, slow cancer progression, and prolong life.109,110 The anatomy and physiology of 
the human pelvis essentially dictates adjuvant therapy approaches to colon and rectal 
cancer. Radiotherapy is used primarily for rectal cancers, which tend to recur locally or  
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regionally because of the close proximity of the rectum to pelvic structures and organs and 
difficulties in achieving wide margins.111 A systemic approach is more appropriate for colon 
cancers, as these tend to recur only at distant sites such as the liver and lungs.112 
Specific adjuvant therapy recommendations are outlined in the current Australian clinical 
practice guidelines for colorectal cancer.97 These guidelines broadly reflect those of the 
European Society for Medical Oncology (ESMO),113,114 the National Comprehensive Cancer 
Network (NCCN) in the USA,96,115 and the International Society of Geriatric Oncology.108 
Treatment approaches are guided by accurate staging of a tumour according to the extent 
of its spread. In Australia, it is recommended that both Australian Clinicopathological 
Staging (ACPS) and Tumor-Node-Metastases (TNM) staging are recorded.97 Both of these 
are extensions of the original Dukes staging method that have evolved to better define 
treatment and prognosis.116 
 Australian clinical practice guideline recommendations for adjuvant therapy according to 
staging are highlighted in Table 2 and detailed below. Guidelines also exist for metastatic 
and recurrent colorectal cancer but are not outlined here. 
Table 2. Staging and guidelines for adjuvant therapy97 
  TNM staging   
Stage ACPS T N M TNM classification notes 
0 - Tis N0 M0 Tis: Carcinoma in situ, confined to mucosa 
I A T1 N0 M0 T1: Invades submucosa 
I A T2 N0 M0 T2: Invades muscularis propria 
II-A B T3 N0 M0 T3: Invades pericolorectal tissues 
II-B B T4a N0 M0 T4a: Penetrates to surface of visceral peritoneum 
II-C B T4b N0 M0 T4b: Invades or adheres to other organs or structures 
III-A C T1-2 N1 M0 N1: 1-3 positive regional lymph nodes 
III-B C T3-4 N1 M0  
III-C C T1-4 N2 M0 N2: 4 or more positive regional nodes 
IV D T1-4 N0-2 M1 M1: Distant metastasis 
 
  Radiotherapy strongly recommended (rectal)  Chemotherapy strongly recommended (colon) 
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Strongly recommended (Level 1 evidence: systematic review)97 
1) People with resected Dukes C (i.e. node-positive) colon cancer should be considered for 
adjuvant chemotherapy. 
2) Adjuvant preoperative or postoperative radiotherapy is recommended for high-risk 
(T3/4 or N+) rectal cancer. 
Recommended (Level 2 evidence: randomised control trial)97 
1) There is a small but statistically significant benefit for the use of adjuvant 
chemotherapy in Stage II colon cancer. High risk sub-groups are more likely to benefit 
from adjuvant chemotherapy. 
2) Preoperative therapy for rectal cancer may lower the incidence of late morbidity. 
3) Where radiotherapy is indicated for rectal cancer, fluorouracil-based chemotherapy 
should be administered. 
Recommended adjuvant therapy regimens 
The standard of care following surgery for stage III colon cancer is six months of FOLFOX, 
which consists of oxaliplatin and fluorouracil (5-FU) with leucovorin (LV), every two weeks 
for 12 cycles.96 This chemotherapy regime has increased disease-free survival and reduced 
recurrence compared to 5-FU/LV alone.117 Other treatment options include bolus 5-
FU/LV/oxaliplatin (FLOX), capecitabine/oxaliplatin (CapeOx or XELOX). Single agent 5-FU/LV 
or capecitabine can be used if patients are felt to be inappropriate for oxaliplatin therapy.96 
Capecitabine is an oral prodrug of 5-FU with equivalent outcomes to 5-FU/LV and a better 
tolerability profile,118 making it particularly attractive for elderly patients, except in the case 
of renal impairment.108 Adjuvant chemotherapy should be initiated within 8 weeks after 
surgery.119 Those with high-risk stage II colon cancer can also be considered for these 
adjuvant chemotherapy regimes.120 A range of active drugs, either in combination or as 
single agents, may be used in metastatic and recurrent disease.96 Radiotherapy in colon 
cancer is generally only considered for select patients with T4 tumours penetrating to a 
fixed structure or for patients with recurrent disease.96 
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For patients with high-risk rectal cancer, preoperative radiation is preferred as it is more 
effective in reducing local recurrence and less toxic than postoperative treatment.114 
Reducing tumour volume with preoperative radiation may also facilitate resection.115 The 
addition of 5-FU-based chemotherapy concurrent with preoperative radiation is 
recommended.121 Evidence of the effectiveness of postoperative chemotherapy following 
preoperative treatment is less clear.122 Recent studies have shown that capecitabine is 
equivalent to 5-FU in perioperative chemoradiation therapy.123 Recommended doses of 
radiation are typically 45-50 Gy in 25-28 fractions to the pelvis using three or four fields.115 
For patients treated with preoperative chemoradiation, an interval of 5 to 10 weeks prior 
to resection after completion of the five and a half week course is recommended to allow 
patient recuperation.115 Short-course radiotherapy may be appropriate in some 
situations.115 Radiation and chemotherapy are also used to manage metastatic and 
recurrent rectal cancer. 
Specific age guidelines 
The Australian Federal Age Discrimination Act (2004) states that taking a person’s age into 
account when making healthcare decisions must be “reasonably based on evidence”. A 
number of evidence-based clinical practice guidelines for colorectal cancer specifically 
outline that: 
• Age alone should not be a contraindication for curative surgery in colon cancer124 
• Advanced chronological age should not be used to exclude patients from being offered 
adjuvant chemotherapy97 
• Age alone should not exclude any stage III colon cancer patient from consideration for 
adjuvant therapy108 
• Irrespective of age, a person who is functionally independent and without serious 
comorbidities should be a good candidate for most forms of cancer treatment.124  
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However, the risk of comorbid conditions and functional impairment increases with age. 
These factors therefore need to be considered both in individual treatment decision 
making and in determining concordance with guidelines. 
1.2.3. Age differences in treatment 
Diagnosis and surgery 
Differences between the treatment of older and younger people with CRC are apparent 
along the pathway of cancer care.125,126 Older people with CRC are more likely to have 
prolonged wait times from diagnosis to first cancer treatment,127-130 though emergency 
resection is also more common with advancing age.58,125,131,132 Many studies report that 
older CRC patients are less likely to undergo surgery than younger patients.58,125,126,133-135 
While comorbidities can justifiably affect eligibility for surgery, age differences remain after 
accounting for this factor.136-138 Differences between younger and older patients also exist 
in rates of surgery for cancer recurrence.139 However, the proportion of older patients 
receiving colorectal cancer surgery has increased considerably over time.140-142  
Age differences in type of surgery for CRC are also apparent. Older people who do undergo 
resection are more likely to have less radical surgery than their younger counterparts,131,143 
even after adjusting for comorbidities.138 Laparoscopic colonic surgery appears to have at 
least equivalent outcomes to conventional open surgery101,102 and may in fact be of most 
benefit to the elderly.144 Yet, increasing age is a significant predictor of non-receipt of 
laparoscopic surgery.145,146 A greater proportion of older people receive APR for rectal 
cancer,147-149 which can be associated with both higher rates of local recurrence and poorer 
survival than restorative rectal resection.104 Inadequate lymph node evaluation (≥12 nodes) 
is also more likely with increased age.58,150-153 
Differences in adjuvant therapy receipt 
Age differences in the receipt of guideline-recommended adjuvant therapy have been 
widely documented, both nationally and internationally, and across a range of cancer 
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types.154-158 Older people are less likely to receive adjuvant chemotherapy for stage III colon 
cancer.95,151,159-162 These differences remain after accounting for age-related factors such as 
comorbidities163-175 and physical function.176,177 Older patients are less likely to be referred 
to178,179 and seen by an oncologist,163,180 which are crucial factors in the receipt of 
chemotherapy.181 For stage II/III rectal cancer, increasing age is a predictor of non-receipt 
of radiotherapy,95,143,182-184 even when accounting for comorbidities,166,185-187 and is 
associated with decreasing use of combined chemoradiation.126,188 Older adults are also less 
likely to receive chemotherapy for metastatic CRC.170,189,190 However, adjuvant treatment 
rates are increasing over time.125,126,134,184,191,192 
A number of additional issues in the receipt of adjuvant chemotherapy exist. Older age is 
associated with significantly longer intervals from surgery to chemotherapy initiation.193 
Doses are routinely reduced even in older patients who are fit,194 and the addition of 
oxaliplatin to the standard 5-FU/LV regime to increase survival is less likely with older 
age.195-197 Early discontinuation or a shorter than recommended treatment duration for 
older patients is also commonly reported.164,195,196,198 
Differences in follow-up 
Increasing patient age is also associated with poorer follow-up care in cancer.199 Older CRC 
survivors are less likely to receive care from both a primary care provider and oncology 
specialist,200 and have fewer physician visits overall.201 They are less likely to receive 
preventative care including cholesterol testing and bone densitometry,200 and surveillance 
procedures such as colonoscopy.201,202 
1.2.4. Age differences in outcomes 
There have been significant increases in colorectal cancer survival over recent decades in 
many developed countries,9 including for those over 70 years.14 However, differences 
continue to exist between younger and older patients for both short-term and long-term 
outcomes. Though greater levels of comorbidity among older people with CRC increases 
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the complexity of cancer management and affects survival,203-205 poorer treatment appears 
to contribute to age differences in outcomes.108  
Differences in perioperative outcomes 
The incidence of 30-day operative mortality is frequently reported to increase with 
age,131,206,207 including after adjusting for comorbidity208-210 and American Society of 
Anaesthesiologists (ASA) physical health status.58,210,211 Older age has been associated with 
longer length of stay132,210,212,213 and hospital readmission within 30 days,212,214 which may 
be the result of a greater frequency of post-operative complications.131,210,215 However, 
other studies report no age association with hospital readmission216 or that older people 
are actually less likely to have an emergency readmission.213 
Side effects and complications of colorectal cancer surgery can include pain, wound healing 
and infection, anastomotic leakage, bowel dysfunction, urinary and sexual dysfunction, and 
issues related to the presence of a stoma.217-219 In a systematic review of surgical outcomes 
in rectal cancer, postoperative morbidity and complications were not consistently 
associated with age.220 However, complications such as anastomotic leakage may have a 
greater impact on the consequent survival of older patients.220 There have also been 
reports that increasing age is not associated with postoperative complications when ASA 
physical status is accounted for,221 and that age is a predictor of higher rates of nonsurgical 
complications but not surgical complications.222 Regardless of any age differences in 
perioperative outcomes, many researchers conclude that colorectal resection for older 
patients has acceptable levels of perioperative morbidity and mortality,212,223-225 particularly 
given that operative mortality has improved considerably over time.140,226 
Differences in survival 
Longer term survival outcomes are often poorer for older adults with CRC, though there is 
large variation between countries.203 Appendix 1.2 outlines the definitions for a number of 
commonly used survival measures. Many studies report that while overall five-year survival 
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 of older patients is poorer, cancer-specific survival is not associated with age.131,223,227,228 
That is, a substantial proportion of deaths in older people with CRC can be attributed to 
factors such as congestive heart failure, diabetes mellitus, and chronic obstructive 
pulmonary disease.229 However, some studies do report decreasing cancer-specific survival 
with age,140,143 and poorer relative survival for those older patients with metastatic disease 
or locally recurrent cancer.139 Other findings suggest that after surviving the first year, older 
patients have the same relative survival as younger patients.230,231 This indicates a 
prolonged effect of surgery and anaesthesia on those with reduced reserves.70 
Conflicting findings may be partly explained by differing methods for estimating cancer 
survival.232 Nonetheless, suboptimal treatment appears to be a major contributor where 
poorer outcomes are reported.108,143,233 Increased rates of radical resection for older 
patients have produced marked improvements in five-year relative survival for this 
group.140,141,226,234 Poorer outcomes may also be explained by age differences in factors such 
as adequate lymph node evaluation, which is important for treatment planning and is 
associated with survival.235,236 Similarly, longer time to adjuvant chemotherapy initiation, 
early discontinuation, and dose reduction are all associated with poorer CRC  
survival.119,237-241 Underuse of laparoscopy in older patients may increase rates of 
complicated postoperative recovery,242 potentially resulting in further omission, delay and 
discontinuation of adjuvant chemotherapy.243 Moreover, deviations from practice 
recommendations may add to the perception that treatment is less effective for older 
patients, resulting in further undertreatment. 
Differences in efficacy and toxicity of adjuvant therapy 
In an analysis of pooled data from seven randomised trials with surgery-alone control arms, 
the addition of 5-FU based adjuvant chemotherapy improved five-year disease-free survival 
in node-positive colon cancer patients from 42% to 58% and five-year overall survival from 
51% to 64%.244 Older adults with node-positive colon cancer derive the same benefit from 
these regimes as younger patients in terms of disease-free and relative survival.245,246  
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However, the absolute survival benefits are smaller with age due to competing causes of 
death.245,247 It also remains uncertain whether the addition of oxaliplatin to 5-FU-based 
therapies increases survival in those aged over 70.117,246,248  
Meta-analyses of randomised trials indicate that radiotherapy improves cancer-related and 
overall survival compared to surgery alone, in addition to considerably reducing rates of 
local recurrence.249,250 While the magnitude of the reported survival benefits are relatively 
small, preventing recurrence is a key treatment aim as pelvic recurrent rectal cancer has 
dismal prognosis and poor quality of life.251 The addition of preoperative chemotherapy to 
radiotherapy improves local control but does not appear to improve disease-free or overall 
survival.252 Nonetheless, the evidence suggests the efficacy of radiotherapy and combined 
chemoradiation is the same irrespective of patient age.108,253 
Chemotherapy side effects are most apparent in healthy cells that multiply quickly, as these 
drugs indiscriminately target rapidly dividing cells. A substantial proportion of patients 
experience nausea and vomiting, despite the availability of modern antiemetics.254,255 
Diarrhoea, oral mucositis, neutropenia, and cognitive dysfunction are also frequently 
reported.256-259 Chemotherapy-induced anaemia can be a contributor to the fatigue 
experienced by many cancer patients.260 Peripheral neuropathy caused by oxaliplatin may 
persist for a number of years for a small subset of patients.261 Radiotherapy targets cancer 
cells within a treatment field, but may also affect normal tissues within this field. Acute side 
effects of pelvic radiotherapy include diarrhoea, skin problems, fatigue, urinary frequency, 
sexual dysfunction and pain.262,263 Late (long-term) effects are less common with modern 
techniques, but typically involve anorectal and sexual function.264 Generally, physical and 
functional well-being is improved by three or more years after diagnosis for most CRC 
survivors.265  
Most evidence suggests that there are minimal age-related increases for fit older patients 
in toxicity of chemotherapy124,245,266,267 and radiotherapy.124,253,268,269 However, poorer 
health among older patients may enhance the risk of treatment-related complications.270  
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Predictors of severe chemotherapy toxicity for older patients identified in prospective 
studies include instrumental ADL score, falls, self-rated health and ECOG performance 
status.271,272 The role of comorbidity in adjuvant treatment is less clear and will depend on 
the specific condition. Significant survival benefits from chemotherapy without increases in 
toxicity-related hospitalisation have been reported for those with chronic obstructive 
pulmonary disease, heart failure, and diabetes.273 However, having diabetes does appear to 
increase the risk of recurrence, as well as short-term and long-term mortality.274,275 While 
those with comorbidities generally have less potential to benefit from adjuvant therapy, it 
is difficult to determine from current research whether poorer survival is a consequence of 
the comorbid condition, reduced tolerability, or decreased treatment use.276  
In the absence of specific comorbid diagnoses, reduced organ function associated with the 
ageing process may increase chemotherapy toxicity. Careful monitoring and dose reduction 
for older people may therefore be required,121 particularly in combined chemoradiation.277 
Decreases in renal blood flow can affect clearance of chemotherapy agents that are renally 
excreted.278 However, 5-FU is primarily metabolized by the liver,279 and the consequences 
of age-related changes in hepatic metabolism on chemotherapy are not well understood.280 
Decreased secretion of gastric enzymes and splanchnic blood flow with age may impact the 
absorption of orally administered agents such as capecitabine.278 The prevalence of 
anaemia also increases with age,281 and appears to be a risk factor for chemotherapy 
toxicity.272 Greater levels of polypharmacy in older age and the possible interactions with 
chemotherapy drugs is an additional concern.282 For older women with rectal cancer, 
increased risk of pelvic fracture following radiotherapy has been reported.283 
Toxicity in clinical trials is rated according to defined objective criteria, such as the National 
Cancer Institute (NCI) common terminology criteria.284 Subjective toxicity is the extent to 
which people’s well-being is influenced by objective toxicity measures.285 There is evidence 
that quality of life (QOL) is not significantly poorer for older patients with CRC who receive 
adjuvant therapy compared to those who do not,286 although it is not clear whether  
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chemotherapy or radiotherapy differentially affects the QOL of older patients compared to 
younger patients.263,287 The recent development of a patient-reported version of the NCI 
common terminology criteria288 may help to accelerate the move towards increased 
collection and reporting of QOL measures. Generally, older patients report similar or better 
QOL than their younger counterparts in the longer term,289 and QOL following surgery does 
not appear to differ by age.220,290 However, older patients may be less willing to sacrifice 
any level of impairment of function or QOL during treatment. 
1.2.5. A focus on adjuvant therapy 
This brief review suggests that pervasive age differences exist in the receipt of guideline-
recommended adjuvant therapy for older CRC patients. Where a person is more likely to 
die of a comorbid condition than of cancer, or where poor health limits the ability to 
withstand treatment, these decisions will be clinically appropriate. However, an increasing 
number of individuals reach old age without measurable loss of functional capacity and 
free of severe medical conditions. These older adults are as likely to beneﬁt from standard 
cancer treatment as younger adults do, with equal or at least manageable toxicity.  
Chemotherapy and radiotherapy treatment decisions would appear to be more complex 
than surgical decision making for CRC, as surgery is now the mainstay of curative 
treatment. Given the expected growth in the number and proportion of older cancer 
patients, further exploration of the barriers and facilitators to the use of adjuvant therapy 
is required to ensure equal access to care and improved outcomes for this population. This 
thesis therefore largely focuses on exploring the reasons for the differences in adjuvant 
treatment of older CRC patients. The use of the term “difference” instead of “disparity” is a 
deliberate choice. While historically meaning “a large difference”, to many, disparity 
implies an inequity or an injustice rather than a simple inequality.291 This term may not 
reflect the many shades of grey in decision making for older CRC patients. 
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1.3. Factors that may influence age differences in treatment 
1.3.1. Underrepresentation in research 
While older patients make up the majority of CRC cases, they are underrepresented both in 
clinical trials and in health research generally. Older people make up only between 22% and 
32% of clinical trial participants.292-294 The median age of patients in clinical trials is 10 years 
younger than the median age of CRC incidence,113 and little data is available for patients 
older than 80 years.124 Reasons for this underrepresentation can be broadly separated into 
barriers to opportunity to participate in trials, barriers to awareness of trials, and barriers 
to acceptance of trial enrolment.295  
Of 323 cancer trials recruiting adults in Australia in 2009, 11.1% had a maximum age 
criteria of 60 or above, with 70-79 years being the most frequent age cut-off.296 Exclusion 
criteria such as comorbidities and functional status are also major contributors to the 
underrepresentation of older people in clinical trials,295 though older people are still less 
likely to be offered participation even when these factors are not present.297 Studies have 
generally found only small differences between the willingness of older and younger 
patients to participate in trials.297 However, they are less likely to actively seek them out,298 
and report other barriers to participation such as transport.299 While there is increasing 
attention on and participation of older people in research,300 most clinical trials conducted 
to date have not addressed the most pressing issues in ageing and cancer, such as the 
impact of comorbidities, reduced physiologic reserve and polypharmacy on treatment 
tolerance, or changes in drug pharmacokinetics and pharmacodynamics.301 There is 
therefore less certainty regarding the safety and effectiveness of adjuvant therapy for the 
very old and those with poorer fitness and functionality, resulting in fewer evidence-based 
guidelines for this population and potentially contributing to practice variation. 
Older people are underrepresented in virtually all aspects of health-related research.302 A 
Medline search was conducted using Medical Subject Headings (MeSH) to determine the  
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total proportion of cancer literature focusing on cancer and ageing (see Appendix 1.3). Of 
over two million articles indexed to cancer, 23.7% of articles were also indexed to a subject 
heading of “aged” or “aging”. Only 0.33% were indexed with an ageing field as a primary 
focus of the article. A colorectal cancer-specific search yielded similar findings, with just 
423 articles focusing on issues of the older patient in CRC (0.29%). A recent literature 
review of the QOL of cancer survivors, for example, noted that just 4 of 173 identified 
studies focused on older patients.303 More non-interventional epidemiologic studies are 
required alongside clinical trials to ensure improved understanding of the unique needs of 
older patients and the causes of health inequalities. 
1.3.2. Issues in measurement 
Inequalities in health care access and outcomes have emerged as a public policy concern 
over the last few decades.304 Originally focusing on racial and ethnic subgroups, more 
recently the scope has been expanded to include other priority populations such as 
women, people with disabilities, those living in rural areas, and older people. A lack of 
consistency across studies in adjusting for confounders is an issue that has been 
documented in racial and ethnic disparities research.305 In the cancer field, the effect of 
older age on surgical and adjuvant therapy outcomes remains conflicting because of 
limitations in measuring and adjusting for comorbidities and health status.306,307 This is a 
particular concern where population-based observational cohorts are used to generate 
evidence for treatment effectiveness, as lower rates of non-cancer deaths or early 
separation of survival curves may indicate methodological biases in favour of the treated 
group.306,308,309 These measurement issues may add an additional layer of complexity for 
clinicians when considering the evidence. 
Issues also appear to exist in the measurement of patient-reported outcomes (PROs) such 
as quality of life (QOL) and supportive care needs. PROs are increasingly being recognised 
alongside traditional survival and recurrence measures as integral to both cancer research 
and treatment decision making.310-312 These measures are particularly valuable in  
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comparing a growing range of treatment options for an ageing population with increasingly 
complex health problems.313 Despite carrying a more substantial burden of disease and 
disability, older people with CRC generally report similar or better QOL and similar or fewer 
unmet needs than younger patients.314-316 It is possible that these contradictory findings 
result from a number of identified concerns, including a lack of elderly-specific tools to 
encompass the scope of relevant issues,317 underreporting of symptoms,318 or missing data 
due to patient attrition.319 The potential implications of these factors for older patients’ 
care and outcomes should be examined further. 
1.3.3. Patient-based factors 
Patients who decide not to undergo adjuvant therapy are significantly older than those 
who accept treatment.165,166,175,320-322 Much of the recent focus on older cancer patients has 
been through a geriatric lens, i.e. exploring the impact of ageing-related conditions on 
cancer and physician decisions for cancer treatment. However, understanding the decision-
making processes of older patients may require greater exploration from a gerontology 
perspective, i.e. including social, cultural, psychological, lifespan and life course concepts.4  
Barriers to adjuvant therapy use in older cancer patients identified in previous studies 
include side effects, QOL, stage of life considerations, social support, transportation and 
costs.323-327 However, older patients may also be more vulnerable to forgoing worthwhile 
treatment because of limited insight into their diagnosis and prognosis, or perceptions of 
treatment benefits and risks.328 This vulnerability could result from a number of 
interrelated factors including poorer health literacy,329,330 difficulties processing and 
remembering information,331 cognitive and sensory deficits,332 asking physicians fewer 
questions,333 and typically preferring less information and less involvement in treatment 
decision making.334-336 Older patients may have more negative attitudes and beliefs 
towards adjuvant treatment,337 and appear to have a greater degree of cancer 
fatalism,338,339 perhaps from growing up in a time when cancer survival was much poorer.68 
However, less is known about whether these factors uniquely affect the adjuvant therapy 
decision making of older cancer patients. 
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Those over 65 years report significantly fewer discussions about chemotherapy.337 The 
involvement of older patients in decision making discussions may also be challenged by 
physician assumptions that they prefer a passive role,329 perceptions that their cognition or 
communication is deficient,340 or the reportedly poorer responsiveness and communication 
that physicians have with older patients in the clinical encounter.329,332 This is a major 
concern, given that most older patients are willing to consider chemotherapy341 and the 
primary determinant of treatment decisions is physician advice.342 
1.3.4. Translation of evidence 
Evidence-based practice (EBP) is the use of current best evidence in conjunction with 
clinical expertise and patient values to guide health care decisions.343 A significant gap 
often exists between scientific evidence or research-based guidelines and actual clinical 
practice.344 The study of the methods, interventions and variables that influence the 
adoption of EBPs by individuals or organisations is described as translational research.345 
General factors identified in systematic reviews of EBP translation include lack of 
knowledge or awareness, physician attitudes and characteristics, evidence barriers, 
organisational or system barriers, and lack of support to implement guidelines.346,347 
Many of these areas have been previously implicated in the uptake of adjuvant therapy in 
older cancer patients. Previous physician surveys have revealed that both surgeons and 
oncologists are less likely to recommend adjuvant therapy for older patients based on their 
age alone.348-351 Differences in treatment recommendations and receipt have been 
associated with physician characteristics such as younger age and higher volume.159,351,352 
Physicians with less awareness of current evidence generally,353 or of geriatrics 
specifically,68 may assume that treatment would cause a loss of function simply on the basis 
of patient age. Negative age-related value judgments have also been implicated in 
surgeons’ general decision-making processes,354 and may reflect wider attitudes of society 
about ageing.355 The associations between physician knowledge and attitudes and how 
these directly influence adjuvant therapy recommendations requires further exploration. 
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Institutional and health system factors may also explain age differences in adjuvant therapy 
receipt. The number of oncologists within a patient’s residential area is associated with 
greater access to chemotherapy after surgery.174 Significant variation between hospitals in 
rates of adjuvant chemotherapy for colon cancer has been noted,173,356 and may be 
explained by hospital characteristics such as running an accredited cancer surgery 
program.357 Colorectal surgeons have also been found to hold significantly stronger 
preferences against all adjuvant options compared with oncologists.358 Referral to oncology 
is therefore a crucial factor in receipt of chemotherapy among older patients.181 Higher 
oncology consultation rates appear to be associated with surgeons who work closely with 
oncologists, both in teaching hospitals and small hospitals, 359,360 and these surgeons are 
less likely to have patients “get lost in the system”.361 Nevertheless, older patients remain 
less likely to receive adjuvant therapy even after seeing an oncologist.175,185  
Clinicians often report high satisfaction with clinical practice guidelines, but may consider 
them impractical or too rigid to apply to individual patients.362 For older patients, the 
increasing prevalence of comorbidity appears to contribute significantly to variation in 
physician recommendations.349 Research to guide clinicians on the impact of treatment on 
these vulnerable adults is sparse. While screening and subsequent comprehensive geriatric 
assessment have been suggested as an effective approach to identify those at risk of 
chemotherapy toxicity,363-365 there remains little consensus on which screening tool 
clinicians should use or which CGA elements should be included.89,366 However, practice 
variation and reduced rates of treatment appear to exist even for fit older patients. 
1.3.5. Is it worth it? 
A substantial debate in the literature exists over whether older patients are actually 
overtreated.306,367-369 Certainly, these adjuvant therapy decisions require careful 
consideration of present-day risks against less well-defined future gains, for a sub-
population that is not as robust as their younger counterparts. Older patients clearly have 
lower potential for absolute survival benefits from adjuvant therapy in terms of years left  
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to live, and may place a different value on the risk of adverse effects and logistical 
challenges of treatment. Treatment decisions also occur against a backdrop of increasing 
public focus on health expenditure and the rising costs of cancer treatment,370 as well as 
frequent discussion about the impending “silver tsunami” that is portrayed as set to cause 
“unimaginable chaos” for public services.371 
Cost-effectiveness is therefore an important concept in the treatment of older patients. 
Benefits are typically measured in terms of the number of quality-adjusted life years 
gained,372 which accounts for both the quantity and quality of life lived. It is increasingly 
argued that cost-effectiveness analysis should take into consideration social concerns,373 as 
opposed to valuing every year of “quality” life equally regardless of the person who gains it. 
There is a general societal preference to prioritise the health of younger adults over older 
adults.372,374 This may be due to a number of reasons including the potential for 
productivity, remaining life expectancy, and the “fair innings” principal.375 However, there 
is also a strong community desire to reduce health inequalities and prioritise disadvantaged 
groups. Johnstone and colleagues believe that much of the political debate around 
population ageing in Australia represents “demographic alarmism”, that is both misleading 
and harmfully prejudicial to the health and social welfare of older Australians.371 There is 
also substantial push-back from community groups against perceived ageism in cancer 
treatment.376 A law banning age discrimination in the provision of healthcare was fully 
implemented in the UK in 2012, following public reports of poor treatment and outcomes 
of older patients in the National Health Service.377 
While the acquisition cost of 5-FU/LV chemotherapy is less than A$1,000 for an average 
course,378 the current recommendation to incorporate oxaliplatin in this regime for an 
additional A$12,000378 perhaps deserves further economic consideration for older patients, 
given the unclear survival benefits.124 These costs occur alongside administration costs 
(≈A$5,000)379 as well as the costs of any adverse events.380 However, the costs of not 
receiving recommended adjuvant therapy may far outweigh this, both in terms of the very  
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high treatment costs for recurrent metastatic cancer381 as well as substantial loss of quality 
and quantity of life. Eighty percent of recurrences arise within the first two years after 
resection, and the median survival following recurrence in stage III CRC is 12.5 months.382 
The average life expectancy of a 70 year old in Australia is 15-17 years.30 This suggests that 
older patients are a vulnerable population from which valuable and sometimes lifesaving 
therapy is withheld. Yet, considerable grey areas mean there is a need to further explore 
how these decisions are made by both patients and clinicians. 
1.4. Specific gaps in existing literature 
1.4.1. Shifting focus to the “whole person” 
The move towards patient-centred models of health care in the last few decades383 appears 
to be a promising step for patients in terms of satisfaction and perceived quality of care.384 
A key attribute of these models is holistic care, i.e. recognising and responding to the 
complete needs of the whole person.385 Health measures most relevant to older adults (e.g. 
comorbidity, functional status) are rarely incorporated into oncology clinical trials.386,387 
Many risk tools only incorporate a limited evaluation of health status,388,389 despite general 
acknowledgement that treatment decisions should be based on the assessment of 
individual life expectancy and predicted treatment tolerance and not on chronologic age. 
Typically, comorbidity is the sole health-related factor used in the exploration of age 
differences in treatment125,126 and in barriers to the treatment of older patients.351  
Much of the research exploring patient preferences for adjuvant therapy also focuses on 
weighing survival benefit against treatment toxicity.390 While survival and toxicity are 
clearly central to these decisions, this emphasis tends to ignore the impact of logistical, 
social and emotional drivers on treatment decision making. The fact that patient and 
treatment characteristics are not a consistent predictor of preferences,391 and the 
willingness of many patients to consider even negligible benefits sufficient to make 
chemotherapy worthwhile,392 imply that there are important “whole person” 
considerations requiring further exploration. 
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1.4.2. Relativity 
If two percent of a treatment group die compared to four percent of a control group, this 
finding can be presented as a two percent absolute risk reduction, or a more impressive-
sounding 50% lower risk of death. Relative or proportional reductions in risk are not readily 
understood by most patients.393 Physicians’ interpretations of the magnitude and 
significance of research findings can also be affected by the reporting of results in 
exclusively relative terms.394 In patient-reported outcomes research, age is often presented 
solely as a relative predictor, potentially affecting clinicians’ perceptions about the 
treatment and care that older patients need. 
Relativity may also sometimes be underused when exploring the barriers to adjuvant 
treatment receipt. A number of studies focusing on barriers to treatment have involved 
older people only. While providing an important overview of the issues, this can make it 
difficult to determine what is uniquely different about the decision-making processes and 
barriers for older patients in comparison to their younger counterparts. 
1.4.3. A local context 
Australia has a land mass roughly the size of the continental United States and a population 
of just under 23 million people.21 While it is one of the least densely populated countries in 
the world, Australia is highly urbanised. One third of Australia’s population resides in New 
South Wales (NSW), and 64% of these people live in the Greater Sydney region.395 More 
than a quarter of Australians were born overseas (26%),396 a considerably higher proportion 
than Canada, the USA, or the UK. Australian life expectancy and health is among the 
highest in the world.397 However, some groups have notably poorer health status, such as 
those living in rural and remote areas398 and Aboriginal and Torres Strait Islander peoples 
(three percent of the population).399 As the most populous state, NSW is a representative 
sample of the sociocultural and geographic diversity of the country, though with fewer 
people living in remote areas. 
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Australia has a taxpayer-funded universal health care system (Medicare), supplemented by 
a substantial private sector that is involved both in health care delivery and financing. 
Medicare consists of three components – medical services (including visits to general 
practitioners and other medical practitioners), hospital treatment as a public patient, and 
prescription pharmaceuticals.397 Since 1993, the Australian Pharmaceutical Benefit Scheme 
(PBS) has insisted on appropriate economic evidence before authorising public funding of a 
new drug.400 The recommended regimes of capecitabine and 5-FU for stage III colon cancer, 
either alone or in combination with oxaliplatin, are all PBS listed. Surgery and 
chemotherapy administration are covered by Medicare for anyone electing to be treated as 
a public patient, and are also covered by private health insurance. Radiotherapy has been 
found to be cost-effective in rectal cancer.401 However, outpatient radiotherapy is not 
covered by private insurance, which can result in substantial out-of-pocket costs in parts of 
the country where the only radiotherapy centre is a private facility.402 
Despite a steadily growing population of older people with cancer, geriatric oncology in 
Australia is in its infancy.403 Australia’s cultural diversity, expansive distances, medical 
funding from public resources and generally high health outcomes, also mean that barriers 
and attitudes in the uptake of adjuvant therapy may be different to other countries and 
regions. In addition, the investigation of Australia-specific issues in treatment receipt and 
the development of tools based on local data may give findings greater clinical credibility. 
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1.5. Thesis aims and hypotheses 
Older people with CRC are a growing and underresearched group who appear to be 
vulnerable to poor treatment and outcomes. The overall aim of this thesis is to explore the 
barriers to evidence-based care for older people with colorectal cancer, with a focus on 
receipt of guideline-recommended adjuvant therapy. More specifically, the aims of this 
thesis are: 
1) To explore issues in the measurement of patient-reported outcomes that may 
contribute to age differences in treatment, by: 
a. Quantifying differences in the levels of need and unmet need of older and 
younger colorectal cancer patients in the three months following surgery 
b. Determining age differences in levels of missing data and the effect of 
imputation methods on estimates of older patients’ quality of life after 
colorectal cancer surgery 
2) To establish current levels of adjuvant therapy utilisation for colorectal cancer in NSW 
and determine patient and hospital-level predictors of treatment receipt 
3) To investigate physician-based and patient-based barriers to the receipt of adjuvant 
therapy, by: 
a. Identifying factors that affect colorectal surgeons’ decisions to refer older 
patients for adjuvant therapy and determining relationships between surgeon 
knowledge, opinions and self-reported practice 
b. Exploring the association between patient age, factors that influence patients’ 
chemotherapy treatment decisions, and preferences for information and 
involvement in treatment decision making 
4) To develop a mortality risk model that could be used by clinicians to assist adjuvant 
chemotherapy decision making 
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It is hypothesised that: 
1) a. Older patients with colorectal cancer will have lower levels of post-operative  
unmet need but a greater proportion of met needs compared to younger patients 
b. Greater levels of missing data in quality of life questionnaires will be associated  
with older age and multiple imputation of missing data will more accurately 
estimate quality of life than simple mean imputation 
2) Rates of adjuvant therapy utilisation for colorectal cancer in NSW will have increased 
from previously measured rates and patient age and hospital of surgery will be a 
significant predictors of adjuvant therapy receipt 
3) a. Patient age will affect colorectal surgeon’s decisions to refer older patients for 
adjuvant therapy and surgeon knowledge and opinions will be associated with  
self-reported practice 
b. Older patients will place greater importance on physician recommendations for  
adjuvant chemotherapy and maintaining quality of life than younger patients  
and will prefer less information and involvement in treatment decision making 
4) A mortality risk model for chemotherapy decision making with good discrimination and 
calibration will be able to be developed using linked population-based data 
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Appendix 1.1. Permission to reproduce published material* 
 
*Refers to Figures 1-3
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Appendix 1.2. Definitions of survival and life expectancy 
Term Definition 
Overall survival  
(all-cause) 
Proportion of people who are alive at a given time point after cancer 
diagnosis or treatment, or the probability of being alive 
Cancer-specific survival Cancer survival in the absence of other causes of death, based on each 
person’s recorded cause of death 
Relative survival Cancer survival in the absence of other causes of death, based on an 
adjustment using a comparable cancer-free cohort 
Disease-free survival Proportion of people who are alive and cancer free at a given time point 
Progression-free 
survival 
Proportion of people who have not experienced any new cancer growth 
or spread at a given time point 
Life expectancy Average remaining years of life a person can expect to live at a given age 
Disability-free life 
expectancy 
Average remaining years of life expectancy without disability* 
Healthy life expectancy Average remaining years of life expectancy in good health* 
*Definitions of “disability” and “good health” may differ 
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Appendix 1.3. Proportion of literature focusing on cancer and ageing* 
 Medline search 
MeSH headings 1 2 3 4 5 6 7 8 
Neoplasms X X X X     
Colorectal neoplasms     X X X X 
AND         
Agedb, OR  X X Xa  X X Xa 
Ageing, OR  X X Xa  X X Xa 
Geriatrics, OR   X Xa   X Xa 
Health services for aged, OR   X Xa   X Xa 
Geriatric assessment, OR   X Xa   X Xa 
Geriatric nursing, OR   X Xa   X Xa 
Geriatric psychiatry   X Xa   X Xa 
Hits 2,556,938 605,621 608,718 8,468 147,997 50,978 51,161 423 
% of cancer research 100.00 23.67 23.81 0.33 100.00 34.45 34.57 0.29 
*Medline search to end of 2012 
aArticles in which the subject term (or sub-branches) are considered to be the primary focus of the article 
bSub-branches include “Aged, 80 and over” and “Frail elderly” 
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2 
Measurement 
 
 
This chapter uses existing prospectively collected data to examine issues in the 
measurement of patient-reported outcomes (PROs) that may affect the treatment and care 
that older patients receive.  
Adjuvant therapy decisions for this population involve careful consideration of the risks of 
treatment against potential survival benefits. These risks are increasingly being measured 
using PROs such as quality of life and supportive care needs. Accurate ascertainment, 
analysis and reporting of PROs in research is therefore required to inform patients’ and 
clinicians’ treatment decision making. Issues in the measurement of PROs may also be 
important considerations in monitoring the effects of treatment on older individuals. 
This chapter is presented as the following papers: 
1. Jorgensen ML, Young JM, Harrison JD, Solomon MJ. Unmet supportive care needs in 
colorectal cancer: differences by age. Supportive Care in Cancer 2012; 20(6): 1275-81. 
Available: http://link.springer.com/article/10.1007/s00520-011-1214-9 
2. Jorgensen ML, Young JM, Solomon MJ. Older cancer patients and missing data in 
quality of life questionnaires. [Submitted] 
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Study 1. Unmet supportive care needs in colorectal cancer: differences by age 
2.1.1. Abstract 
PURPOSE: Cancer is primarily a disease of ageing, yet the unmet supportive care needs of 
older cancer patients are not well understood. This study aims to explore how unmet needs 
differ by age over the 3 months following colorectal cancer surgery. 
METHODS: Control groups from pilot phases of an ongoing randomised trial completed the 
Supportive Care Needs Survey-Short Form 34 (SCNS-SF34) at one and three months 
following hospital discharge (n=57). Multiple regression was used to investigate whether 
age was an independent predictor of unmet needs in each of the five SCNS-SF34 domains. 
The proportion of patients with unmet needs and the pattern of item responses were 
compared between patients aged <65 and ≥ 65 years at both time points. 
RESULTS: Older age independently predicted significantly lower levels of unmet need than 
younger age in nearly all SCNS-SF34 domains. However, more than half of all older patients 
had unmet needs at both time points (56% and 65%), and age differences in unmet needs 
were less apparent by 3 months. Older patients were less likely than younger patients to 
report 'satisfied' needs, as older patients were significantly more likely to report items were 
'not applicable' at both one month (mean difference 29%, p<0.001) and three months 
(mean difference 23%, p=0.01). 
CONCLUSIONS: While older patients reported lower levels of unmet need than younger 
patients, the high prevalence of unmet needs and age differences in item response 
patterns indicate that further research is needed to determine whether older patients' 
needs are being accurately captured. 
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This is an author-created version of the accepted manuscript. The final publication is 
available at www.springerlink.com. 
2.1.2. Introduction 
Colorectal cancer is primarily a disease of the elderly. More than 65% of colorectal cancer 
cases occur in patients over 65 years of age,2 and this figure is expected to rise with 
population ageing.29 Yet little is known about how older patients cope with cancer and 
cancer treatment.  
Supportive care includes treatment to optimise cancer patients' physical comfort and 
functional ability, as well as non-tumour specific treatment such as social, informational, 
economic, psychological and spiritual support.1,16 When needs for supportive care are not 
met, patients' quality of life and satisfaction with care may be affected.5 Vulnerable patient 
groups can be identified through exploring socio-demographic and clinical predictors of 
unmet needs. Predictors of unmet needs vary across studies, and include income, advance 
disease and depression.16 Patients with poor health status and those lacking social support, 
for example, are more likely to have higher levels of unmet need.16 These factors have been 
associated with increasing age.9,26,34 However, older patients are generally reported to have 
lower levels of unmet need than younger patients across a range of cancer types.4,6,14,28,30-33  
The cause of these conflicting findings is difficult to determine as patient age is not often 
the focus of unmet needs research. For example, previous studies have not explored 
whether older patients have lower levels of unmet need because they are more likely to 
have their needs ‘met’ than their younger counterparts. The absolute prevalence of unmet 
needs in older patients is also difficult to determine from previous research, as relative 
comparisons of levels of unmet need are typically used. While valuable, these relative 
comparisons may ignore the impact that any unmet needs have on patients who are older 
and perhaps more unwell. In addition, unmet needs are not often measured prospectively  
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over time.16 Apparent age differences in unmet needs could be affected by the timing of 
assessment, as older patients tend to recover more slowly from cancer treatment.10 Thus, 
more research is needed to provide a clearer picture of age-related differences in 
supportive care needs. 
A greater understanding of the needs and unmet needs of older patients is also vital to 
ensuring that the best decisions are made for treatment and care. It has been suggested 
that many older people do not report their health care needs for a range of complex 
reasons.35 This may mean that they are less likely to receive care which could improve their 
health outcomes, and may in turn affect physicians' decisions about suitability for adjuvant 
treatment such as chemotherapy.22 Given the conflicting predictors of unmet needs in 
previous research and the unexplored issues in the unmet needs of older patients, the aims 
of this study were to determine (a) whether age independently predicts unmet needs over 
the three months following colorectal cancer surgery, and (b) whether the extent of need 
and unmet needs differs by age. 
2.1.3. Method 
Participants 
The study used existing data collected from participants in the control groups of two trials 
of a supportive care intervention for people with colorectal cancer, which were approved 
by their local area health service ethics review committees. Control groups were used so 
that the measurement of their needs would not be affected by the receipt of an 
intervention. Eligibility criteria and recruitment processes were identical for both studies. 
All patients aged over 18 years who were admitted to Royal Prince Alfred Hospital, Sydney 
for surgery for colorectal cancer between July and December 2006 (for study 1)38 and 
between June 2007 and June 2008 (for study 2)15 were assessed for eligibility. Patients 
were considered ineligible if they were discharged to another health facility (such as a 
hospice), died during admission, or were cognitively impaired such that they could not give 
informed consent or complete questionnaires.  
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Procedure 
Prior to discharge from hospital, baseline demographic and clinical information was 
obtained. Several outcomes were assessed at baseline, one month and three months after  
discharge from hospital as part of the aforementioned supportive care intervention 
trials.15,38 Unmet supportive care needs were measured using the Supportive Care Needs 
Survey- Short Form 34 (SCNS-SF34).7 Responses to this survey at both one and three 
months formed the dataset for the present analyses. 
The SCNS-SF34 is a validated self-administered questionnaire that asks patients to rate 
their level of need for additional support over the last month on a range of items in five 
needs domains.7 These are psychological, health system and information, physical and daily 
living, patient care and support and sexuality. Patients are asked whether each item is ‘not 
applicable’ (no need), ‘satisfied’ (need already satisfied), ‘low need’, ‘moderate need’ or 
‘high need’ (need for additional help). Standardised scores are calculated for each domain 
(possible range 0–100).23 The instrument has high internal consistency and convergent 
validity with three other measures of psychological well-being.7 
Data analysis 
Participants were divided into ‘younger’ (<65 years) and ‘older’ (≥65 years) age groups for 
analysis. The age of 65 was selected to divide the sample as (1) this was the median age of 
the sample, and (2) this cut-off is frequently used to define older age.25 Mean standardised 
scores in each of the five SCNS-SF34 domains at one and three months were calculated for 
the younger and older groups.23 Demographic/clinical characteristics (e.g. education, 
cancer site) of both age groups were compared using t-tests and chi-square tests.  
Multiple regression analyses were used to test for independent associations between 
demographic/clinical characteristics and (1) mean scores for all five needs domains at both 
one and three months, and (2) the mean differences in domain scores between one and 
three months, to determine independent predictors of change in unmet needs scores over  
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time. A manual backwards elimination approach to modelling was used. Any of the 
demographic/clinical characteristics measured at baseline which indicated a possible 
relationship to domain scores (p<0.25) were included in the base models.17 Plots of each 
demographic/clinical variable against domain scores were also examined for outliers and 
approximate linearity before inclusion in the models. Variables with the least effect on 
domain scores were dropped out of the models one at a time until all predictors were 
statistically significant. Age, as the variable of interest, was retained in all models. Only the 
results for the final models in all five needs domains at both one and three months are 
presented, as multiple regression was used primarily to determine independent 
associations between age and domain scores. 
The extent of supportive care needs was measured in two ways. The proportion of patients 
who reported any unmet needs (‘low/moderate/high need’) was calculated for both time 
points and compared between younger and older patients using chi-square tests. The study 
also investigated whether older patients were more likely than younger patients to have 
their needs ‘met’ (‘satisfied’). The mean differences in the proportion of ‘not applicable’ 
and ‘satisfied’ responses were compared between older and younger patients using 
independent samples t-tests at both one and three months. 
2.1.4. Results 
Of 57 patients, 28 were younger than 65 years of age and 29 were aged 65 and over (see 
Table 1). Older patients were significantly less likely than the younger patients to have 
completed high school or tertiary education (p=0.02), be employed (p<0.001), live with 
others (p=0.02), receive adjuvant therapy (p=0.04) and have no comorbid conditions 
(p=0.05). All other characteristics were comparable between age groups.  
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Table 1. Characteristics of participants by age group at baseline 
Characteristic Younger group, n (%) Older group, n (%) p level 
Total participants 28 (100) 29 (100)  
Age in years (mean/SD) 50.9 (11.6) 74.3 (6.3) <.001** 
Male 14 (50) 19 (66) .24 
Born in Australia 17 (61) 18 (62) .92 
English spoken at home 23 (82) 23 (80) .79 
Completed high school or  
tertiary education 
20 (71) 9 (31) .02* 
Employed full or part time 19 (68) 5 (17) <.001** 
Private health insurance 12 (43) 8 (28) .23 
Lives alone 5 (18) 14 (48) .02* 
Site of cancer 
Colon 
Rectosigmoid 
Rectal 
 
13 (46) 
2 (7) 
13 (46) 
 
13 (45) 
4 (14) 
12 (41) 
.88 
Dukes stage of cancer 
A 
B 
C 
D 
Non-cancerous tumoura 
 
7 (25) 
9 (32) 
8 (29) 
2 (7) 
2 (7) 
 
6 (21) 
6 (21) 
10 (34) 
3 (10) 
4 (14) 
.81 
Metastatic disease 3 (11) 2 (7)  .61 
Received adjuvant therapy 14 (50) 7 (24) .04* 
One or more comorbid conditions 12 (43) 20 (69) .05* 
aPathological stage identified after randomisation, all surgically treated with curative intent; *p≤0.05; **p≤0.01 
Decreasing age independently predicted unmet needs for nearly all domains at both time 
points (see Table 2). Older patients had significantly lower levels of unmet need in all SCNS-
SF34 domains except patient care/support at one month after hospital discharge. At three 
months, older patients had significantly lower levels of unmet need in all SNCS-SF34 
domains except patient care/support and health system/information. Unmet needs were 
highest in both groups in the physical and psychological domains (see Figure 1). Notably, 
the older group had very low scores for unmet needs in the sexuality domain. While levels 
of unmet need decreased over time for both age groups, the decrease in mean scores 
tended to be larger in the younger group. These results were not significant however.  
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Table 2. Multiple regression results for age and other independent predictors 
Domain Timea Model statistics Variable b  (95% CI) p level 
Psychological 1 m R2adj=0.096, F1,49=6.34, p=0.02 Age 17.1 (3.5-30.7) .02* 
3 m R2adj=0.19, F2,44=6.42, p=0.004 Age 22.3 (8.3-36.3) .003** 
  Private health 16.3 (1.7-30.8) .03* 
Diff R2adj=-0.02, F1,44=0.34, p=0.57 Age  .57 
Physical & 
daily living 
1 m R2adj=0.12, F1,50=7.64, p=0.008 Age 16.5 (4.5-28.4) .008** 
3 m R2adj=0.06, F1,45=4.11, p=0.05 Age 15.1 (0.2-29.9) .05* 
Diff R2adj=0.15, F3,42=3.68, p=0.02 Age  .12 
  Cancer stage 13.8 (1.9-25.8) .03* 
  n in household 14.9 (0.7-29.2) .04* 
Sexuality 1 m R2adj=0.30, F4,44=6.20, p<0.001 Age 17.6 (4.4-30.7) .01** 
  Gender 18.0 (5.1-31.0) .008** 
  Comorbidity 17.5(1.5-33.6) .03* 
  Cancer site 13.8 (0.0-27.5) .05* 
3 m R2adj=0.42, F4,41=9.05, p<0.001 Age 15.8 (4.4-27.2) .05* 
  Gender 19.2 (8.2-30.1) .001** 
  Comorbidity 18.0 (4.1-31.9) .01** 
  Cancer site 13.2 (1.6-24.8) .03* 
Diff R2adj=0.12, F2,40=3.78, p=0.03 Age  .60 
  Metastases 22.6 (5.7-39.6) .01** 
Health 
system & 
information 
1 m R2adj=0.22, F3,47=5.75, p=0.002 Age 11.0 (1.0-20.9) .03* 
  Metastases 20.1 (3.1-27.1) .02* 
  Language 12.9 (0.2-25.6) .05* 
3 m R2adj=0.01, F1,44=1.47, p=0.23 Age  .23 
Diff R2adj=0.15, F2,42=4.93, p=0.01 Age  .11 
  Gender 12.8 (2.9-22.8) .01** 
Patient care 
& support 
1 m R2adj=0.04, F1,49=3.02, p=0.09 Age  .09 
3 m R2adj<0.001, F1,44=1.01, p=0.32 Age  .32 
Diff R2adj=0.05, F1,43=3.11, p=0.09 Age  .09 
a1 m = 1 month, 3 m = 3 months, diff = difference (3 months – 1 month); *p≤0.05; **p≤0.01 
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Figure 1. Levels of unmet need by domain and age group* 
 
*Higher scores indicate higher levels of unmet need 
A number of other factors also independently predicted unmet needs. For example, 
gender, comorbidity and type of cancer predicted unmet needs in the sexuality domain at 
both one and three months (model p<0.001). Other predictors of domain scores included 
language, stage of disease, private health insurance and living alone (see Table 2).  
A significantly greater proportion of younger patients than older patients had unmet needs 
at one month (89% vs 56%; χ2=7.137, p=0.008). However this difference was no longer 
significant at three months (79% vs 65%; χ2=1.142, p=0.29). The pattern of item responses 
was also calculated (see Figure 2). Older participants reported items were ‘not applicable’ 
(no need) significantly more often than younger participants. This occurred both at one 
month (54% vs 25%, p<0.001, 95% CI 14.4–43.5) and three months (67% vs 44%, p=0.01, 
95% CI 5.1–41.0). Consequently, older patients were significantly less likely than younger 
patients to report ‘satisfied’ needs at one month (29% vs 42%, p=0.04, 95% CI 0.9–24.4). At 
three months they were only as likely as younger patients to report ‘satisfied’ needs (19% 
vs 23%, p=0.52, 95% CI 8.1–15.9).  
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Figure 2. Percentage of answers in each response category by age group 
 
2.1.5. Discussion 
In this study, age was the most frequent independent predictor of unmet needs. Older 
patients reported significantly lower levels of unmet need compared to younger patients in 
nearly all SCNS-SF34 domains at both one and three months after surgery for colorectal 
cancer. However, a considerable proportion of older patients had unmet needs, and age 
differences in unmet needs were less apparent by three months. Older patients were also 
less likely than younger patients to report ‘satisfied’ needs, as they were significantly more 
likely to report that items were ‘not applicable’ (no need).  
Many other studies have similarly reported that older patients have significantly lower 
levels of unmet need compared to younger patients, across a range of cancer 
types.4,6,14,28,30-33 Yet the absolute prevalence of unmet needs in older cancer patients is 
unclear. In this current study, more than half of all older patients still had some unmet 
needs at both one and three months after hospital discharge. While younger patients may 
express greater unmet needs, it is possible that older patients have less capacity to cope  
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with any level of unmet needs due to poorer general health and lower levels of social 
support.26 In addition, the unmet needs scores of older patients did not decrease as much 
as younger patients over time, and the proportion of older patients with unmet needs 
actually increased from one to three months. This suggests that their unmet needs are 
potentially more persistent and harder to address. The impact of unmet needs on older 
patients therefore requires further exploration.  
This study was unique in comparing the extent of ‘met’ and ‘unmet’ need by age. One 
priority of needs assessment is to determine whether existing healthcare resources are 
meeting the needs of a given population.36 There is widespread recognition that older 
cancer patients are a vulnerable group requiring special evaluation throughout treatment.27 
Without reporting the extent of ‘met’ needs, it may therefore be assumed that the low 
unmet needs of older patients are due to high levels of ‘met’ need. However in this study, 
older patients were less likely than younger patients to report ‘satisfied’ needs. Instead, 
older patients were significantly more likely than younger patients to report that items 
were ‘not applicable’ (no need). Other results from this study suggest that the large 
proportion of ‘not applicable’ responses may not truly reflect an absence of need in the 
older cohort. Older patients had significantly higher levels of comorbidity and were more 
likely to live alone. These are two factors which have consistently been identified as putting 
older patients at risk of increased need for assessment and care.11 Contradictory predictors 
of unmet needs may therefore indicate that older patients are less likely than younger 
patients to express their needs for help.  
Stoic attitudes of older patients have been found to account for age-related differences in 
the reporting of chronic pain, for example.37 Other traditionally taboo issues such as 
psychological or sexuality needs may be underreported because of cohort attitudes. In this 
study decreasing age had the strongest association with unmet needs in the psychological 
domain at three months, and second strongest at one month. Similar findings for 
psychological unmet needs were reported by Smith and colleagues.30 Issues around age 
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differences in the reporting of sexuality have been discussed in quality of life research12 and 
could account for the very low mean score for older patients in this domain. Sanson-Fisher 
and colleagues commented that older patients may keep their needs private in the belief 
that they should be able to cope.28 Older patients may also underreport needs as they are 
worried about being a burden to the cancer team or their family,24 worried that they will 
lose their independence if they report problems,21 or may minimise their problems in order 
not to fulfil negative stereotypes about age.35 Qualitative research examining the attitudes 
of older patients towards the expression of unmet needs is warranted.  
Studies focusing on the needs of older patients are scarce,18 despite increasing 
commentary on the unique and complex management of older cancer patients. Age 
differences in unmet needs and the high proportion of ‘not applicable’ responses imply 
that older patients have a different needs profile to younger patients. Age-specific 
instruments have been suggested in quality of life research,13,19 both to capture additional 
information about older patients and to overcome identified measurement issues. Some 
quality of life instruments, for example, have demonstrated a heavy response burden and 
increased requirement for interview administration with advancing age.8 Older patients, 
who are particularly vulnerable to the effects of poor health literacy,3 may also have 
difficulty distinguishing between level of need when completing unmet needs 
assessments.20 Developing age-specific unmet needs instruments may ensure that older 
patients' needs are accurately identified and measured.  
This was a small study, and the results should be interpreted with caution. For example, 
unmet needs were only explored at one and three months after hospital discharge. A 
recent systematic review of cancer patients' unmet supportive care needs identified that 
predictors of unmet needs, including age, were highly variable in all domains at all time 
points.16 In this current study, levels of unmet need similarly depended not only on age, but 
also the timing of assessment from discharge and other demographic and clinical 
predictors. Predictors of unmet needs also did not explain much of the variability in some  
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of the unmet needs domains. These results suggest that needs should be monitored 
throughout each individual patient's journey and interventions tailored accordingly. In 
addition, more insight is needed to determine whether older patients' low unmet needs 
scores genuinely reflect low levels of need or a reluctance to disclose needs. Without more 
information to determine how age-related factors affect outcomes and their measurement, 
decisions about treatment and care for this growing population will continue to be 
problematic.  
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Study 2. Older cancer patients and missing data in quality of life questionnaires 
2.2.1. Abstract 
BACKGROUND: For older adults with cancer, treatment decision making often involves 
careful consideration of the predicted impact of treatment on quality of life (QOL). 
However, issues may exist in the measurement and management of QOL data in cancer 
research. This study aimed to determine whether increasing age was associated with item 
non-response in the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) and 
whether methods commonly used to manage missing data produced unbiased QOL 
estimates. 
METHODS: Control groups from pilot phases of a randomised trial completed the FACT-C at 
baseline, one and three months following hospital discharge (n=57). Extent of item non-
response was examined and mean patient age compared between responders and non-
responders. A checklist was applied to determine whether the suggested simple mean 
imputation method should be used for the missing items. Complete case and multiple 
imputation methods were also compared. 
RESULTS: Missing data was greatest at one month after discharge. Non-responders were 
significantly older than responders for the items “sex life”, “diarrhoea”, and “body 
appearance”. Older age was also associated with greater levels of missing data overall. QOL 
in the social/family domain was overestimated when simple mean imputation was used for 
the “sex life” item. 
CONCLUSIONS: Older age is a risk factor for item non-response in the FACT-C, and a 
commonly used imputation method may overestimate QOL. Exploring reasons for missing 
items, checking of missing data patterns and imputation methods, and transparency of 
reporting in patient-reported outcomes research is required to ensure the QOL of older 
patients is accurately represented. 
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2.2.2. Introduction 
Missing data are inconvenient yet inevitable in most patient-reported outcomes research. 
The amount and reasons for missing data need to be determined for results to be 
appropriately analysed and interpreted. Loss of data through missing or incomplete 
questionnaires can reduce power to detect change over time or differences between 
groups. False conclusions may be drawn if there is a systematic difference between 
responders and non-responders and missing data are not handled adequately. However 
many studies reporting patient health-related quality of life (QOL) outcomes do not provide 
any details about missing data.1-3 Without transparency of reporting, the reader cannot 
determine whether authors’ conclusions are valid. 
Colorectal cancer is primarily a disease of older age, with more than half of all cases 
occurring in those over 65 years.4 Accurate measurement and reporting of QOL is 
particularly important for this growing patient group, as treatment decisions often involve 
a delicate balance between extension of life and the predicted impact of treatment on 
QOL.5,6 However, older adults appear to be at risk of inadequate and inaccurate 
measurement of QOL. Older patients are often excluded from clinical trials due to 
comorbidities or functional status limitations.7 These premorbid health conditions and a 
higher risk of postoperative morbidity8 may contribute to missing or incomplete 
questionnaires when older patients are actually included in research.9 While increasing age 
has previously been reported to be associated with item non-response in a number of QOL 
instruments,10-14 it is not often explored whether this missingness matters – that is, 
whether non-response is associated with QOL or whether it can be managed adequately 
using the methods suggested by the QOL instrument developers. Further exploration of 
these potential biases is needed to ensure that patient-reported outcomes such as QOL are 
utilized in clinical decision making2 and that the QOL of older adults undergoing cancer 
treatment is being accurately represented. 
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General guidelines do exist for the management of missing data in QOL research. Simple 
mean imputation is typically recommended when there are less than 5% missing data and 
multiple imputation when this figure is larger.15 The use of simple mean imputation when 
>50% of items in a subscale and >80% of all items are completed has been suggested for 
the commonly used Functional Assessment of Cancer Therapy (FACT) instrument.10,16 A 
syntax package that accompanies the colorectal version of this questionnaire is based on 
these calculations.17 While unquestionably useful, such recommendations may dissuade 
researchers from assessing their particular data for patterns of missingness and bias. 
Cheung and colleagues (2006) investigated the use of the simple mean imputation 
procedure for the FACT-General in a culturally-diverse Singaporean population.18 Our study 
focused on another potentially vulnerable group – older colorectal cancer patients – and 
aimed to determine 1) the extent of missing data, 2) whether age was a significant 
predictor of item non-response, and 3) whether methods commonly used to manage 
missing data produce unbiased estimates in the FACT-Colorectal quality of life instrument. 
2.2.3. Method 
Participants 
Data from control group participants of two trials of a supportive care intervention for 
people with colorectal cancer were used for the analysis.19,20 Control groups were used as 
their questionnaire completion would not be affected by the receipt of intervention. Both 
trials used identical eligibility criteria and recruitment processes, and participant 
characteristics (as listed in Table 1) did not significantly differ between the studies. All 
eligible patients who received surgery for colorectal cancer at Royal Prince Alfred Hospital, 
Sydney were invited to participate. Those who were under 18 years, had cognitive 
impairment, died during admission, or were discharged to another health facility (such as a 
hospice) were considered ineligible. All participants gave informed consent to be included 
in the trials and approval was received from their local area health services ethics review 
committees. 
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Questionnaire 
Baseline demographic and clinical information was obtained prior to discharge from 
hospital. As part of a comprehensive assessment of needs and QOL, participants self-
completed the Functional Assessment of Cancer Therapy – Colorectal (FACT-C) at baseline 
and at one and three months after discharge from hospital. 
The FACT-C is a self-report quality of life questionnaire designed for use with colorectal 
cancer patients.21 It consists of 27 core items which assess patient concerns in four 
domains: physical, social/family, emotional, and functional well-being. An additional 12 
items address site specific concerns related to colorectal cancer. Each item is rated on a 0 
to 4 Likert type scale. Item responses are combined to produce subscale scores for each 
domain, and then summed to produce a total score. Higher scores reflect better QOL. 
If missing items are present, it is suggested that subscale scores be estimated from the 
mean of the items that have been completed (simple mean imputation). This method is 
recommended only when more than 50% of the items in a subscale are answered. 
Calculating total FACT scores from subscale scores is considered appropriate as long as the 
overall item response rate is greater than 80%.16 Prorated subscale scores and total scores 
can be performed automatically using the FACT-C scoring program for SPSS or SAS.17   
Data analysis 
Extent of missing data 
Rates of non-response for each FACT-C item were tabulated. The percentage of participants 
who had none, one, two, or three or more FACT-C items missing at each time point were 
also calculated. Data from participants who were lost to follow up were excluded from 
each time point analysis. 
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Association with age 
To determine whether age was associated with missing data, the mean age of responders 
was compared to non-responders for items with greater than 5% missing data at baseline, 
one month and three months using t-tests. Similarly, t-tests were used to compare the 
mean age of participants with few missing items overall (none or one item) to those with 
more missing data (two or more items).  
Assessment of simple mean imputation 
The checklist proposed by Fayers and colleagues11 was then applied to establish whether 
the suggested simple mean imputation method would be appropriate for the data: 
(i) Patients with missing items should be similar to other patients. Part (i) was addressed 
by examining the association between missing items and patient age (as above). The 
overall QOL (mean total FACT-C score) was also compared between responders and 
non-responders for these missing items, and between those with few or more missing 
items overall. 
(ii) Items with missing data should not behave differently from other items in their 
subscale (domain) or be correlated with external factors. For part (ii), the two missing 
items most strongly associated with age were used as examples of how to apply the 
checklist: 
a) Items comprising the scale should all have similar mean values. The mean value of 
the item with missing data was compared to the mean value of the other subscale 
items. 
b) The scale should not be ordered or hierarchical. That is, where an item builds on a 
previous item e.g. “I can walk 5 metres”; “I can walk 10 metres”. 
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c) Items within a scale should be strongly correlated. A correlation matrix was used to 
determine the level of correlation between the item with missing data and other 
items in the subscale. 
d) Items should have similar between-patient standard deviations. Standard 
deviations of the missing data item and other subscale items were compared. 
e) Items should not be strongly correlated with external or baseline variables. 
Correlations between mean item scores and external factors (e.g. living 
arrangements, presence of an ostomy appliance) were examined. 
Comparison with other methods 
A complete case analysis was then used to determine the size and direction of any bias 
resulting from the use of the simple mean imputation method. For the two example items, 
answers to that item were removed from the data of complete cases then the domain 
scores were estimated using simple mean imputation. The resulting imputed mean domain 
score was then compared to the real mean domain score for the complete cases. 
Multiple imputation was also performed on the data of all participants for all of the 
domains where items were significantly associated with age, using the PROC MI command 
in SAS. Each missing value was replaced by five simulated values to reflect the uncertainty 
about imputed values.22 Multiple imputation also assumes that missingness is not 
completely random but depends on observed data (e.g. age). Thus, other items in the 
domain and participant characteristics listed in Table 1 were included in the imputation 
model. The mean domain scores for all participants produced by simple mean imputation 
and multiple imputation were compared. 
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2.2.4. Results 
The characteristics of the 57 participants are presented in Table 1. The mean age of 
participants was 63 years (median 65 years; range 27 to 86 years). 5 (9%) of the 57 
participants were lost to follow up by one month and a further 5 participants by three 
months. Of these 10 participants lost during the course of the study, 8 no longer wanted to 
participate and 2 were too sick to continue. Age and QOL in the previous assessment was 
not significantly associated with loss to follow up at either time point. 
Table 1. Characteristics of participants at baseline 
Characteristic n (%) 
Total participants 57 (100) 
Mean age in years (SD) 63 (15) 
Male 33 (58) 
Born in Australia 35 (61) 
English spoken at home 46 (81) 
High school or tertiary education 29 (51) 
Employed full or part time 24 (42) 
Private health insurance 20 (35) 
Lives alone 19 (33) 
Site of cancer  
Colon 26 (46) 
Rectosigmoid 6 (11) 
Rectal 25 (44) 
Dukes stage of cancer  
A 13 (23) 
B 15 (26) 
C 18 (32) 
D 5 (9) 
Non-cancerous tumoura 4 (7) 
Received adjuvant therapy 21 (37) 
One or more comorbid conditions 32 (56) 
aPathological stage identified after surgery and randomisation; 
 all patients surgically treated with curative intent 
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Extent of missing data 
Seven questionnaire items had a non-response rate of over 5% at either baseline, one 
month or three months after hospital discharge (see Table 2). These appeared to be the 
more sensitive or potentially “not applicable” items. The most commonly missed item was 
“I am satisfied with my sex life” (54% at one month), followed by “I feel close to my partner 
(or main support)”, “I like the appearance of my body”, “I have diarrhoea”, “I have control 
of my bowels”, “My work (including work at home) is fulfilling” and “I am losing weight”. 
For the “sex life” question, participants have the option to check a box if they prefer not to 
answer. At one month, 75% who did not answer the question checked this box (n=21). 
Table 2. FACT-C items with a non-response rate of over 5% at each time point 
 Missing data 
FACT-C item Baseline, 
n (%) 
One month, 
n (%) 
Three months, 
n (%) 
I am satisfied with my sex life 29 (51) 28 (54) 24 (51) 
I feel close to my partner (or main support) 3 (5) 11 (21) 6 (13) 
I like the appearance of my body 5 (9) 7 (13) . 
I have diarrhoea 3 (5) 6 (12) 3 (6) 
I have control of my bowels 3 (5) 6 (12) . 
My work (including work at home) is fulfilling 4 (7) 3 (6) . 
I am losing weight . 4 (8) . 
Most participants had none or only one item missing from their questionnaires. At 
baseline, 39% of participants had complete data, 33% had one item missing, 13% had two 
items missing and the remaining 13% had three or more items missing. A similar 
distribution of missing data was seen at one and three months after discharge (see Figure 
1), though there was a greater proportion of patients with three or more items missing at 
one month (21%). 
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 Figure 1. Percentage of participants with FACT-C items missing at each time point 
 
Association with age 
Non-responders were significantly older than responders for the items “I am satisfied with 
my sex life” (one and three months), “I like the appearance of my body” (baseline), and “I 
have diarrhoea” (baseline and three months) (see Table 3). Increasing age was also 
associated with greater levels of missing data overall. Those missing two or more items 
tended to be older than those with none or one item missing, although this was only 
significant at one month (mean age 69 vs 59 years, p=0.01). 
Table 3. Significant associations between age and item non-response at each time point 
Time point FACT-C item % missed item 
Mean age (SD) 
completed item 
Mean age (SD) 
missed item Test result 
Baseline Diarrhoea 5 62 (15) 80 (6) t55=2.06, p=0.04 
 Appearance 
of body 
9 62 (15) 75 (5) t55=2.02, p=0.05 
1 month Sex life 54 57 (13) 67 (14) t50=2.71, p=0.009 
3 months Sex life 51 58 (13) 66 (15) t45=2.04, p=0.05 
 Diarrhoea 6 61 (15) 81 (5) t45=2.33, p=0.02 
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Assessment of simple mean imputation 
The results of the Fayers and colleagues checklist11 for determining whether simple mean 
imputation would be appropriate for the data were as follows: 
(i) Patients with missing items should be similar to other patients. While patients with the 
missing items listed above were older than responders, the overall QOL of responders 
and non-responders only differed significantly for one of these items. At baseline, 
those who missed the “body appearance” item had a significantly lower overall QOL 
than those who responded (mean FACT-C score 66 vs 92, p=0.02). People with more 
missing items overall only tended to have poorer QOL than those with none or one 
item missing at baseline (mean FACT-C score 80 vs 92, p=0.09). 
(ii) Items with missing data should not behave differently from other items in their 
subscale (domain) or be correlated with external factors. “I am satisfied with my sex 
life” (one month) and “I have diarrhoea” (three months) were the two missing items 
most strongly associated with age and were used as examples for applying part (ii) of 
the checklist: 
a) Items comprising the scale should all have similar mean values. The “sex life” item 
had a lower mean value than other items in the social/family domain (1.3 vs >3.1). 
The “diarrhoea” item from the colorectal specific domain had a similar mean score 
to other domain items (1.7 vs 1.3-2.8). 
b) The scale should not be ordered or hierarchical. Items in the social/family or 
colorectal specific domain did not build on other items in their domain. 
c) Items within a scale should be strongly correlated. “Sex life” did not correlate 
significantly with any other items in the domain. “Diarrhoea” was significantly 
correlated with three other items in its domain (“swelling or cramps” p<0.01, 
“losing weight” p<0.01, “appetite” p<0.05). 
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d) Items should have similar between-patient standard deviations. The standard 
deviation of the “sex life” item was greater than other domain items (1.4 vs <1.0). 
For the “diarrhoea” item, the standard deviation was similar to other domain items 
(1.6 vs 1.1-1.7). 
e) Items should not be strongly correlated with external or baseline variables. “Sex 
life” scores were hypothesised to be associated with participants’ living 
arrangements. Indeed they were, with participants who lived alone having a 
significantly higher score (mean 3.0) than those who lived with others (mean 1.1) 
(p=0.03). Any imputation method should therefore allow for this factor. Scores for 
the “diarrhoea” item were not associated with presence of an ostomy appliance 
(p=0.42) or any other tested factor (age, gender, language, stage). 
Based on the checklist, it appears that using simple mean imputation method for the “sex 
life” item could lead to biased results. 
Comparison with other methods 
The complete case analysis showed that the size and direction of bias resulting from simple 
mean imputation for the “sex life” item in our dataset was a 2 point overestimate of QOL 
(see Table 4). The imputed mean social/family domain score (23.6) was significantly higher 
than the real mean domain score (21.6) for the complete cases (p<0.001). This difference is 
greater than the minimally clinically important difference for this domain.23,24 When the 
same procedure was applied to the “diarrhoea” item, the imputed and real mean colorectal 
specific domain scores for complete cases were statistically similar (14.4 vs 14.1, p=0.17).  
Simple mean imputation also produced a higher mean score than multiple imputation 
when the data of all participants were used to calculate one month social/family domain 
scores (22.6 vs 21.7, p=0.002). While only a one point difference, this multiple imputation 
score was closer to the real mean of the complete cases (21.6). The mean social/family 
domain score at three months was also overestimated by simple mean imputation  
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compared to multiple imputation (22.2 vs 21.4, p=0.008). For the colorectal specific domain 
where items were also significantly associated with age, both imputation methods 
produced similar domain scores at baseline (p=0.98) and at three months (see Table 4). 
Table 4. Two examples comparing imputation methods for mean domain scores 
aSI = simple mean imputation; bMI = multiple imputation 
2.2.5. Discussion 
In this study, non-responders were significantly older than responders for the FACT-C items 
“sex life”, “diarrhoea”, and “body appearance”. Older age was also associated with greater 
levels of missing data overall. Sensitive or potentially “not applicable” items were most 
commonly missed by all participants, and the greatest amount of missing data occurred at 
one month after discharge from hospital. QOL in the social/family domain was significantly 
overestimated when simple mean imputation was used for the “sex life” item. 
Increasing age appears to be a considerable risk factor for item non-response in QOL 
questionnaires. In our study, those missing two or more FACT-C items were significantly 
older than those with none or one item missing at one month after discharge. Similar 
findings have been noted in other reports.10,12-14 The types of items that older patients omit 
also appear to be comparable across QOL instruments. For example, questions about 
symptoms (“acid indigestion”) and the body (“self conscious when nude”) were less likely 
to be responded to by older patients in studies using the EORTC QLQ-C30.11 These items 
are similar to the “diarrhoea” and “body appearance” FACT-C items in our study. While 
these associations between age and missingness should be noted, exploring whether 
estimates of QOL are affected is of greater importance. 
 Complete cases  Non-complete cases  All participants  
FACT-C item 
(domain) 
n Mean (SD) 
score real 
Mean (SD) 
score SIa 
p n Mean (SD) 
score SIa 
 Mean (SD) 
score SIa 
Mean (SD) 
score MIb 
p 
Sex life 
(social) 
21 21.6 (3.8) 23.6 (4.4) <.001 28 23.3 (5.2)  22.6 (4.7) 21.7 (4.5) .002 
Diarrhoea 
(colorectal) 
42 14.1 (5.2) 14.4 (5.2) .17 4 20.0 (4.2)  14.6 (5.4) 14.6 (5.3) .97 
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The major concern with missing data is that QOL will be overestimated due to poorer QOL 
of non-responders.25 While older cancer patients would appear to be at risk for poorer QOL 
than younger patients due to greater morbidity, the opposite is generally reported in the 
literature.26-29 However, it is difficult to determine whether the QOL of older patients is 
being accurately represented, as many studies exclude patients with missing data or do not 
disclose analysis methods.30 In our study, those missing two or more items tended to have 
poorer overall QOL at baseline, and overall QOL was poorer for non-responders to the 
“body appearance” item. This means that QOL could be overestimated if these 
(predominantly older) people are excluded from analysis. QOL may be further 
overestimated as a result of the tendency for older adults to minimize their problems due 
to stoic attitudes31 or worries about being a burden.32 For example, older colorectal cancer 
patients are significantly more likely than their younger counterparts to report that their 
needs are “not applicable”.33 Without accurate information about their needs and QOL, 
older patients may be less likely to receive care which would enable them to better cope 
with their cancer and cancer treatment.  
Efficace and colleagues (2007) suggest that poor methodological rigour in QOL reporting 
could contribute to the underutilization of this research in clinical decision making.2 This 
may help to explain why there is considerable variation between physicians in 
chemotherapy recommendations for otherwise healthy older colorectal cancer patients,34 
despite reports that QOL is not significantly impacted.35 While the quality of QOL reporting 
has improved over time,2 missing data was addressed in less than a third of randomized 
controlled trials with QOL outcomes from 2002-20081 and non-response is not mentioned 
in a validation study of the FACT-G for older patients with cancer.36 In our study of the 39 
item FACT-C, the majority of participants had none or only one or two items missing (85%). 
This is similar to the findings of Fairclough and colleagues (1996) for the 28 item FACT-G, 
where 90% of participants answered all or missed only one item.10 This amount of non-
response may not impact on a large study’s power to detect differences, but can be a 
problem for small pilot studies if missing data are not managed.  
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Sexuality items appear to cause the most difficulty in QOL assessment. Considerable non-
response rates to such items have been noted in studies using the Rotterdam Symptom 
Checklist11 and on the FACT-G in a Singaporean population.18 More than half of participants 
did not respond to the “sex life” question at all time points in our study. A psychometric 
analysis of the Spanish version of the FACT-G revealed that the “sex life” question did not 
fit well with other items.37 In our study, the “sex life” item had a lower mean score, greater 
standard deviation and low correlation with other items in the social/family domain. Simple 
mean imputation may therefore result in biased estimates as the average of other items in 
the domain is used to estimate the subscale score.11 The complete cases analysis showed 
that the size and direction of the bias from simple mean imputation in the social/family 
domain was a 2 point overestimate of mean QOL, which is greater than the reported 
minimally clinically important difference for this domain.23,24 Simple mean imputation also 
produced a higher estimate than multiple imputation for the mean social/family domain 
score of all participants. This means that the QOL of older patients, who are less likely to 
complete the “sex life” item, may be overestimated in this domain if the suggested simple 
mean imputation method is used. 
Exclusion of the “sex life” item when calculating domain scores has been suggested.18 
However exploring the reasons why older participants do not answer certain questions may 
provide insights for how to manage this question without losing information on an 
important aspect of cancer recovery. In our study, 75% of those who did not answer the 
“sex life” item checked a box to indicate that they “preferred not to answer it”. Older 
patients may have found the question too personal or offensive, or they may have felt that 
this question was not applicable to them, being more likely to live alone and perhaps 
viewing sexuality as dependent on having a partner. The 25% of non-responders who did 
not check the “prefer not to answer” box could have less systematic reasons for missing 
that particular item. Ageing issues such as poorer eyesight and cognitive or physical 
difficulties are possible explanations for missingness that is not item specific.9 
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Prevention is usually preferable to analytical cure. Missing data may be reduced through 
selecting QOL assessment tools with a known higher item response rate in older 
patients.38,39 Age-specific instruments for the assessment of QOL issues that are unique to 
older adults have also been proposed,3 though missingness does not appear to have been 
addressed as yet in the recently developed EORTC QLQ-ELD15 questionnaire for older 
patients.40 Where research involves patients of all ages, other suggested prevention 
strategies include using practice questions41 and considering where assessment takes 
place.42 In our study, the FACT-C may have had higher non-response rates as it was the last 
questionnaire in a comprehensive assessment of needs and QOL. Compliance with QOL 
assessment can also be affected by different factors at various time points.43 The greater 
item non-response occurring at one month after hospital discharge in our study may 
indicate that this is a difficult time period for cancer patients, where greater attention to 
individual QOL is required and where particular care should be taken in evaluating non-
response. 
This was a small study and analysis of missingness was not an a priori aim. Nevertheless, 
increasing age was associated with non-response for a number of items, and using simple 
mean imputation as suggested for the FACT-C resulted in overestimates of QOL scores. 
While guidelines for analysis methods are useful, patterns of missing data should be 
checked in all datasets to avoid biased results. Multivariable analysis for non-response was 
also not performed in our study, meaning that other factors could be influencing 
missingness. Nevertheless, older patients represent an at-risk group who should be 
considered during study design to ensure that valuable information is not lost. Ultimately, 
greater transparency of reporting is needed so that readers can assess whether the QOL of 
those at risk of missing data is being accurately represented. 
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3 
Local context 
 
 
This chapter examines the effect of patient age on receipt of adjuvant therapy in NSW. 
While age differences in adjuvant therapy receipt have been documented extensively 
worldwide, it is important to routinely monitor the treatment of at-risk patient groups as 
well as identify other local factors that may hinder or facilitate adjuvant therapy use. 
This study is one of the first analyses to use treatment data from the NSW Clinical Cancer 
Registries (ClinCR). ClinCRs were established in five health service areas in 2006, with a 
sixth registry commencing in 2007. Data are collected for patients treated within public 
facilities only. Items comprise a minimum data set developed by NSW Oncology Groups. 
Because the combined registry data have not been used previously, considerable data 
cleaning and harmonisation was required. The quality and usefulness of the data was 
examined before the commencement of the current study, with consultation from an 
advisory group of data managers, coders, and clinicians. Further information is available in 
Appendix 3.1 and in a full report online: http://ses.library.usyd.edu.au/handle/2123/8936 
This chapter is presented as the following paper: 
Jorgensen ML, Young JM, Dobbins TA, Solomon MJ. Does patient age still affect receipt of 
adjuvant therapy for colorectal cancer in New South Wales, Australia? Journal of Geriatric 
Oncology. [Accepted] 
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Does patient age still affect receipt of adjuvant therapy for colorectal cancer in New South 
Wales, Australia? 
3.1. Abstract 
OBJECTIVES: To investigate the effect of patient age on receipt of stage-appropriate 
adjuvant therapy for colorectal cancer in New South Wales, Australia. 
MATERIALS AND METHODS: A linked population-based dataset was used to examine the 
records of 580 people with lymph node-positive colon cancer and 498 people with high-risk 
rectal cancer who underwent surgery following diagnosis in 2007/2008. Multilevel logistic 
regression models were used to determine whether age remained an independent 
predictor of adjuvant therapy utilisation after accounting for significant patient, surgeon 
and hospital characteristics. 
RESULTS: Overall, 65-73% of eligible patients received chemotherapy and 42-53% received 
radiotherapy. Increasing age was strongly associated with decreasing likelihood of receiving 
chemotherapy for lymph node-positive colon cancer (p<0.001) and radiotherapy for high-
risk rectal cancer (p=0.003), even after adjusting for confounders such as Charlson 
comorbidity score and ASA physical health status. People aged over 70 years for 
chemotherapy and over 75 years for radiotherapy were significantly less likely to receive 
treatment than those aged less than 65. Emergency resection, intensive care admission, 
and not having a current partner also independently predicted chemotherapy nonreceipt. 
Other predictors of radiotherapy nonreceipt included being female, not being discussed at 
multidisciplinary meeting, and lower T stage. Adjuvant therapy rates varied widely between 
hospitals where surgery was performed. 
CONCLUSION: There are continuing age differences in adjuvant therapy utilisation in NSW 
that are not explained by patients’ comorbidities or health status. Further exploration of 
these complex treatment decisions is needed. Variation by hospital and patient 
characteristics indicates opportunities to improve patient care and outcomes. 
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3.2. Introduction 
Colorectal cancer is primarily a disease of ageing, with those over 65 years accounting for 
two-thirds of all incident cases.1 Surgical resection is the mainstay of curative treatment. To 
reduce the risk of recurrence after surgery, current clinical practice guidelines recommend 
that all lymph node-positive colon cancer cases be considered for adjuvant chemotherapy, 
and all high-risk (T3-4 or N+) rectal cases be considered for adjuvant preoperative or 
postoperative radiotherapy, regardless of patient age.2 However, increasing age was an 
independent predictor of non-concordance with adjuvant treatment guidelines in a 
patterns of care study conducted in the state of New South Wales (NSW), Australia in 
2000.3 Similar findings have been reported internationally.4-7  
The collection of patient and treatment information to determine patterns of care often 
requires resource- and time-intensive surveys of clinicians or medical record audits. There 
is now potential to conduct such studies in NSW using routinely collected data. Clinical 
Cancer Registries (ClinCR) have been in operation in public facilities in NSW since 2006 and 
contain comprehensive staging and treatment information that is not routinely collected 
elsewhere. When linked to other health datasets, ClinCR data may be able to be used to 
monitor the uptake of evidence-based guidelines and identify those at risk of suboptimal 
treatment.  
Determining whether treatment variation is due to patient, physician or hospital 
characteristics requires the use of multilevel modelling techniques and adequate 
adjustment for factors such as preoperative health. This often does not occur in 
population-based studies. Since rates of appropriate treatment among older colorectal 
cancer patients appear to be increasing over time,8,9 it is also important to routinely 
examine whether age remains a barrier to the implementation of evidence-based cancer 
care. 
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The aim of this study was to use a linked population-based dataset to examine the effect of 
patient age on the receipt of stage-appropriate adjuvant therapy for colorectal cancer in 
NSW. 
3.3. Materials and methods 
Data source 
One-third of Australia’s population resides in NSW. People with a colon, rectosigmoid 
junction or rectal cancer mandatorily registered by the population-based NSW Central 
Cancer Registry (CCR) in 2007 and 2008 formed the basis of a linked dataset. Hospital 
separations data from the NSW Admitted Patients Data Collection (APDC) and records from 
the NSW Registry of Births, Deaths and Marriages (RDBM) were linked by the Centre for 
Health Record Linkage (CHeReL) to the CCR cohort. Linkage to the Clinical Cancer Registry 
(ClinCR) was also possible for 85% of people receiving surgery in a public hospital in 2008,10 
providing in-depth information on cancer staging, adjuvant therapy, and specialist 
consultations that was not available in the CCR. These data are based on a minimum 
dataset that is collected locally then collated through a central information exchange. The 
cohort was restricted to the first unique cancer of any person who had an admission for a 
surgical resection in the month of their diagnosis or thereafter. The study was approved by 
the NSW Population & Health Services Research Ethics Committee. 
Determining chemotherapy and radiotherapy receipt 
Because chemotherapy and radiotherapy data are only available from the ClinCR, those 
receiving surgery in private hospitals and the two area health services where ClinCR data is 
not collected were excluded (see Figure 1).  
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Figure 1. Flowchart defining the denominator for receipt of adjuvant chemotherapy and 
radiotherapy 
 
*Private hospitals and Greater Western/Greater Southern Area Health Service  
According to current national clinical practice guidelines, all lymph node-positive (N+M0 or 
stage III) colon cancer cases should be considered for adjuvant chemotherapy, and all high-
risk rectal cases (T3-4N0M0 or T1-4N+M0 or stage II/III) should be considered for adjuvant 
preoperative or postoperative radiotherapy.2 Those with any other stage of cancer at 
diagnosis were excluded from the cohort. People with colon cancer who died during 
admission for their resection were also excluded as they could not receive postoperative 
chemotherapy. Rectosigmoid junction cancers were not included in the analysis, as there is 
a lack of consensus in the literature on whether these cancers should be classified with 
colon or rectal cancers. All those with a ClinCR record containing any details of 
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chemotherapy commencement (for node-positive colon) or radiotherapy commencement 
(for high-risk rectal) were considered to have received adjuvant therapy. 
Identifying predictors of chemotherapy and radiotherapy receipt 
Multivariable cross-classified multilevel logistic regression models were used to determine 
predictors of receipt of chemotherapy and radiotherapy.11 Because surgeon and hospital 
data were available, three-level models were fitted to take into account the clustering of 
patients by surgeon and the clustering of surgeons within hospitals. Cross-classified models 
were used as some surgeons performed resections at more than one hospital. Any 
available patient, surgeon or hospital characteristic that indicated a possible univariate 
relationship with adjuvant therapy use (p<0.25) were initially included in multivariable 
models. Characteristics are listed in Tables 1 and 2, and included Charlson comorbidity 
score,12 socioeconomic disadvantage (SEIFA),13 remoteness (ARIA),14 and surgeon and 
hospital caseload (divided into patient quintiles). Backwards elimination was used to 
exclude non-significant predictors one at a time until all variables were significant (p<0.05) 
or their exclusion worsened model fit.  
Sensitivity analyses 
Although those undergoing surgery in a private hospital were excluded from the ClinCR 
cohort, some people may have received adjuvant treatment in a private facility that was 
not recorded in the ClinCR. A series of sensitivity analyses were undertaken to examine the 
potential impact of missing treatment and covariate data. 
1) Chemotherapy sensitivity model: It is likely that many people receiving chemotherapy 
in the private sector would have private health insurance, as Australians are entitled to 
treatment free of charge in public hospitals. For this sensitivity model, all those with 
private insurance or no insurance status recorded were additionally assumed to have 
received chemotherapy. 
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2) Radiotherapy sensitivity model: Outpatient radiotherapy is not covered by private 
health insurance, however there were only 18 facilities (5 private) that a patient could 
attend in NSW in 2008.15 For this model, all patients whose nearest radiotherapy centre 
was private were additionally assumed to have received radiotherapy. A patient’s 
nearest facility was calculated based on road distance between postcode centres using 
GIS software. 72.8% of people who had radiotherapy recorded attended their nearest 
radiotherapy centre. 
3) Health status sensitivity models: Poor functional status predicts treatment outcomes 
independently of comorbidity and age.16 A measure of functional status, the Eastern 
Cooperative Oncology Group (ECOG) performance status, was only recorded for 24.6% 
of the ClinCR cohort. The American Society of Anesthesiologists (ASA) physical health 
status score may be a useful alternative17 and was available for 83.8% of the cohort. 
However, it could not be included in the original models as the characteristics of those 
who had ASA recorded differed from those who did not. Additional complete-case 
models including ASA score were therefore built for both chemotherapy and 
radiotherapy receipt, to determine whether age remained a significant predictor when 
a measure of health status was included. 
Comparing rates of oral chemotherapy to a secondary data source 
Capecitabine, an orally-administered chemotherapy drug, was approved for use as a single-
agent adjuvant treatment for stage III colon cancer in 2005. There was concern about the 
adequacy of recording of capecitabine, as it does not require a physical consultation for 
administration and prescription rates increase with patient age.18 Rates of solitary 
capecitabine use in the ClinCR cohort were therefore compared to another data source 
that has been used previously to describe adjuvant therapy use.19 The Biogrid Australia 
Colorectal Cancer Database is a prospective data repository that contains detailed 
information on staging and treatment from five hospitals in Victoria and Tasmania, 
Australia. Data for those diagnosed with stage III colon cancer from 2006 to 2009 (inclusive) 
were used. 
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3.4. Results 
Of the state-wide cohort of 6,890 people with colorectal cancer treated in 105 hospitals, 
3,294 (47.8%) had a ClinCR record that could be used to determine adjuvant therapy 
receipt. People who had a ClinCR record were similar to those who did not have a ClinCR 
record with regard to sex, age, and site of cancer (all p>0.05, see Table 1). However, people 
with a ClinCR record were significantly more likely to be disadvantaged, have no private 
health insurance, have had their resection following emergency admission, have a higher 
Charlson comorbidity score, and live in a less remote location. 
Rates of chemotherapy and radiotherapy receipt 
Of 580 people with lymph node-positive colon cancer in the ClinCR cohort, 65.2% had a 
chemotherapy ClinCR record (95% CI: 61.3-69.1%). There was a steady decline in 
chemotherapy receipt by increasing age (see Figure 2). Of 498 people with high-risk rectal 
cancer, 41.6% had a radiotherapy record (95% CI: 37.2-45.9%). Radiotherapy rates 
decreased with increasing age, though not as markedly as for chemotherapy. 
In the chemotherapy sensitivity analysis, where all people with private health insurance 
were assumed to have received treatment, the estimated proportion receiving 
chemotherapy increased to 72.6% (95% CI: 68.9-76.2%). In the radiotherapy sensitivity 
analysis, where all people whose nearest radiotherapy centre was private were assumed to 
have received treatment, estimated radiotherapy use increased to 53.2% (95% CI: 48.8-
57.6%). 
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Table 1. Characteristics of patients receiving surgery for colorectal cancer in NSW, 2007-08 
 ClinCR cohort, n (%) Rest of NSW, n (%) p value 
Sex   0.754 
Male 1,795 (54.5) 1,946 (54.1)  
Female 1,499 (45.5) 1,650 (45.9)  
Age at diagnosis (mean/SD) 68.7 (12.5) 68.3 (11.9) 0.145 
0-59 732 (22.2) 810 (22.5)  
60-69 857 (26.0) 1,055 (29.3)  
70-79 1,029 (31.2) 1,046 (29.1)  
80+ 676 (20.5) 685 (19.0)  
Site of cancer   0.964 
Colon 2,201 (66.8) 2,411 (67.0)  
Rectosigmoid junction 274 (8.3) 301 (8.4)  
Rectum 819 (24.9) 884 (24.6)  
Socioeconomic disadvantage (SEIFA)*   <0.001 
1 Least disadvantaged 533 (16.2) 860 (23.9)  
2 616 (18.7) 570 (15.9)  
3 604 (18.3) 848 (23.6)  
4 776 (23.6) 792 (22.0)  
5 Most disadvantaged 764 (23.3) 522 (14.5)  
Remoteness (ARIA)   <0.001 
Highly accessible 2,554 (77.5) 2,153 (59.9)  
Accessible 592 (18.0) 1,044 (29.0)  
Moderately accessible/remote 148 (4.5) 399 (11.1)  
Discharged to nursing home 62 (1.9) 23 (0.6) <0.001 
Born in Australia 2,093 (63.5) 2,850 (79.3) <0.001 
Private health insurance 666 (20.2) 2,644 (73.5) <0.001 
Resection following emergency admission 539 (16.4) 127 (3.5) <0.001 
Degree of spread of cancer*   <0.001 
Localised 1,143 (34.7) 1,468 (40.8)  
Regional spread 1,618 (49.1) 1,625 (45.2)  
Distant metastasis 523 (15.9) 337 (9.4)  
Charlson Index (comorbidity)   <0.001 
0 2,665 (80.9) 3,132 (87.1)  
1 313 (9.5) 259 (7.2)  
2 176 (5.3) 136 (3.8)  
3+ 140 (4.3) 69 (1.9)  
Hospital type   - 
Public 3,294 (100.0) 943 (26.2)  
Private - 2,653 (73.8)  
Hospital location   <0.001 
Metropolitan 2,637 (80.1) 2,101 (58.4)  
Rural/regional 657 (19.9) 1,495 (41.6)  
*Some data missing 
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Figure 2. Unadjusted rates of chemotherapy and radiotherapy receipt by age group 
 
Predictors of chemotherapy and radiotherapy receipt 
Table 2 presents the results of the multivariable models for treatment receipt. Increasing 
age was a significant independent predictor of decreasing chemotherapy use, both in the 
original and chemotherapy sensitivity models (p<0.001). After adjustment, those aged 70-
74 (OR=0.36), 75-79 (OR=0.18), 80-84 (OR=0.12) and 85+ (OR=0.04) were significantly less 
likely to receive chemotherapy than those aged less than 65. People with higher Charlson 
comorbidity score, emergency resection, those admitted to intensive care after their 
surgery, and people without a current partner were also significantly less likely to receive 
adjuvant chemotherapy. In the chemotherapy sensitivity model, socioeconomic status was 
an additional significant predictor of treatment receipt. This predictor may be partly 
explained by higher rates of private insurance among people with higher SES, given that the 
sensitivity model assumed that all those with private insurance received chemotherapy. 
For radiotherapy, increasing age was also an independent predictor of underutilisation in 
both the original (p=0.003) and radiotherapy sensitivity models (p=0.017). Significant age 
differences only emerged for those over 75 years however. Other independent predictors 
of radiotherapy receipt included being discussed at a multidisciplinary team (MDT) 
meeting, being male, having higher T stage (T3/T4 vs. T2), and having an abdominoperineal 
resection or ultra-low anterior resection (both indications for low rectal cancer). These  
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predictors were the same in the radiotherapy sensitivity model, where radiotherapy was 
assumed for all those whose closest facility was private. Distance to nearest radiotherapy 
facility was not an independent predictor in either of the models. 
In the health status sensitivity model that included ASA score, age remained an 
independent predictor of both chemotherapy (p<0.001) and radiotherapy receipt 
(p=0.006). People with poorer health status were significantly less likely to receive 
chemotherapy (p=0.015) but not radiotherapy (p=0.096) in these models. 
Model statistics are displayed in Table 2. All models had good discrimination (area under 
ROC curve > 0.80). While rates of adjuvant therapy varied widely by surgeon, most of this 
variation was accounted for by adding the hospital where surgery was performed into the 
models. In the radiotherapy model, approximately 28% of the total variability in 
radiotherapy receipt was attributable to hospitals (ICC=0.28), 2% was attributable to 
surgeons and the remaining 70% to patient characteristics. For chemotherapy, most of the 
variability was attributable to patient characteristics (≈84%), with hospital of surgery 
accounting for the remaining variability (ICC=0.16).  
Comparison of rates of oral chemotherapy to a secondary data source 
In the ClinCR cohort, 23.3% of those who had chemotherapy had capecitabine alone 
recorded. An additional 8.5% did not have any drug specified. Rates of capecitabine use 
were greatest for those aged 70-79 (38.3%). In the Biogrid cohort (mean age 66.9 years 
(SD=12.6), 55.8% male, 68.0% colon cancer), 104 of 146 people with stage III colon cancer 
had chemotherapy recorded (71.2%). Of these people, 24.0% received capecitabine as a 
single agent treatment. This rate was not significantly different from the rate of solitary 
capecitabine use recorded in the ClinCR cohort (χ2[1]=0.02, p=0.896). 
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Table 2. Results of multivariable models for receipt of adjuvant chemotherapy and 
radiotherapy 
 Chemotherapy (node-positive colon) Radiotherapy (high-risk rectal) 
 
CTx recorded 
OR (95% CI) 
Sensitivitya 
OR (95% CI) 
RTx recorded 
OR (95% CI) 
Sensitivitya 
OR (95% CI) 
Age at diagnosis (ref=<65 years) p<0.001 p<0.001 p=0.003 p=0.017 
65-69 0.58 (0.28-1.21) 0.40 (0.19-0.87) 0.59 (0.30-1.18) 0.75 (0.37-1.51) 
70-74 0.36 (0.18-0.74) 0.34 (0.16-0.73) 0.55 (0.27-1.12) 0.72 (0.35-1.48) 
75-79 0.18 (0.09-0.35) 0.19 (0.09-0.39) 0.44 (0.21-0.93) 0.46 (0.22-0.95) 
80-84 0.12 (0.06-0.24) 0.14 (0.07-0.29) 0.19 (0.07-0.47) 0.26 (0.11-0.61) 
85+ 0.04 (0.02-0.11) 0.09 (0.04-0.21) 0.24 (0.08-0.76) 0.34 (0.12-0.95) 
Charlson comorbidity (ref=0) p=0.008 p=0.071 p=0.373 p=0.223 
1 0.34 (0.16-0.72) 0.52 (0.25-1.08) 0.93 (0.40-2.14) 0.97 (0.43-2.17) 
2 0.75 (0.29-1.94) 1.01 (0.40-2.55) 0.75 (0.24-2.31) 1.39 (0.46-4.20) 
3+ 0.28 (0.09-0.89) 0.31 (0.10-0.94) 0.24 (0.05-1.21) 0.24 (0.06-1.00) 
Marital status (ref=Partner) p=0.023 p=0.004 - - 
No current partner  0.60 (0.39-0.93) 0.52 (0.34-0.81)   
Intensive care (ref=No) p=0.024 p=0.007 - - 
Yes 0.51 (0.29-0.91) 0.47 (0.27-0.81)   
Emergency resection (ref=No) p=0.047 p=0.773 - - 
Yes 0.60 (0.36-0.99) 0.93 (0.55-1.55)   
SEIFA (ref=1 Least disadvantaged) p=0.338 p=0.049 - - 
2 1.06 (0.47-2.41) 0.94 (0.40-2.21)   
3 0.72 (0.30-1.72) 0.38 (0.16-0.90)   
4 1.58 (0.66-3.78) 0.77 (0.32-1.84)   
5 Most disadvantaged 0.97 (0.41-2.29) 0.47 (0.20-1.13)   
Sex (ref=Male) - - p=0.002 p<0.001 
Female   0.44 (0.26-0.73) 0.42 (0.25-0.69) 
T stage (ref=T2) - - p=0.003 p<0.001 
T3   3.91 (1.75-8.75) 4.24 (2.02-8.86) 
T4   2.75 (0.97-7.76) 1.87 (0.69-5.02) 
Type of resection (ref=Other) - - p<0.001 p=0.014 
Abdominoperineal excision   3.77 (1.97-7.25) 2.51 (1.31-4.80) 
Ultra-low anterior resection   1.82 (1.03-3.24) 1.64 (0.91-2.94) 
Discussed at MDT (ref=No) - - p<0.001 p=0.004 
Yes   3.12 (1.78-5.47) 2.36 (1.33-4.20) 
Model statistics     
Discrimination (area under curve) 0.85 (0.81-0.88) 0.82 (0.78-0.86) 0.86 (0.83-0.89) 0.86 (0.83-0.90) 
Calibration (Hosmer-Lemeshow χ2) 7.81, p=0.648 8.22, p=0.607 8.13, p=0.616 11.34, p=0.332 
Surgeon variance (SE), [ICC]b 0 0 0.11(0.22),[0.02] 0.11(0.22),[0.02] 
Hospital variance (SE), [ICC]b 0.61(0.29),[0.16] 0.41(0.22),[0.11] 1.32(0.59),[0.28] 2.46(1.14),[0.42] 
aReceipt assumed for all those with private insurance (for CTx) or whose nearest treatment centre was private (for RTx) 
b Intraclass correlation coefficient (ICC): estimated proportion of total variability attributable to surgeons or hospitals 
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3.5. Discussion 
Chronological age was an independent predictor of receipt of stage-appropriate adjuvant 
therapy across all models. After adjusting for confounders, people aged over 70 years for 
chemotherapy and over 75 years for radiotherapy were significantly less likely to receive 
treatment than those aged less than 65. While much of the variation in adjuvant therapy 
utilisation was due to patient characteristics, the hospital where surgery was performed 
accounted for a considerable proportion of variation in these patterns of care. This 
indicates that there are opportunities to improve care at both a hospital and patient level. 
Linked administrative health data may be more useful for routinely monitoring patterns of 
treatment than data collected though other methods, as it is less resource intensive, 
potentially timelier, and removes some of the bias that may occur through the self-
selection of physicians into surveys or the use of single area data.20 ClinCR data from local 
districts have been used previously to determine adjuvant therapy use.21 However, the 
quality of recording of treatment receipt across the combined registry requires validation. 
Potential undertreatment of older patients through reduced dose or early discontinuation 
could also not be explored as these data are incomplete in the ClinCR at present.10 While 
the current analysis was restricted to those who received surgery in a public hospital, the 
original models likely underestimate utilisation rates due to the collection of ClinCR data in 
public facilities only, and the sensitivity models likely overestimate rates by assuming 
everyone with private insurance or living near a private facility received adjuvant therapy. 
The present coverage of the ClinCR data also limits the ability to extrapolate the estimates 
to the whole state. Underestimates may result from the ClinCR subset being more 
disadvantaged than the state-wide cohort and so less likely to receive treatment,5 though 
the absence of data for two rural areas may mean state figures are overestimated, as travel 
distance has been reported to be a barrier to treatment.22 Nonetheless, the available data 
account for half of the treated cases in NSW, and may be useful for monitoring patterns of 
care in the public hospitals it is collected. The above issues are also more likely to increase 
age differences than reduce them. 
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Results from previous state-wide and other international population-based research 
suggest that our estimates of overall chemotherapy use (65-73%) and radiotherapy use 
(42-54%) are reliable. In a clinician survey conducted in NSW in 2000, 59% of node-positive 
colon cancer patients received chemotherapy and 33% of high-risk rectal cancer patients 
received radiotherapy.23 The current results represent a considerable increase on these 
figures, consistent with reported trends for increasing utilisation over time. The results are 
also comparable to internationally reported rates of chemotherapy use for node-positive 
colon cancer of between 56% and 75%4,5,24,25 and rates of radiotherapy use for high-risk 
rectal cancer of between 45% and 63%.6,7,9,26 The accuracy of our estimates is additionally 
supported by the similar rates of oral capecitabine to the Biogrid dataset, a high proportion 
of younger patients receiving chemotherapy as in the previous NSW study,23 and similar 
predictors of chemotherapy and radiotherapy receipt to other studies.3,4,7,27 
In our study, people over age 70 without significant comorbidity were less likely to receive 
adjuvant chemotherapy, despite having a life expectancy of up to 9 years.28 The reason for 
the apparent underutilisation of adjuvant therapy among older adults is likely multifaceted. 
Previous research suggests that both surgeons and oncologists are less likely to 
recommend chemotherapy for older patients on the basis of age alone.29,30 The magnitude 
of these age differences increases for patients with comorbidities, where there is emerging 
but less definitive evidence for treatment tolerance and less potential survival benefit. The 
current study was unique in determining whether variation in treatment receipt occurred 
at the level of the surgeon or hospital. Lack of variation across surgeons in adjuvant 
chemotherapy rates when accounting for hospitals and patient characteristics indicates 
that surgeons may hold similar preferences against the referral of older patients and those 
with comorbidity. The unexplained hospital variation after accounting for patient 
predictors could point to differing practices of oncologists or MDTs, breakdowns in the care 
pathway, or unmeasured patient characteristics such as treatment refusal, which 
accounted for up to 10% of patients in a previous NSW study.23 Routine recording of 
reasons for non-receipt is needed to further illuminate the continuing barriers to evidence-
based care for all patients. 
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Determining whether patient age is an independent predictor of care requires adequate 
adjustment for factors that are associated with ageing and may impact treatment 
outcomes, such as poor functional status. Most population-based studies only include a 
measure of comorbidity. In the current study, older adults were significantly less likely to 
receive treatment after additionally adjusting for ASA physical health status, however more 
complete data or the inclusion of other measures of daily function or physiologic reserve 
could reduce the effect of age in the models. In addition, it is likely that some comorbidities 
were underascertained from the administrative data.20 While a validated comorbidity index 
was used to increase the comparability of findings across studies, the non-linear association 
between Charlson score and chemotherapy receipt both in this study and elsewhere31 
suggests that clinicians may weigh specific comorbidities differently in chemotherapy 
decision making than in the original mortality index. 
Identifying factors that contribute to differences in the treatment of older patients also 
provides insight into ways to facilitate better care. Having a current partner was an 
independent predictor of chemotherapy receipt in our study, as in previous research.32 
Increasing access to social support programs for older people, who are more likely to live 
alone, may improve their treatment and outcomes. Similarly, discussion at multidisciplinary 
team meeting was associated with increased radiotherapy use in the current study, as in 
previous research.33 Greater implementation of MDTs would likely result in better care as 
well as survival.34 Interestingly, those in the middle of the socioeconomic strata were the 
least likely to receive chemotherapy. This may reflect the access to care in major public 
tertiary institutions that is available to the most disadvantaged as part of Australia’s 
universal healthcare system. Even with this safety net, however, it appears that many older 
patients are not receiving the recommended standard of care. 
While it is clear that adjuvant chemotherapy for colon cancer substantially increases 
disease-free and overall survival,35 the magnitude of survival benefit from radiotherapy in 
rectal cancer is reported to be relatively small.36 Increases in local control due to the  
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introduction of improved rectal surgery techniques such as total mesorectal excision could 
mean that physicians decide the small additional survival benefits are not always worth the 
potential morbidity. The overall lower rates of radiotherapy use compared to 
chemotherapy use in the current study may reflect this uncertainty. The dependence of 
radiotherapy receipt on type of resection, and the variation attributed to rectal surgeons in 
our models, further indicate that surgery-related factors must be considered if the targets 
for optimal radiotherapy utilisation in rectal cancer37 are to be met.  
Despite increases on previous state-wide rates of adjuvant therapy utilisation and universal 
health care coverage, there are continuing age differences in this aspect of evidence-based 
care in NSW that are not explained by patients’ comorbidities or health status. Further 
exploration and support for these complex treatment decisions is needed to improve the 
survival outcomes of older colorectal cancer patients. Though limitations exist, the 
routinely collected dataset used in this study provides a useful way to identify and monitor 
at-risk patient groups in the hospitals it is collected. Feedback on comparative performance 
to providers may be a starting point to reducing variation in care. 
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Appendix 3.1. Additional information about the NSW ClinCR 
Clinical cancer registries (ClinCR) were established in five Area Health Services (AHS) (North 
Coast, Northern Sydney Central Coast, South Eastern Sydney Illawarra, Sydney South West, 
and Sydney West AHS) in 2006, and in Hunter New England AHS in 2007. Clinical Cancer 
Registries were not established in Greater Southern AHS or Greater Western AHS. Each 
ClinCR is managed locally, with data collection, data entry, quality control and data 
governance the responsibility of the AHS. The ClinCR covers only patients treated within 
public facilities within the AHS. However, a major strength of this dataset is the depth of 
clinical information collected. Data items contained in the ClinCR include: 
• Demographic details: sex, age, country of birth, postcode, indigenous status 
• System details: AMO registration number, facility code 
• Diagnostic and staging items: date of diagnosis, primary site of cancer, best basis for 
diagnosis, histopathological grade, morphology, degree of spread, TNM staging 
• Clinical details: performance status at diagnosis, date of death, cause of death 
• Treatment items: date of admission, date of discharge, ICD-10-AM procedure codes, 
date of radiotherapy start, date of radiotherapy end, radiotherapy type, dose and 
fractions, date of systemic therapy start, date of systemic therapy end, systemic 
protocol, number of cycles, date of referral to cancer specialist, date of consultation 
with specialist, date of decision to treat, date of clinical trial enrolment, date of MDT 
meeting, date of referral to palliative care, psycho-social referral to (type) 
Creation of collated ClinCR dataset. Many data items were common across all ClinCRs, 
however some were unique to individual area datasets and many were recorded in 
different ways. Data were harmonised to best resemble the current data dictionary and to 
enable stacking (combining) of the datasets. This process included standardising data item 
names, cleaning erroneous data, standardising default codes, transforming data recorded 
as text strings to standard codes, determining meaning of area-specific coding not recorded 
in the minimum dataset dictionary and reassigning codes, standardising items where 
different coding systems had been used (e.g. systemic protocol).   
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4 
The surgeon 
 
 
In Chapter 3, increasing age was strongly associated with decreasing likelihood of receiving 
guideline-recommended adjuvant therapy. Multilevel modelling accounting for patient and 
hospital characteristics revealed that surgeons may hold similar preferences against the 
referral of older patients. This chapter outlines the findings of a self-administered survey of 
Australian and New Zealand colorectal surgeons. The survey aimed to determine surgeon’s 
knowledge, opinions and self-reported practice regarding referral for, and use of, adjuvant 
therapy for older patients. 
The study also contained a randomised comparison of postal and internet survey methods 
on surgeon response rates, survey completeness, and characteristics of responders. The 
findings of this study are reported in Appendix 4.2, and an example screenshot of the 
online version of the survey is provided in Appendix 4.3. A copy of the postal survey is 
available in Appendix 4.4. 
This chapter is presented as the following paper: 
Jorgensen ML, Young JM, Solomon MJ. Older patients and adjuvant therapy for colorectal 
cancer: surgeon knowledge, opinions, and practice. Diseases of the Colon & Rectum 2011; 
54(3): 335-41.  
Available: http://journals.lww.com/dcrjournal/Abstract/2011/03000/Older_Patients.13 
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Older patients and adjuvant therapy for colorectal cancer: surgeon knowledge, opinions, 
and practice 
4.1. Abstract 
BACKGROUND: Increasing patient age independently predicts non-referral and non-receipt 
of adjuvant therapy among patients with colorectal cancer. This study aimed to identify 
factors affecting surgeons’ decisions to refer older patients for adjuvant therapy. 
METHODS: A self-administered survey was sent to all Australian and New Zealand 
colorectal surgeons (n=146). The survey consisted of three sections: 1) knowledge of 
research evidence, 2) opinions on evidence and adjuvant therapy in older patients, and 3) 
self-reported practice, or likelihood of patient referral in different scenarios. Demographic 
information was also obtained. 
RESULTS: Seventy percent of surgeons responded. Surgeons were significantly less likely to 
refer older patients than younger patients for adjuvant therapy in all scenarios (p<0.001). 
The difference in referral recommendations was greatest when patients lived a long way 
from treatment, had a comorbid condition, or had little social support. There was greater 
variation in referral recommendations for older patients, and marked disagreement 
between surgeons in knowledge and opinion questions. Surgeon age was the only 
significant predictor of survey responses. Greater knowledge and more positive opinions 
predicted similar referral recommendations for older and younger patients (p=0.02, 
p=0.01). 
CONCLUSIONS: Chronological age alone appears to impact colorectal surgeons’ decisions to 
refer patients for adjuvant therapy. Sociodemographic and physiological factors further 
decrease the likelihood of referral of older patients. A lack of consensus among surgeons 
suggests that more research is needed both to predict how older patients with cancer will 
react to treatment, and to determine how information from emerging evidence can be best 
used to assist physicians’ treatment decisions. 
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This is a non-final (post-print accepted) version of an article published in final form in  
Diseases of the Colon & Rectum 2011; 54(3): 335-341. 
4.2. Introduction 
More than half of all colorectal cancer (CRC) cases occur in those over 70 years of age.1 
However, older patients may be at risk for receiving suboptimal care. Patients over 70 years 
are significantly less likely to receive adjuvant therapy than younger patients, even after 
adjusting for age-related factors such as disease stage and comorbidity.2-4 
Although receipt of adjuvant therapy may appear to rest in the hands of oncologists, 
surgeons play a critical gate-keeping role. Referral to medical oncology is one of the most 
important factors associated with receipt of chemotherapy among older patients with 
stage III colon cancer.5 Yet in an Australian patterns of care study, increasing patient age 
independently predicted nonconcordance with national clinical practice guidelines for the 
referral of patients with colorectal cancer for adjuvant therapy.6 Colorectal surgeons have 
also been found to hold significantly stronger preferences against all adjuvant options for 
rectal cancer compared with oncologists.7 Because physician opinion has a major impact on 
the treatment decisions of older patients,8,9 the views of surgeons regarding adjuvant 
therapy in older adults should be explored further. 
Randomized trials of adjuvant chemotherapy typically find no significant interaction 
between age, efficacy of treatment, and incidence of toxicity.10,11 However, treatment 
decision making for older patients is inherently more complex. Individual physicians must 
balance factors such as physiological and psychosocial health, life expectancy, and the 
effects of cancer and cancer treatment on quality of life. Limitations of current evidence, in 
particular, because of the underrepresentation of older patients in clinical trials,12 make 
these decisions all the more difficult. 
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Previous surveys have focused primarily on the impact of comorbidity or general health on 
physicians’ adjuvant therapy recommendations.13-16 Where other factors are considered, 
differences by age are generally not compared.8,17 The association between knowledge of 
evidence, opinions, and practice in the treatment of older patients with adjuvant therapy 
has also not been explored. Therefore, the aim of this study was to identify factors 
affecting surgeons’ decisions to refer older patients with colorectal cancer for adjuvant 
therapy by determining surgeon knowledge, opinions, and self-reported practice in a range 
of scenarios. 
4.3. Method 
Participants 
The study sample comprised colorectal surgeons from Australia and New Zealand. 
Surgeons were identified through the Colorectal Surgical Society of Australia and New 
Zealand (CSSANZ). All members of CSSANZ were eligible for participation, unless they were 
no longer practicing medicine, were on extended leave of more than 6 weeks, or no longer 
resided in Australia or New Zealand. 
Surgeons were randomly allocated to receive either a hard-copy mailed survey, or an email 
with a link to an online survey with identical content. Three reminder letters/emails were 
sent to non-respondents at 2-week intervals. Further information and results by survey 
type will be presented elsewhere. The study was approved by CSSANZ and Sydney South 
West Area Health Service Ethics Review Committee. 
Survey Instrument 
A self-administered survey was developed to measure knowledge, opinions, and practice 
regarding referral of older patients by colorectal surgeons for adjuvant therapy. Survey 
questions were pilot tested by colorectal fellows for content, clarity, and ease of use. 
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Knowledge questions were based on recommendations of the current Australian clinical 
practice guidelines18 and current research evidence. Opinion questions were based on 
literature review. Level of agreement with statements in these sections were measured 
using a 5-point Likert scale (strongly disagree to strongly agree). For the self-reported 
practice section, surgeons were asked to indicate how likely they would be to refer 2 
patients of different ages (60 years and 80 years) with node-positive colon cancer, given a 
number of patient-based and structural barriers to adjuvant chemotherapy. Self-reported 
practice was measured using 11-point visual analog scales (definitely would not refer to 
definitely would refer) (Figure 1). 
Figure 1. Example of self-reported practice question 
 
Data Analysis 
Self-reported practice was analysed in 2 ways. 
1. Absolute analysis: the likelihood of referral of patients in the different scenarios overall. 
That is, which factors had the greatest impact on the decision to refer in both patient 
groups. Mean scores for each scenario were calculated. 
2. Relative analysis: the likelihood of referral of an older patient compared with a younger 
patient in the same scenario. That is, which factors (eg, comorbidity) produced the greatest 
differences on the decision to refer between the older and younger patient. Mean 
differences were analysed using paired t-tests. The total of the mean difference scores for 
each participant provided a total self-reported practice score.  
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Knowledge questions were dichotomized as either “consistent” or “inconsistent” with 
national guidelines and current research evidence. Responses were considered consistent if 
participants selected either “strongly agree/agree” or “strongly disagree/disagree” as 
appropriate to the question. The number of responses consistent with the evidence were 
tallied to provide a knowledge score for each participant. Correlation coefficients were 
obtained for the relationship between knowledge and self-reported practice scores. 
Opinion questions were dichotomized in a similar manner to knowledge questions. Tally 
points were given to responses indicating similar opinions toward older and younger 
patients and belief in adequacy of current evidence. A summary score was calculated and 
correlation coefficients were obtained for the relationship between opinion and self-
reported practice scores. 
Multiple regression was used to test for independent associations between surgeon 
characteristics (eg, age, sex, practice location) and total scores for the knowledge, opinions, 
and self-reported practice sections. Any demographics that indicated a possible 
relationship to total scores (p<0.25) were used as predictors in the models. Predictors with 
the least effect on total scores were dropped out of the models one at a time until all 
predictors were significant.19 
4.4. Results 
Of 146 eligible colorectal surgeons from Australia and New Zealand, 102 responded to the 
survey (70%). The mean age of responding surgeons was 49 years, and most surgeons were 
male (95%). The majority reported practicing in a capital city or other major urban area 
(94%) and 73% considered their major appointment as visiting medical officer/consultant. 
Eighty-one percent of surgeons reported attending multidisciplinary team meetings often 
(Table 1). 
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Table 1. Characteristics of colorectal surgeons responding to survey 
  n % 
Responding surgeons (of 146) 102 69.9 
Age in years (mean/SD) 48.9 8.7 
Sex Male 95 93.1 
Female 7 6.9 
Practice location Capital city 68 66.7 
Other major urban area 28 27.5 
Rural area 6 5.9 
Hospital of majority work  
(not mutually exclusive) 
Tertiary referral teaching hospital 60 58.8 
District general hospital 9 8.8 
Rural hospital 1 1.0 
Private hospital 47 46.1 
Appointment  
(not mutually exclusive) 
Conjoint staff/academic 22 21.6 
VMO/consultant 74 72.5 
Staff specialist 9 8.8 
Salaried university academic 10 9.8 
Multidisciplinary team meeting 
attendance 
Often 83 81.4 
Sometimes 13 12.7 
Never 4 3.9 
Not available 2 2.0 
Chemotherapy services at hospital Yes 93 91.2 
No 9 8.8 
Radiotherapy services at hospital Yes 69 68.3 
No 32 31.7 
VMO = visiting medical officer 
Self-Reported Practice (Relative) 
Surgeons were significantly less likely to refer an older patient with node-positive colon 
cancer for adjuvant chemotherapy than a younger patient in all 8 self-reported practice 
questions (p<0.001). The scenarios that produced the greatest difference in referral 
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recommendations between a younger and older patient were living a long distance from 
available treatment, having a comorbid condition, and having no close social supports 
(Table 2). For example, 93% of surgeons would likely refer a 60-year-old patient with node-
positive colon cancer for adjuvant chemotherapy if they lived 300 km from the nearest 
treatment facility. However, only half as many surgeons (47%) would likely refer an 80-
year-old patient in the same scenario. There was also much greater variation in referral 
recommendations for older patients (table 2). 
Table 2. Likelihood of referring an older and younger patient for adjuvant chemotherapy* 
 60-year-old, 
mean (SD) 
80-year-old 
mean (SD) 
Difference, 
mean (SD) p 
The patient lives 300km from the nearest  
treatment facility 
10.2 (1.5) 6.6 (3.6) 3.6 (3.2) <.001 
The patient has an ASA status of III  
(e.g. controlled congestive heart failure) 
9.5 (1.9) 6.2 (3.5) 3.3 (2.9) <.001 
The patient has no close family or friends to  
support them 
10.2 (1.4) 7.0 (3.6) 3.3 (3.2) <.001 
The patient has some degree of cognitive 
impairment (i.e. needs some help with daily tasks) 
8.0 (2.9) 5.2 (3.5) 2.8 (2.7) <.001 
The patient may have difficulty coping with 
additional medical costs or loss of income 
9.9 (1.7) 7.3 (3.6) 2.6 (3.1) <.001 
The patient needs some assistance with personal 
care (e.g. bathing, dressing) 
8.6 (2.7) 6.2 (3.5) 2.4 (2.6) <.001 
The patient refuses referral initially 8.0 (3.8) 5.6 (3.8) 2.4 (3.0) <.001 
The patient has no other medical problems 10.9 (0.5) 9.5 (2.5) 1.4 (2.4) <.001 
*11-point Likert scale used 
Self-Reported Practice (Absolute) 
The greatest barriers to referral for adjuvant chemotherapy overall were the same for both 
the younger and older patient. Cognitive impairment, initial patient refusal, and the need 
for assistance with personal care were the scenarios where patients were least likely to be 
referred (Table 2). For example, only 68% of surgeons would likely refer a 60- year-old 
patient if they had some degree of cognitive impairment, and 33% for an 80-year-old 
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patient in the same scenario. Not surprisingly, the scenario that produced the greatest 
referral rates for adjuvant chemotherapy, and the least difference in referral between the 
older and younger patient, was if there were no other medical problems. Nearly all 
surgeons (96%) would “definitely refer” an otherwise healthy younger patient with node-
positive colon cancer, compared with 61% for the older patient in the same scenario.  
Knowledge 
The majority of surgeons “strongly agreed” or “agreed” with specific recommendations of 
the national clinical practice guidelines for the treatment of older patients with adjuvant 
chemotherapy (81%) and preoperative radiotherapy (97%). On the issues of toxicity, 
benefits, and quality of life, there was greater disagreement (Table 3). Interestingly, only 
39% of surgeons agreed that adjuvant chemotherapy is underused in older patients. 
Surgeons with a greater knowledge score were significantly more likely to have similar 
referral recommendations for older and younger patients (p=0.018).  
Table 3. Responses to knowledge questions 
 Strongly agree 
/ agree (%) 
Neutral 
(%) 
Strongly disagree 
/ disagree (%) 
Total 
% (n) 
Older people derive similar benefits from 
adjuvant chemotherapy as younger 
people  
72.5 14.7 12.7 100 (102) 
Adjuvant chemotherapy is underutilised  
in elderly patients  
39.2 43.1 17.6 100 (102) 
The risk of toxicity from adjuvant 
chemotherapy increases with age 
72.5 15.7 11.8 100 (102) 
All patients with node positive colon 
cancer should be considered for adjuvant 
chemotherapy regardless of age 
81.2 2.0 16.8 100 (101) 
Adjuvant chemotherapy has a greater 
impact on the quality of life of older 
people than younger people 
50.0 28.4 21.6 100 (102) 
Elderly patients with high-risk  rectal 
cancer should be considered for 
preoperative radiotherapy, either alone  
or as combined modality therapy 
97.1 2.9 0 100 (102) 
 148 
Opinions 
Opinions were also significantly associated with self-reported practice, with higher opinion 
scores predicting similar referral of older and younger patients (p=0.01). Most surgeons 
believed that older patients preferred less aggressive treatment and that younger patients 
should have preference over elderly patients, but that the side effects of adjuvant 
chemotherapy were generally worth the benefits for older patients (Table 4). Thirty-nine 
percent of surgeons believed there is an upper age limit after which chemotherapy is no 
longer worthwhile (mean age, 82 y; range, 75-90 y). Yet the majority of responders 
reported that they believed there is adequate evidence to justify the use of adjuvant 
chemotherapy and radiotherapy in patients over 70 years. 
Table 4. Responses to opinion questions 
 Strongly agree 
/ agree (%) 
Neutral 
(%) 
Strongly disagree 
/ disagree (%) 
Total 
% (n) 
For the elderly, the side effects of 
adjuvant chemotherapy are generally 
not worth the benefits 
9.8 20.6 69.6 100 (102) 
Older people often prefer less aggressive 
treatment to younger people 
66.7 13.7 19.6 100 (102) 
Considering the limited resources of the 
health system, younger patients should 
have preference over the elderly for 
adjuvant chemotherapy 
19.8 23.8 56.4 100 (101) 
Older people generally prefer the 
physician to make treatment choices for 
them 
38.2 26.5 35.3 100 (102) 
There is adequate evidence to justify the 
use of adjuvant chemotherapy in the 
elderly 
71.6 18.6 9.8 100 (102) 
There is adequate evidence to justify the 
use of preoperative radiotherapy in the 
elderly with high-risk rectal cancer 
78.4 8.8 12.7 100 (102) 
Do you believe there is an upper age 
limit after which adjuvant chemotherapy 
is no longer worthwhile? 
38.8 
(yes) 
82* 
(75-90) 
61.2 
(no) 
98 (100) 
*Mean age limit (range) 
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Physician Predictors 
Surgeon age was the only significant independent predictor of survey responses. Younger 
surgeons were more likely to have a higher knowledge score (p=0.006) and a higher 
opinion score (p=0.027). However, surgeon age did not explain much of the variation in 
scores (R2=0.048 and R2=0.074). Surgeons who practiced in a capital city or other major 
urban area were more likely to have similar referral recommendations for older and 
younger patients than those who practiced in a rural location (mean total difference, 21 
and 32), but this result was not significant. Referral recommendations did not vary by age, 
sex, hospital location, appointment, multidisciplinary team meeting attendance, or the 
availability of on-site chemotherapy or radiotherapy services at the surgeon’s hospital. 
4.5. Discussion 
In this study, colorectal surgeons were significantly less likely to self-report referral of an 
older patient with node-positive colon cancer for adjuvant chemotherapy than a younger 
patient across a range of scenarios. Both knowledge of evidence and opinions about older 
patients and adequacy of evidence were strongly associated with referral 
recommendations. Surgeon age was the only factor that independently explained 
knowledge and opinion scores. 
Older patients with colorectal cancer are less likely than younger patients to receive 
adjuvant therapy both in Australia3,20,21 and internationally.2,4 The results of this study may 
provide some insight into the underlying reasons for these differences. Although many 
consider that older patients with cancer are undertreated, there is also significant debate 
about the overtreatment of this population.22 This was reflected in physician disagreement 
in this survey. Only 39% of surgeons agreed that adjuvant therapy is underused in older 
patients, whereas 18% disagreed and 43% were neutral. Life expectancy is a function of 
age, comorbidity, disability, and cancer type and stage.23 For some older patients, decisions 
to forgo adjuvant treatment may be appropriate, in particular where patient quality of life  
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might be significantly compromised. However, in this survey, an 80-year-old patient with 
no other medical problems was much less likely to be referred than a similar 60- year-old 
patient.  
Patient age alone has also been reported to influence physicians’ recommendations across 
other surveys.13-17 An otherwise healthy 80-year-old has a life expectancy of 9 years,24 and 
there is evidence that adjuvant chemotherapy achieves significant 5-year survival for older 
patients25 and may not have a significant negative impact on quality of life.26 The 
differences in the treatment of older patients perhaps stem from a more delicate issue, 
that is, whether treatment is worth the cost (both for the patient and as a society) for 
potentially little long-term gain. Certainly 20% of surgeons reported that younger patients 
should have preference over older patients given the limited resources of the health 
system. These economic considerations deserve substantial research and debate given the 
expected rise in the number of older patients with cancer because of population ageing. 
Until this occurs, the question of benefit and burden is perhaps best answered by the well-
informed patient, although too frequently adjuvant therapy is not discussed with 
patients.27 
Lack of consensus among surgeons about the treatment of older patients was a major 
feature of this survey. Although several surgeons noted that referral to medical oncology is 
mandatory, others reported not routinely referring patients over a certain age. Greater 
variation between referral recommendations was particularly evident where patients were 
older and sicker. Comorbidity is a major concern in the management of older patients, 
because it can have a substantial impact on treatment tolerance.28 As a result, increasing 
comorbidity has been found to predict non-receipt of adjuvant chemotherapy in both 
population studies20,29 and other physician surveys.15,17 In this study, having a comorbid 
condition produced the second greatest difference in referral recommendations between 
an older and younger patient. Emerging evidence suggests that chemotherapy improves 
survival among patients with certain chronic conditions without increasing the probability  
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of hospitalization.30 However, cohort studies do not account for inherent differences 
between treatment and nontreatment groups. Randomized control trials are needed to 
disentangle the effects of patient age, comorbidity, and other factors such as patient 
preference. Without this information, it is likely that physicians’ views will continue to 
diverge,17 and the individual surgeon a patient sees will be an important variable in 
determining whether they are referred for, and perhaps in turn receive, adjuvant therapy. 
The focus on comorbidity in other physician surveys is warranted given the frequency of 
chronic conditions in older patients. Yet this focus tends to ignore the possible impact of 
other factors on treatment decision making. In this study, an older patient was much less 
likely to be referred for adjuvant chemotherapy than a younger patient if they lived a long 
distance from available treatment. Travel has been reported to affect the treatment 
decisions of older patients and those who do not receive chemotherapy.8 Living in an urban 
area has also been found to independently predict chemotherapy use in patients 80 years 
and older.31 Population-based studies have not always found this association, however,32,33 
and travel factors have not previously been reported to affect physicians’ treatment 
decisions. Nevertheless, the role of structural barriers in the treatment of older patients 
should be further explored, in particular, in a local context. 
In addition, patients with cognitive impairment, those who initially refused referral, and 
those who needed assistance with personal care, were the least likely to be referred for 
adjuvant chemotherapy overall. Krzyzanowska and colleagues17 similarly found that patient 
preference against therapy affected physicians’ recommendations, and cognitive 
impairment has been reported to affect patient and physician decision making for older 
patients with cancer.28 Although other factors such as life expectancy, social support, cost, 
and quality of life have been reported in previous surveys,8,17 this study was unique in 
allowing comparison between overall (absolute) barriers and age-comparative (relative) 
barriers. The differences between relative and absolute barriers to adjuvant therapy in this 
study, and the variety of factors that have been considered elsewhere, further 
demonstrate the complex nature of cancer treatment decisions for older patients. 
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The findings of this study should be interpreted in light of a number of limitations. Although 
necessary for the brevity of the survey, the self-reported practice section only contrasted 
two specific ages, and other factors that may influence referral were not included. 
Furthermore, any underuse of appropriate adjuvant therapy is most likely multifactorial. 
This study only assessed surgeons’ perceived barriers to referral. If oncologists, for 
example, perceive fewer or different barriers to adjuvant therapy use in older patients, 
then variation in management could be reduced by increasing multidisciplinary planning.34 
The concordance between patient and physician views should also be explored further. 
Patient knowledge and beliefs about treatment, as well as medical mistrust, have been 
associated with underuse of adjuvant therapy in breast cancer.35 Facilitating 
communication between physicians and patients, for example, through the use of decision 
aids,36,37 may help patients make the optimal treatment decision. 
Nevertheless, older patients frequently cite physician judgment as the most important 
factor influencing their treatment decision making.8 Opinions and knowledge were highly 
associated with self-reported practice in this study. Because older patients are likely to 
follow physician advice, increasing awareness of evidence may therefore increase the rates 
of referral and ultimately the receipt of adjuvant therapy. Targeting specific physician 
groups for education is one possibility. In multivariate analysis, younger surgeons were 
more likely to have a greater knowledge of evidence and similar opinions toward older and 
younger patients. Physician age has also been reported to predict referral and receipt of 
adjuvant therapy in previous studies.15,35 However, targeting older physicians may not have 
a major impact on referral rates because physician characteristics explained so little of the 
results. Screening tools such as the Vulnerable Elders Survey (VES- 13),38 a self-
administered survey that is highly predictive of impaired functional status,39 could be a 
useful alternative to aid treatment decision making. 
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Conclusion 
Chronological age alone appears to impact colorectal surgeons’ decisions to refer patients 
for adjuvant therapy. Sociodemographic and physiological factors further decrease the 
likelihood of referral of older patients. The lack of consensus among surgeons suggests that 
more research is needed both to predict how older patients with cancer will react to 
treatment, and to determine how information from emerging evidence can be best used to 
assist physicians’ treatment decisions.  
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Appendix 4.2. Comparison of postal and internet survey methods 
Internet-based surveys have the potential to save time, effort and financial resources. With 
increasing professional usage of the internet by clinicians,i electronic surveys may no longer 
perform more poorly than traditional mailed surveys with regard to response rates and 
representativeness.ii Australian surgeons were randomly allocated to receive the survey 
described above either through the post (n=64) or through an email linked to an online 
survey with identical content (n=62). Both surveys included endorsements by a colorectal 
surgeon and the chairman of the research support committee of the CSSANZ. All New 
Zealand colorectal surgeons received an email invitation to the online survey (n=20), and 
were excluded from the present analysis. One surgeon allocated to online group requested 
a postal survey. Respondents were analysed as allocated. 
While 77% of the postal group returned their surveys, only 65% of the internet group 
completed the online survey. However, these response rates were not statistically 
significantly different (X²[1]=1.6, p=0.19). Survey completeness was nearly 100% for both 
groups. 25% of all online responders had completed the survey within 2 days of the initial 
invitation, but there were no differences between groups in median response time overall 
(median [IQR] = 15 [26] days vs 16 [25] days). The characteristics of responders in the 
online and postal group did not differ significantly by physician age, sex, qualification, type 
of hospital, or survey scores (all p>0.05), although more responders in the online group 
practiced outside of a capital city (32% vs 24%). Internet-based surveys may therefore be 
an effective tool for engaging surgeons in health services research, and could be a 
preferred option for regional or rural surgeons. 
References 
i. Masters K. For what purpose and reasons do doctors use the Internet: a systematic 
review. Int J Med Inf 2008;77(1):4-16.  
ii. Braithwaite D, Emery J, De Lusignan S, et al. Using the Internet to conduct surveys of 
health professionals: a valid alternative? Fam Pract 2003;20(5):545-51. 
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Appendix 4.3. Example screenshot of online version of surgeon survey 
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Appendix 4.4. Postal version of surgeon survey 
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 5 
The patient 
 
 
In Chapter 4, factors affecting colorectal surgeons’ decisions to refer older patients for 
adjuvant therapy were explored. Surgeons placed emphasis on practical barriers to 
treatment such as travel distance, as well as on patients’ chronological age, social support 
and health status. This chapter investigates patient-based barriers to adjuvant 
chemotherapy use through a self-administered survey of colorectal cancer patients. 
Although the strength of patients’ preferences has been explored previously, less is known 
about the processes that influence these preferences. The survey aimed to identify factors 
that uniquely affect older patients’ decisions to undergo treatment, including preferences 
for information and involvement in treatment decision making. A copy of the patient 
survey is available in Appendix 5.2. 
This chapter is presented as the following paper: 
Jorgensen ML, Young JM, Solomon MJ. Adjuvant chemotherapy for colorectal cancer: age 
differences in factors influencing patients’ treatment decisions. Patient Preference and 
Adherence 2013; 7: 827-34.  
Available: http://www.dovepress.com/articles.php?article_id=14146 
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Adjuvant chemotherapy for colorectal cancer: age differences in factors influencing 
patients’ treatment decisions 
5.1. Abstract 
PURPOSE: Older colorectal cancer patients are significantly less likely than younger patients 
to receive guideline-recommended adjuvant chemotherapy. Previous research has 
indicated that patient refusal of treatment is a contributing factor. This study aimed to 
identify potential barriers to adjuvant chemotherapy use in older patients by examining the 
associations between patient age, factors influencing chemotherapy treatment decisions, 
and preferences for information and decision-making involvement. 
METHODS AND RESULTS: Sixty-eight patients who underwent surgery for colorectal cancer 
in Sydney, Australia, within the previous 24 months completed a self-administered survey. 
Fear of dying, health status, age, quality of life, and understanding treatment procedures 
and effects were significantly more important to older patients (aged ≥65 years) than 
younger patients in deciding whether to accept chemotherapy (all p<0.05). Reducing the 
risk of cancer returning and physician trust were important factors for all patients. Practical 
barriers such as traveling for treatment and cost were rated lowest. Older patients 
preferred less information and involvement in treatment decision making than younger 
patients. However, 60% of the older group wanted detailed information about 
chemotherapy, and 83% wanted some involvement in decision making. Those preferring 
less information and involvement still rated many factors as important in their decision 
making, including understanding treatment procedures and effects. 
CONCLUSION: A range of factors appears to influence patients' chemotherapy decision 
making, including, but not limited to, survival benefits and treatment toxicity. For older 
patients, balancing the risks and benefits of treatment may be made more complex by the 
impact of emotional motivators, greater health concerns, and conflicts between their need 
for understanding and their information and decision-making preferences. Through greater 
understanding of perceived barriers and motivators for treatment choice, physicians may 
be better able to support older patients to make informed decisions about their care.
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Reprinted from Patient Preference and Adherence, Volume 7, Jorgensen ML, Young JM, 
Solomon MJ, Adjuvant chemotherapy for colorectal cancer: age differences in factors 
influencing patients’ treatment decisions, pp 827-834, Copyright 2013, with permission 
from Dove Medical Press Ltd. 
5.2. Introduction 
Colorectal cancer (CRC) is the second most commonly diagnosed cancer in Australia, with 
those aged over 65 years accounting for two-thirds of all cases.1 Current clinical practice 
guidelines for CRC state that advanced age alone should not be used to exclude patients 
from being offered effective treatment.2 For fit older patients, adjuvant chemotherapy 
appears to achieve similar survival benefits with no greater toxicity than for younger 
patients.3,4 However, older patients are significantly less likely to be referred for and 
receive guideline-recommended adjuvant chemotherapy, even after adjusting for age-
related factors such as comorbidity.5-7 While patient age is reported to be a strong 
influence of both surgeons’ and oncologists’ recommendations for chemotherapy,8-10 
patient-based factors also appear to contribute to differences in treatment rates. A 
proportion of patients refuse adjuvant chemotherapy, and these patients are significantly 
more likely to be older than those who accept treatment.5,11,12 
Patients’ preferences for chemotherapy in CRC have previously been examined by 
determining the amount of life cancer patients are willing to forgo to avoid treatment,13 
the survival benefit needed to make chemotherapy worthwhile,14 and the recurrence rate 
at which patients will change their preference from surgery alone to surgery plus 
chemoradiation.15 Although the strength of patients’ preferences has been explored, less is 
known about the processes that influence these preferences. Treatment-related 
determinants (eg, treatment benefits and toxicities) and patient characteristics appear to 
only partially explain cancer patients’ preferences for adjuvant chemotherapy.16 Patient 
age is not a consistent predictor of preferences,16,17 yet the higher rate of treatment refusal 
in older cancer patients implies age differences in treatment decision making. As treatment 
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decisions are often made in the highly stressful period following cancer diagnosis, cognitive 
and affective determinants such as fear have been suggested as possible predictors.16 
A range of other factors that may influence patients’ chemotherapy decisions has also been 
proposed, for example, physician opinion, family support, and quality of life (QOL). Such 
factors have been explored in a qualitative study of older patients with breast cancer18 and 
a survey of older patients with colon cancer.19 However, these studies involved only 
patients aged 65 years and over, making it difficult to determine whether the reported 
factors actually distinguish the decision-making processes of older patients from younger 
patients. Other research involving cancer patients of all ages20,21 does not focus on 
determining age differences in treatment decision making. Greater understanding of 
factors that uniquely affect older patients’ decisions to undergo treatment is needed to 
ensure optimal treatment and outcomes. 
Preferences for information and decision making might also affect patients’ decisions to 
accept treatment. Older patients appear to be at greater risk of being inadequately 
informed about their cancer and treatment, as they generally prefer to receive less 
information and to be less actively involved in making treatment decisions than younger 
patients.22,23 Physicians may also underestimate the absolute numbers of older patients 
who prefer to be fully informed and involved in decision making, as patient age is often 
reported solely as a predictor of preferences.21,24 In a study of CRC patients aged over 70 
years, about half preferred an active or collaborative role in treatment decision making.25 It 
has also been suggested that older people want specific information about treatment and 
side effects.26 To create a more complete picture of older patients’ decision making, age 
differences in specific chemotherapy preferences and their relationship to other 
influencing factors should be determined. 
Thus, the aim of this study was to identify potential barriers to adjuvant chemotherapy use 
in older patients by examining the associations between patient age, factors influencing 
chemotherapy treatment decisions, and preferences for information and involvement in 
treatment decision making. 
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5.3. Materials and methods 
Participants 
Participants were recruited from a single tertiary referral hospital in Sydney, Australia. 
Patients aged over 18 years who had been admitted for CRC surgery within the previous 24 
months were invited to participate either during their hospital stay or during a follow-up 
appointment with their surgeon. Eligible patients had sufficient English skills to participate, 
did not have cognitive impairment, and were not currently receiving chemotherapy. A 
surgical team member provided the researchers with the details of patients who gave their 
consent to be approached. Patients were given written information and the survey to 
complete in their own time. Those who received the survey during a follow-up 
appointment were provided with a reply-paid envelope, and non-responders were 
contacted at 2 weeks and 4 weeks. The study was approved by the Sydney South West Area 
Health Service Ethics Review Committee. 
Survey instrument 
A self-administered survey was developed to determine CRC patients’ views on factors 
influencing chemotherapy treatment decisions, preferences for treatment information, and 
preferences for involvement in treatment decision making. 
Using a 10 cm visual analog scale, participants were asked to rate how important various 
factors were (or would be) when deciding about chemotherapy treatment. The list of 
factors was based on a literature review and included items about survival, health impacts, 
opinion of others, practical barriers (eg, cost), and cognitive/affective aspects (eg, fear). 
Information preferences were measured using a modified version of the validated Cassileth 
Information Styles Questionnaire.27 Participants were asked to choose a statement that 
best described their general attitude toward information regarding their illness, as well as 
specific preferences for chemotherapy information, such as side effects, treatment 
progress, and effectiveness in other patients. Decision-making preferences were measured  
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using the Degner and Sloan scale,28 where participants can choose between five decision-
making styles. Participant characteristics (eg, age, sex, education, and comorbidity) were 
also obtained. 
Data analysis 
For the purposes of this analysis, participants were divided into “younger” (<65 years) and 
“older” (≥65 years). The age of 65 years was selected to divide the sample because (1) the 
median age of the sample was 66 years, and (2) this cut-off is frequently used to define 
older age.29 
Factors influencing chemotherapy treatment decisions 
A score for each factor was produced by measuring the distance from the lowest anchor 
point to the point that the participant marked on the scale, to the nearest half centimeter. 
To determine whether the importance of each factor differed significantly by age, mean 
scores for the older group were compared with mean scores for the younger group, using 
independent-samples t-tests. Mann-Whitney rank sum tests were also performed to 
determine whether any skewing to the high end of the scale affected these results. 
Because treatment preferences appear to become more favorable after the decision has 
been made to proceed with adjuvant chemotherapy,30 multiple regression was used to 
assess whether any age differences in the importance of factors remained significant after 
adjusting for received or planned adjuvant chemotherapy. 
Mean scores were also used to rank the overall importance of factors in chemotherapy 
decision making. Factors were tabulated by highest to lowest importance for the older age 
group. As a measure of complexity of decision making, the mean number of factors that 
participants rated as “important” was calculated. Factors with a rating over 5 were 
considered “important,” as this was the midpoint value of the visual analog scale (“not at 
all important” to “very important”). 
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Preferences for information and involvement in decision making 
X² tests were used to examine age differences in information and decision-making 
preferences. Participants could select from four possible responses for their preferences 
for general information about illness. The proportions of older and younger participants 
who preferred as much information as possible about their illness were compared. Eight 
questions assessed specific preferences for chemotherapy information. The difference in 
the proportions of younger and older participants who reported that they “needed” or 
“wanted” all detailed chemotherapy information was examined. There were five options 
for preferred level of involvement in treatment decision making. The proportions of older 
and younger participants preferring active or collaborative decision-making roles were 
compared.28 
Associations between preferences and factors influencing decisions 
Specific associations between information and decision-making preferences and factors 
influencing decisions were examined. To determine whether those who preferred minimal 
treatment information felt that understanding was still important in their decision making, 
the mean of the two factors about understanding (“understanding what is going to happen 
during treatment” and “understanding the benefits and side effects”) was calculated for all 
participants. A t-test was used to compare these mean scores between those who 
preferred not to have detailed information about chemotherapy and those who did. 
To determine whether those who preferred less involvement in decision making still 
considered a range of factors when making treatment decisions, the mean number of 
factors rated as “important” (mean score >5 on a 10-point visual analog scale) was 
compared between those who preferred a passive role and those who preferred an 
active/collaborative role, using a t-test. 
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5.4. Results 
Of 75 patients with CRC who consented to participate in the study, 68 returned the survey 
(91%). The participants ranged in age from 25 years to 82 years, with a mean age of 64 
years. More participants were male and most spoke English at home (see Table 1 for 
further details). Nonparticipants did not differ significantly from participants for any of the 
characteristics listed in Table 1, though nonparticipants were slightly older (67 years versus 
64 years). 
Table 1. Characteristics of colorectal cancer patients responding to survey 
Characteristic Older group n (%) 
Younger group 
n (%) P-value
a 
Total participants 35 (51) 33 (49)  
Age in years (mean/SD) 73.9 (4.8) 53.6 (9.1)  
Male 22 (63) 17 (52) 0.34 
English spoken at home 25 (71) 28 (85) 0.18 
High school or tertiary 14 (40) 24 (73) 0.007 
Employed full or part time 5 (14) 22 (67) <0.001 
Private health insurance 16 (46) 20 (61) 0.22 
Lives alone 14 (40) 5 (15) 0.02 
One or more comorbidities 27 (77) 14 (42)  
Site of cancer 
Colon 
Rectum 
 
20 (57) 
13 (37) 
 
14 (42) 
17 (51) 
0.32 
Dukes stage of cancer 
A 
B 
C 
D 
 
5 (14) 
14 (40) 
11 (31) 
2 (6) 
 
4 (12) 
11 (33) 
12 (36) 
1 (3) 
0.79 
Adjuvant chemotherapy 
(received or planned) 
10 (29) 17 (51) 0.08 
aP-values based on X² tests. Abbreviation: SD, standard deviation. 
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Factors influencing chemotherapy treatment decisions 
Six factors were significantly more important to older patients than younger patients in 
deciding whether to have chemotherapy: “fear of dying from cancer” (t[66]=7.07; p<0.001), 
“how unwell I am to start with” (t[66]=3.87; p<0.001), “how old I am” (t[63]=2.87; 
p=0.006), “maintaining a good QOL during treatment” (t[66]=2.94; p=0.005), 
“understanding the benefits and side effects” (t[66]=2.87; p=0.005), and “understanding 
what is going to happen during treatment” (t[66]=2.95; p=0.004). After adjusting for 
received or planned chemotherapy, all of these factors remained significant except for 
“how old I am” (p=0.07). 
“Reducing the risk of the cancer coming back” was the most highly rated item, on average, 
for both older and younger groups (see Table 2). “Having a doctor whose expertise I trust” 
and “having a doctor whom I feel comfortable asking questions of” both rated very highly. 
Another factor rated highly by both groups was “returning to my normal QOL after 
treatment.” Factors of lowest importance were also comparable between age groups. 
Traveling for treatment and treatment cost and duration were rated low by both older and 
younger patients, and “avoiding side effects” and “the opinion of my family” were also of 
low importance. 
On average, both groups rated nearly all of the 22 factors as “important” in chemotherapy 
decision making (ie, mean score >5 on a 10-point visual analog scale). The older group 
rated more factors as “important” (mean [standard deviation {SD}] = 18.1 [3.1]) than the 
younger group (mean [SD] = 16.7 [3.6]) and had a slightly higher mean score for the 
importance of all factors (8.0 versus 7.4), but these differences were not significant. 
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Table 2. Factors of importance in chemotherapy decision makinga 
Factor Older group, mean (SD) 
Younger group, 
mean (SD) P-value
b 
Reducing the risk of the cancer coming back 9.3 (0.5) 9.3 (0.8) 0.44 
Having a doctor whose expertise I trust 9.2 (0.5) 9.2 (0.6) 0.49 
Understanding the benefits and side effects 9.2 (0.7) 8.5 (1.3) 0.02 
Understanding what is going to happen during treatment  9.2 (0.6) 8.1 (2.2) 0.02 
Returning to my normal QOL after treatment 9.1 (0.6) 9.3 (0.8) 0.10 
Having a doctor who I feel comfortable asking questions 9.1 (0.6) 9.0 (1.0) 0.68 
Maintaining a good QOL during treatment 9.1 (0.7) 8.1 (2.0) 0.04 
The recommendation of the doctor 9.0 (0.9) 8.6 (1.2) 0.19 
Increasing my chance of living longer 8.9 (1.3) 8.5 (1.6) 0.17 
Doing everything possible to fight the cancer 8.9 (1.3) 8.4 (2.7) 0.71 
Fear of dying from cancer 8.9 (1.3) 4.8 (3.2) <0.001 
How unwell I am to start with 8.5 (1.5) 6.0 (3.6) 0.03 
Having someone to look after me during treatment 7.9 (2.5) 6.8 (2.8) 0.13 
Maintaining my independence 7.8 (2.5) 8.4 (1.5) 0.70 
Being able to look after significant others 7.5 (3.1) 7.5 (2.5) 0.97 
How old I am 7.5 (3.1) 5.0 (3.8) 0.009 
Having time to decide about treatment 7.3 (2.9) 7.7 (2.9) 0.28 
Avoiding side effects 6.7 (3.2) 6.2 (3.3) 0.45 
The opinion of my family 6.7 (3.6) 6.0 (3.0) 0.21 
Total duration of the treatment 5.8 (3.3) 6.8 (3.5) 0.25 
Cost of treatment 5.5 (3.6) 5.5 (3.6) 0.81 
How far I would have to travel for treatment 3.8 (2.8) 5.5 (4.0) 0.05 
Mean score of all factors 8.0 (1.0) 7.4 (1.4) 0.27 
aRanked highest to lowest for older group, based on 10-point visual analog scale;  
bP-values based on Mann-Whitney rank sum tests. Abbreviation: SD, standard deviation. 
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Preferences for information and involvement in decision making 
Fifty percent of older participants preferred to have as much information as possible about 
their illness, compared with 76% of younger participants (χ2[1]=4.75, p=0.03). However, the 
majority of the older group reported wanting or needing as much detailed information 
about chemotherapy as possible (60%), and this proportion was not significantly different 
from the younger group (76%) (χ2[1]=1.93, p=0.17). Most patients from both the older and 
younger groups had a preference for some degree of involvement in decision making (83% 
and 91%, respectively); no one expressed a preference for sole decision making. Although a 
greater proportion of younger participants preferred an active/collaborative role than older 
participants, this difference was not significant (χ2[1]=2.37, p=0.12). These results are 
summarized in Table 3. 
Table 3. Patient preferences for information and involvement in decision making 
 
Older group, 
n (%) 
Younger group, 
n (%) 
P-valuea 
Preference for information about illness:   0.03 
As much information as possible, good and badb 17 (50) 25 (76) 
Only the information needed to care for self properly 4 (12) 6 (18)  
Additional information only if it is good news 3 (9) 0 (0)  
Leave it up to the doctor 10 (29) 2 (6)  
Preference for detailed information about chemotherapy:   0.17 
Would like or needs to have all detailed informationb 21 (60) 25 (76) 
Does not want all detailed information 14 (40) 8 (24)  
Preference for treatment decision making:   0.12 
Shared responsibility with doctor for decisionsb 13 (37) 14 (42) 
Select treatment by self after seriously considering 
doctor’s opinionb 
5 (14) 9 (27)  
Make final selection of treatment by selfb 0 (0) 0 (0)  
Doctor makes final decision but considers their opinion 11 (31) 7 (21)  
Leave all decisions about treatment to doctor 6 (17) 3 (9)  
aP-values based on χ² tests; bindicates grouping for significance testing of proportions. 
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Associations between preferences and factors influencing decisions 
Participants who preferred to have detailed information about chemotherapy rated the 
understanding of treatment procedures and their effects as significantly more important in 
their decision making than those who preferred not to have detailed information (mean 
[SD] = 9.1 [0.9] versus 8.2 [1.7], p=0.04). However, the high mean score (8.2) for those 
preferring not to have detailed information indicates that understanding treatment 
procedures and effects was still important for these participants. 
Those who expressed a preference for involvement in decision making rated significantly 
more factors as “important” than those who preferred to leave all decisions about 
treatment to the doctor (mean [SD] = 17.8 [3.2] versus 14.9 [3.4], p=0.01). Although a 
significant difference, participants preferring to leave all decisions to the doctor still rated a 
mean 15 of 22 factors as “important” in their decision making. 
5.5. Discussion 
In this study, fear of dying, health status, age, QOL, and understanding treatment and its 
benefits and side effects were significantly more important to older patients than younger 
patients in deciding whether to accept chemotherapy. Reducing cancer recurrence and 
physician trust were highly important to both age groups, and practical barriers such as 
travel and cost were of low importance. Older patients preferred less information and less 
involvement in treatment decision making than younger patients. However, 60% of the 
older group still wanted detailed information about chemotherapy, and 83% wanted some 
degree of involvement in treatment decision making. Those preferring less information and 
less involvement in decision making still rated many factors as important in their decision 
making, including understanding treatment procedures and effects. 
Much of the literature that investigates patient preferences for chemotherapy focuses on 
weighing survival benefit against treatment toxicity.31 That these preferences are difficult 
to predict on the basis of patient or treatment characteristics implies that other factors  
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may influence patients’ decisions to accept treatment.16 In our study, fear of dying was 
significantly more important to older patients than younger patients in deciding whether to 
have chemotherapy. Fear has been noted in other studies as both a barrier to adjuvant 
chemotherapy use20 and a factor involved in decision making generally.32 Although fear of 
death is typically reported to decrease with age,33 the greater fear of dying from cancer for 
older people in this study could stem from a historical belief that no treatment will work 
against cancer. This is a major concern, as those with higher levels of fear are more likely to 
avoid cancer information34 that could actually help to dispel negative expectations about 
chemotherapy use and cancer survival. 
Attitudes toward ageing may be another cognitive/affective factor influencing treatment 
decisions. In our study, age was significantly more important in chemotherapy decision 
making for older patients than younger patients. Older physicians also appear to place 
greater importance on patient age than younger physicians.8,10 Although age alone may be 
an important consideration for the oldest old, even those aged 80-84 years can experience 
treatment-associated survival benefit,35 and current evidence supports the safety of 
adjuvant chemotherapy in fit older patients.4 Attitudes toward older age and treatment 
may change with the ageing of the “baby boomer” generation, as this group appears to 
have high expectations for their health, longevity, and care.36 Until such a time, ensuring 
that both patients and physicians are aware of current research on the effectiveness of 
adjuvant chemotherapy for older adults could help to reduce the impact of attitudes on 
treatment receipt. 
Practical barriers such as cost, duration, and traveling for treatment were factors of low 
importance for both older and younger participants in our study. Cost and travel were also 
factors that least influenced chemotherapy decisions in a previous survey of older patients 
with colon cancer.19 However, in a self-reported practice survey, traveling a long distance 
for adjuvant chemotherapy was the factor that most decreased the likelihood that 
surgeons would refer an older patient compared with a younger patient.8 Physician and  
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patient views frequently differ in many aspects of treatment decision making.13,19,25 As 
emotional motivators appear to play a large role in patient preferences, and practical 
considerations such a small one, the question then arises whether patients are best placed 
to make difficult treatment decisions at such a highly stressful time. On the other hand, 
physicians may also make decisions based on their own attitudes, under the pressure of a 
finite health system where the benefits to older patients are much less clearly defined. 
Given the expected rise in the number of cancer cases due to population ageing, these 
motivational and economic considerations deserve substantial attention. 
Many of the other findings in this study are comparable to those of previous research in 
treatment decision making. Trust in the physician and physician recommendation, rated 
highly by the participants in our study, are often reported as important factors influencing 
treatment decisions.19,21 Reducing recurrence and increasing survival are the benefits 
against which risks are commonly weighed in patient preference studies, and these were 
factors that both age groups rated highly in our study. Function preservation and 
maintenance of QOL represent major goals for an increasing proportion of older patients.37 
In our study, QOL and health status were indeed factors that older patients considered 
more important in their decision making than younger patients. Comorbid health status is 
similarly a key consideration in the treatment decisions of physicians.8-10 Although 
emerging evidence suggests that adjuvant chemotherapy does not substantially alter the 
QOL of older patients38 and can provide a significant survival benefit in some chronic 
conditions,39 further research is needed if QOL and comorbidity are to cease being barriers 
to treatment. 
The preferences of older patients for information and involvement in decision making may 
also create a barrier to adjuvant chemotherapy use. Older patients are generally reported 
to prefer less information than younger patients and to prefer a more passive role in 
treatment decision making.22,23 This was the case in our study, with 40% not wanting 
detailed information about chemotherapy and 17% wanting to leave all treatment  
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decisions to the doctor. However, older patients were actually significantly more likely than 
younger patients to report that both understanding treatment procedures and 
understanding treatment benefits and side effects were important factors in decision 
making. In addition, those participants preferring not to be involved in decision making still 
rated 15 of 22 factors as important considerations. Similar paradoxes have been reported 
elsewhere,24,26 and may help to explain why physicians have difficulty predicting patient 
preferences.25 It has been suggested that patients seek to understand the rationale behind 
doctors’ recommendations rather than to make decisions themselves.40 Given that older 
patients have greater difficulty understanding and remembering the information they 
receive24,41 and may not feel comfortable asking questions of their physicians,23 the 
responsibility for ensuring that all patients are adequately informed and involved likely lies 
with physicians. Decision aids may be useful in increasing understanding, even where 
patients prefer a passive role in treatment decision making.42 
This was a relatively small single-site study, and the results should be interpreted with 
caution. None of the participants in our study refused chemotherapy, and therefore 
insights into actual barriers for this population could not be explored. Nevertheless, the 
results largely match previous findings about the decision-making processes of older adults 
and further illuminate specific age differences in CRC patients’ treatment decisions. 
Conclusion 
A range of factors appears to influence patients’ chemotherapy decision making, including, 
but not limited to, survival benefits and treatment toxicity. For older patients, balancing the 
risks and benefits of treatment may be made more complex by the impact of emotional 
motivators, greater health concerns, and conflicts between their need for understanding 
and their preferences for information and involvement in decision making. The variability in 
perceived barriers to treatment and preferences for information and involvement 
demonstrates the need for explicit and individualized assessment of both of these areas. 
Without formal assessment, physicians might assume that older patients would not travel  
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for adjuvant chemotherapy or that they do not want information on their prognosis and 
treatment. Through greater understanding of perceived barriers to treatment and unique 
motivators for treatment choice, older patients may be better supported to make fully 
informed decisions about their care. 
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6 
A risk model 
 
 
In Chapter 3, continuing age differences in the receipt of guideline-recommended adjuvant 
therapy in NSW were identified. The results of Chapter 4 indicate that surgeon knowledge 
and views are a contributing factor to these differences. The variability in older patients’ 
perceived barriers to treatment in Chapter 5 and their preferences for less information and 
decision-making involvement may also impact treatment receipt. Together, these findings 
suggest that more evidence-based tools should be developed to guide adjuvant therapy 
decisions and facilitate discussion of patient preferences and treatment benefits and risks. 
This chapter presents a mortality risk prediction model that could be used by clinicians to 
assist the treatment decision-making process. The model identifies older lymph node-
positive colon cancer patients who are unlikely to survive the first year after surgery and so 
would not benefit from adjuvant chemotherapy. The emphasis on a range of factors that 
predict mortality may help to reduce variation in guideline-recommended treatment that 
occurs on the basis of patient age alone.  
This chapter is presented as the following paper: 
Jorgensen ML, Young JM, Dobbins TA, Solomon MJ. A mortality risk prediction model for 
older adults with lymph node-positive colon cancer. [Submitted] 
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A mortality risk prediction model for older adults with lymph node-positive colon cancer 
6.1. Abstract 
BACKGROUND: Surgeons and oncologists are less likely to recommend adjuvant 
chemotherapy for older adults based on their age alone. Physicians may rely on 
chronological age as a proxy for other age-related factors when making treatment 
recommendations. The aim of the study was to develop a mortality risk model to assist 
treatment decision making by identifying patients who are unlikely to survive the first year 
after surgery and thus will not benefit from adjuvant chemotherapy. 
PATIENTS AND METHODS: All lymph node-positive patients aged ≥65 years receiving 
surgery for colon cancer in New South Wales, Australia in 2007/2008 were identified using 
a linked routinely collected population-based dataset (n=1,550). Multilevel logistic 
regression was used to build a model for predicting the risk of one-year all-cause mortality. 
Scores derived from each factor in the model were summed for each patient.  
RESULTS: One-year mortality was 11.5% after excluding those who died within 30 days of 
surgery (n=67). The risk model consisted of fourteen factors, including patient 
comorbidities, hospital admission factors, and other markers of frailty or health status. Age 
was not an independent predictor of mortality in the adjusted model. People with a total 
risk score of 0, 1 or 2 were considered at low risk (predicted one-year mortality of 3.0%), 
those scoring 3 to 6 at medium risk (7.5% mortality), and those with a score of 7 or above 
were considered at high risk of mortality (25.8% mortality). The model had good 
discrimination (AUC=0.791, 95% CI: 0.754-0.828) and calibration (p=0.46).   
CONCLUSION: The risk model developed in this study accurately predicts one-year 
mortality in older lymph node-positive cancer patients. The model may be useful in shifting 
the emphasis in treatment decision making from chronological age to the identification of 
those of any age who will live to benefit from these resources. 
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6.2. Introduction 
The majority of colorectal cancer cases occur in those aged over 65 years.1 For lymph node-
positive colon cancer, surgical resection followed by adjuvant chemotherapy is the widely 
recommended standard of care.2 Clinical practice guidelines explicitly state that age alone 
should not be used to exclude patients from being offered chemotherapy, as even those 
over 80 years can derive survival benefits.3 However, both surgeons and oncologists are 
less likely to recommend adjuvant chemotherapy for older adults on the basis of their age 
alone.4,5 Physicians may be relying on chronological age as a proxy for other age-related 
factors when making treatment recommendations.6 
The heterogeneity of the ageing process means that chronological age is not a reliable way 
to estimate life expectancy or the risk of treatment complications. Better predictors of 
patient outcomes include comorbidity, functional status, and other specific markers of 
frailty.7,8 Determining how these factors contribute to mortality risk for this subset of node-
positive patients is important, as survival is the primary benefit against which the risks of 
treatment are balanced. Results of randomised trials suggest that survival benefits from 
chemotherapy begin to emerge between one to two years after surgery.9,10 For those who 
are not likely to survive the first year, the potential impact of treatment on quality of life 
would make adjuvant chemotherapy untenable. Older patients who do survive this period 
may be as likely to benefit from treatment as younger patients, since mortality in the first 
postoperative year accounts for much of the age differences in survival following colorectal 
cancer surgery.11 
Prognostic indices appear to be a useful way to help move clinical decision making beyond 
arbitrary age cut-offs.12 A number of models and tools exist for determining mortality risk 
in older cancer patients, but these tend to focus on postoperative mortality for surgical 
decision making13-15 or are developed on single area samples.16 Risk tools for chemotherapy 
are generally developed to predict treatment toxicity17,18 or only involve a limited 
evaluation of health status as they are not specifically designed for older patients.19  
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Thus, the aim of the current study was to use population-based data to develop a mortality 
risk model for older node-positive colon cancer patients, which could be used in treatment 
decision making to clarify which patients would not benefit from adjuvant chemotherapy.  
6.3. Methods 
Data source 
A linked dataset was used that consisted of the records of all people with a first unique 
cancer of the colon, rectosigmoid junction or rectum registered in 2007 or 2008 by the 
population-based NSW Central Cancer Registry (CCR). Data on all public and private 
hospital separations from the NSW Admitted Patients Data Collection (APDC) and death 
data from the NSW Registry of Births, Deaths and Marriages were linked to the CCR data by 
the Centre for Health Record Linkage (CHeReL). Ethics approval was provided by the NSW 
Population & Health Services Research Ethics Committee. 
All people aged 65 years and over with lymph node-positive colon cancer that had an 
admission to a hospital for a surgical resection were identified from the dataset (see Figure 
1). Those who died within 30 days of surgery were subsequently excluded, as initiation of 
adjuvant chemotherapy does not generally occur before this time.20 
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Figure 1. Flowchart defining the denominator for the mortality risk model  
 
Developing the risk model 
Multilevel logistic regression was used to build a model for predicting the risk of one-year 
all-cause mortality. Multilevel models take into account the clustering of patients within 
hospitals (n=90 in the current study). Candidate predictors for the risk model were based 
on previously established prognostic risk factors for older cancer patients. These were 
patient age,7,13,21,22 marital status,22,23 emergency resection,13,21,24 long length of stay,16,24 
comorbidities as outlined in the revised Charlson comorbidity index,25 as well as 
depression, malnutrition, and falls risk, which are commonly assessed domains in geriatric  
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oncology.7 All of the candidate predictors were included in the final risk model.  A full 
model approach using a small number of pre-established candidate variables attempts to 
avoid overfitting and selection bias that is known to occur when variables are included in a 
risk model based on significance testing in univariate analysis.26 Age was categorised into 
five-year age intervals for ease of interpretation and usability of the risk model. 
Interactions between age group and all of the other variables in the final model were 
tested to determine whether there were any multiplicative effects of increasing age and 
other factors on mortality. 
Comorbidities were identified from the APDC hospital separations data using ICD-10-AM 
diagnosis codes.25 Malnutrition was similarly identified using diagnosis codes for mild, 
moderate or severe protein-energy malnutrition (E40-E46). Reduced mobility was defined 
from the codes for immobility (R26.3), other reduced or poor mobility (R26.8), difficulty in 
walking (R26.2), need for assistance due to reduced mobility (Z74.0), or presence of 
pressure ulcer (L89). The codes for falls (R29.81) and tendency to fall (R29.6) were used to 
identify those at high risk of falls. The accuracy of recording of comorbidities has been 
previously validated in NSW administrative data collections.27 While a number of the other 
health markers have been used in previous Australian research,28,29 their validity has not 
been assessed.  
The American Society of Anesthesiologists (ASA) physical health status score was available 
for 79.0% of the cohort. However, this variable couldn’t be used in the main model as the 
characteristics of those with missing ASA score differed from the rest of the cohort, 
indicating potential systematic bias in its recording. Those with missing ASA score were 
more likely to be treated in a private hospital (χ2[1]=54.4, p<0.001), have no comorbidities 
(χ2[1]=9.0, p=0.003), and have low socioeconomic disadvantage (χ2[4]=51.4, p<0.001) than 
those with ASA recorded. Two separate sensitivity models were run using the subset with 
ASA recorded to determine whether the inclusion of this variable improved the accuracy of 
the risk model. 
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Determining model accuracy and validity 
Model discrimination, or how well the model distinguishes between those who do and do 
not have the outcome, was assessed by calculating the area under the receiver operating 
characteristic curve (AUC or C-statistic). Model calibration, or how well the predicted 
outcome rates match the observed rates, was measured using the Hosmer-Lemeshow 
goodness-of-fit chi-square test. The internal validity of the risk model was assessed using 
bootstrap resampling.30 This technique simulates the process of sample generation from an 
underlying population by taking a large number of random samples of the same size as the 
original dataset, with replacement. With replacement means that an observation can be 
included repeatedly within a bootstrap sample while others may not be included at all. An 
optimism-corrected AUC was obtained by fitting the model to the bootstrap samples 
(n=500) and subtracting the average difference between the AUC in the samples and the 
original prediction model from the AUC in the original model.30 Because all data are used 
for model development, bootstrapping provides a more efficient and accurate estimation 
of internal validity than other techniques such as split-sample validation.30 
Developing risk scores 
A score for each factor in the risk model was calculated by dividing the beta coefficient of 
each variable by the lowest beta coefficient in the model, and rounding to the nearest 
whole number.31 A total risk score was assigned to each person by summing the scores for 
each present risk factor e.g. a person with pulmonary disease (5 points) who was 70 years 
old (1 point) but who did not have long length of stay (0 points) would have a total of 6 
points. Predicted outcome rates were calculated for each total score level using the model 
regression formula.  
Categories of low, medium, and high risk were created by dividing the cohort into three 
equal sized groups, ordered by total risk score. This is the preferred method in the absence 
of an a priori clinical consensus on grouping cut-points.32 Rates of one-year mortality for 
each risk category were based on the predicted model estimates from the risk model. 
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6.4. Results 
1,483 people aged ≥ 65 years were diagnosed with lymph node-positive colon cancer in 
2007/2008 and survived longer than 30 days after surgery. Of these people, 170 (11.5%) 
had died within one year. Patient characteristics are presented in Table 1. Notably, 42.6% 
of the one-year mortality occurred within the first 30 days for those over 85 years, 
compared to 24.0% for the rest of the cohort.  
Risk model predictors 
Table 2 presents the adjusted odds ratios for the 14 factors included in the risk model. 
While increasing patient age was a significant predictor of one-year mortality in univariate 
regression (χ2[5]=15.8, p=0.008), this association was no longer evident after adjusting for 
other risk factors (p=0.79). Most of the other factors in the risk model were significant 
independent predictors of mortality, including hospital admission factors (emergency 
admission, long length of stay), comorbidities (dementia, pulmonary disease, kidney or liver 
disease, other cancer), and other markers of frailty or health status (previous emergency 
admissions, malnutrition, reduced mobility or falls risk). There were no significant 
interactions between age group and any other factor in the risk model. 
One-year mortality following surgery varied between hospitals. Approximately 2.5% of the 
total variability in one-year mortality was attributable to hospitals in the risk model 
(hospital variance [SE] = 0.08 [0.10], intraclass correlation coefficient = 0.025). Adding 
hospital type and location to the patient characteristics in the model did not help to explain 
this variation (intraclass correlation coefficient = 0.023). 
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Table 1. Characteristics of older patients receiving surgery for node-positive colon cancer 
 n (%) 
Age at diagnosis (65-69) 319 (21.5) 
70-74 344 (23.2) 
75-79 338 (22.8) 
80-84 293 (19.8) 
85-89 157 (10.6) 
90-95 (max) 32 (2.2) 
Male 728 (49.1) 
No current partner (single/divorced/widowed) 562 (38.4) 
Socioeconomic status (SEIFA)  
1 Least disadvantaged 334 (22.5) 
2 260 (17.5) 
3 304 (20.5) 
4 291 (19.6) 
5 Most disadvantaged 293 (19.8) 
ASA physical health status*  
1 Healthy 62 (4.2) 
2 Mild systemic disease 523 (35.3) 
3 Severe systemic disease 504 (34.0) 
4 Severe systemic disease, constant threat to life 82 (5.5) 
Hospital type – public (vs private) 924 (62.3) 
Hospital location – metropolitan (vs rural/regional) 1,023 (69.0) 
Emergency admission for resection 252 (17.0) 
Length of stay > 21 days 247 (16.7) 
Comorbidities  
Congestive heart failure 48 (3.2) 
Dementia 15 (1.0) 
Chronic pulmonary disease 50 (3.4) 
Kidney or liver disease 66 (4.5) 
Diabetes with chronic complications 38 (2.5) 
Other malignancy (non-colorectal) 43 (2.9) 
Depression 22 (1.5) 
Markers of frailty or health status  
Previous emergency admissions (1 or more) 688 (46.4) 
Malnutrition 21 (1.4) 
Reduced mobility or high falls risk 56 (3.8) 
*Some data missing; SEIFA = Socio-economic indexes for areas43  
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Table 2. Risk factors for one-year mortality in multilevel logistic regression model 
 Adjusted OR (95% CI) P value 
Age group (ref= 65-69)  0.79 
70-74 1.3 (0.7-2.3)  
75-79 1.2 (0.7-2.2)  
80-84 1.5 (0.8-2.7)  
85-89 1.0 (0.5-2.1)  
90+ 1.2 (0.4-3.7)  
No current partner 1.2 (0.8-1.8) 0.29 
Hospital admission factors    
Emergency admission for resection 1.6 (1.1-2.5) 0.02 
Length of stay > 21 days 2.1 (1.4-3.3) <0.001 
Comorbidities    
Congestive heart failure 1.5 (0.7-3.3) 0.27 
Dementia 4.4 (1.4-14.0) 0.01 
Chronic pulmonary disease 2.3 (1.1-4.8) 0.02 
Kidney or liver disease 2.5 (1.3-4.7) 0.007 
Diabetes with chronic complications 1.2 (0.6-2.4) 0.53 
Other malignancy (non-colorectal) 2.8 (1.8-4.5) <0.001 
Markers of frailty or health status   
Depression 1.2 (0.3-5.6) 0.83 
Previous emergency admissions 1.6 (1.1-2.4) 0.01 
Malnutrition 4.1 (1.5-11.3) 0.007 
Reduced mobility or high falls risk 2.7 (1.3-5.3) 0.006 
Model accuracy and validity 
The AUC for the risk model was 0.791 (95% CI: 0.754-0.828), indicating good to very good 
discrimination.12 There was evidence that this model had considerably better 
discrimination than a model with age as the sole predictor of mortality (AUC=0.634, 95% CI: 
0.589-0.678; p<0.001). The Hosmer-Lemeshow test for the risk model indicated no 
significant lack of fit (χ2[10]=9.74, p=0.46). No multicollinearity was apparent in the model, 
with all variance inflation factors less than 2.  
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The optimism-corrected AUC based on the bootstrap resampling was 0.736 (95% CI: 0.645-
0.828). This measure of interval validity indicates that the model would still have good 
discriminatory power when applied to new patients with similar characteristics. 
ASA health status was significantly associated with one-year mortality in univariate analysis 
(χ2[3]=55.6, p<0.001). However, the discriminatory ability of the risk model was not 
substantially increased by the inclusion of this variable in a subset sensitivity analysis for 
those with ASA recorded. Without ASA score in the model, the AUC for the risk model in 
this subset population was 0.805 (95% CI: 0.765-0.845). Adding ASA score to the model, the 
AUC was 0.811 (95% CI: 0.773-0.849). There was some evidence of multicollinearity 
between ASA score and the variable “previous emergency admission”. These factors were 
independent predictors of mortality when entered into the model separately, but when 
both factors were in the model neither was significant and their variation inflation factors 
were between 4 and 7. Indeed, ASA status was significantly associated with previous 
emergency admission in univariate regression (χ2[3]=52.4, p<0.001). Previous emergency 
admission may therefore be a useful proxy variable for ASA status. 
Risk scores 
Scores for each factor in the risk model are presented in Table 3. A person with all of these 
risk factors (excluding age) would receive a total risk score of 54. In our cohort, total scores 
ranged from 0 to 31 (mean [SD] = 5.4 [5.1], median = 4.0). Figure 2 displays the observed 
and predicted rates of one-year mortality by total risk score. For this figure, the 14 people 
scoring over 22 (0.9% of the cohort) were grouped with those scoring 22 to create a more 
reliable point estimate. 
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Table 3. Scores for each factor in mortality risk model 
 β coefficient (SE) Score 
Age group   
70-74 0.24 (0.30) 1 
75-79 0.20 (0.30) 1 
80-84 0.40 (0.30) 2 
85-89 0.02 (0.36) 0 
90+ 0.18 (0.58) 1 
Depression 0.17 (0.79) 1 
No current partner 0.20 (0.19) 1 
Diabetes with chronic complications 0.21 (0.34) 1 
Congestive heart failure 0.43 (0.39) 2 
Previous emergency admissions 0.48 (0.19) 3 
Emergency admission for resection 0.50 (0.21) 3 
Length of stay > 21 days 0.76 (0.22) 4 
Chronic pulmonary disease 0.85 (0.36) 5 
Kidney or liver disease 0.90 (0.33) 5 
Reduced mobility or falls risk 0.98 (0.36) 6 
Other malignancy 1.05 (0.23) 6 
Malnutrition 1.40 (0.52) 8 
Dementia 1.49 (0.59) 9 
Predicted rates of one-year mortality for each risk category were calculated from the 
model estimates. Those with a total score of 0, 1 or 2 were considered at low risk 
(predicted one-year mortality of 3.0%), those scoring 3 to 6 at medium risk (7.5% 
mortality), and those with a score of 7 or above were considered at high risk of mortality 
(25.8% mortality). The proportion of people at high risk of one-year mortality increased 
with age (χ2[5]=100.6, p<0.001), from 15.0% of those aged 60-64 years to 46.9% of those 
aged ≥ 90. 
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Figure 2. One-year mortality by total risk score 
 
6.5. Discussion 
This study used population-based data to develop a risk model that predicts one-year 
mortality in older node-positive colon cancer patients with considerably greater accuracy 
than a model based on patient age alone. While age was associated with mortality in 
univariate regression, it was not an independent predictor in the risk model after 
accounting for other factors such as comorbidities, hospital admission factors, and markers 
of frailty or health status. The model could be useful in clarifying which patients would not 
benefit from adjuvant chemotherapy. 
There is evidence that older colon cancer patients experience similar survival benefits from 
adjuvant chemotherapy as younger patients, without substantial increases in toxicity.3 
However, the diminishing returns of any curative treatment with increasing age may cause 
clinicians to apply an arbitrary age cut-off, if it is not clear which older patients will live to 
benefit from treatment. In our study, age was not associated with one-year mortality after  
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adjusting for comorbidities and other health-related factors. Similar findings have been 
reported in a number of studies of mortality in cancer patients.33,34 Patel and colleagues 
(2013) suggest that higher rates of 30-day mortality in older patients account for much of 
the overall age differences in survival.35 This was also a likely contributing factor to our 
finding for age, as the large proportion of people over 85 who died within 30 days were 
necessarily excluded. Those elders who survive this period and do not have significant 
health problems may therefore represent a group who could benefit from adjuvant 
chemotherapy well into their 80s and beyond. While older age was not an independent risk 
factor in our study, a greater proportion of the older groups were deemed at high risk of 
one-year morality due to increasing prevalence of health conditions, and these people 
clearly have less to benefit from chemotherapy. Nonetheless, the risk model may be useful 
in helping to shift the emphasis in treatment decision making from chronological age alone 
to the identification of those of any age who will live to benefit from these resources. 
Our risk model may also be useful for identifying older adults who require more 
comprehensive assessment and ongoing management to better cope with treatment. 
While routine screening to identify vulnerable and frail elderly is widely recommended,36 
there is no consensus on the definition of frailty, 37 and current screening tools have 
insufficient discriminative power to select cancer patients for further evaluation.38 
However, consistent predictors of risk across the literature imply that programs known to 
improve outcomes should be more regularly employed. Targeting malnutrition and physical 
mobility or function in cancer prehabilitation can decrease treatment-related morbidity 
and improve health outcomes.39 Length of stay can be reduced through the incorporation 
of Enhanced Recovery After Surgery (ERAS) protocols to ease surgical stress and minimise 
complications,40 and improved screening of older people can help to lessen the risks 
associated with emergency resection.41 Poorer survival for those without a current partner 
suggests that social support remains a key target area. In addition, the variability in 
mortality that was attributable to the hospital where surgery was performed indicates the 
need to further explore and address potential differences in the provision of care. 
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Markers of patient frailty or health status are frequently unavailable in routinely collected 
administrative datasets and are not often incorporated in prognostic models, though they 
can add important information about mortality risk8 and would readily form part of 
clinician judgement in practice. In the current study, ASA physical status could not be used 
as the characteristics of those with missing ASA score differed from the rest of the cohort. 
The variable ‘previous emergency admissions’ could be a potential substitute for ASA status 
in research or peer comparisons that rely on administrative data, as there was a strong 
association between these variables, and model performance was similar whether one or 
other of these variables was used. The discrimination and calibration results for our risk 
model were also as good or better than many other mortality models.12 Nonetheless, more 
complete data for ASA status or the incorporation of other health measures such as ECOG 
performance status or activities of daily living could further increase the accuracy of the 
risk model and therefore its usefulness. 
Although routinely collected population data can lack breadth, one advantage that it has 
over other methods of data collection is a reduction in the potential for sampling bias. The 
risk model developed in this study may be more clinically acceptable than similar models in 
that it uses population-based data as well as incorporates markers of frailty and health 
status. The optimism-corrected AUC also indicated that the model should perform well 
when applied to other patients that are similar to the development sample. However, 
external validation is required if the risk model is to be used outside of NSW, particularly as 
colorectal cancer mortality in this state is relatively low compared to many other areas.42 
Another limitation of this study is the high likelihood of underascertainment of 
comorbidities and other health status markers through the use of hospital separations 
data.27 While many of these factors have been reported to have high specificity,27 some 
comorbidities may not have been recorded where they were not perceived to directly 
impact on the patient’s cancer or treatment. Finally, any prognostic model will ultimately 
only be useful if there is evidence of its clinical effectiveness. The proposed risk model is 
currently being developed into an online tool where its ability to impact treatment decision 
making and improve patient assessment and management will be evaluated. 
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For older cancer patients, treatment decisions involve careful consideration of the 
potential risks and benefits of treatment. Major gaps in evidence from clinical trials about 
the optimal treatment of older patients,3 and the significant financial costs associated with 
chemotherapy within a finite health system, make these decisions all the more difficult. 
Despite limitations of the data, the current study creates a greater understanding of how 
pre-existing patient factors influence outcomes for a specific population who are 
potentially at risk of suboptimal care. A tool developed from the risk model may be useful 
in helping to supplement clinicians’ judgements about prognosis and the utility of adjuvant 
chemotherapy, and could be incorporated into shared decision-making discussions 
alongside quality of life considerations, patient preferences, and the potential for 
treatment toxicity. By shifting the emphasis from chronological age to better predictors of 
survival, the variation that occurs on the basis of age alone may be reduced and the care 
and outcomes of older cancer patients may improve. 
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7 
Conclusions 
 
 
This thesis has presented a series of studies exploring the barriers to evidence-based care 
for older people with colorectal cancer, with a focus on the receipt of guideline-
recommended adjuvant chemotherapy and radiotherapy. While differences in the 
treatment of older patients continue to exist in NSW (Chapter 3), decision making for this 
population is inherently complex. Issues in the measurement of outcomes (Chapter 2), 
surgeon knowledge and views (Chapter 4), and patient preferences (Chapter 5) appear to 
contribute to age differences in treatment. A risk model that could be used by clinicians to 
assist treatment decision making was developed (Chapter 6). This final chapter outlines the 
unique contributions of this thesis to the literature, addresses limitations, and discusses 
implications for clinical practice and future research that will be needed to ensure greater 
understanding and improved outcomes for this growing and potentially vulnerable group.  
7.1. Summary of unique research findings 
7.1.1. Measurement 
Chapter 2 examined potential issues in the measurement of patient-reported outcomes 
(PROs) that may affect the treatment and care that older patients receive. In Study 1, the 
supportive care needs of older and younger patients were compared at one month and 
three months after hospital discharge for colorectal cancer surgery. As in prior research,
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younger age was an independent predictor of unmet need for nearly all domains at both 
time points. However, this study was unique in exploring whether this counterintuitive 
finding resulted from older patients being more likely to have their needs met (‘satisfied’). 
In this study, older patients were actually less likely than younger patients to report 
‘satisfied’ needs, instead being more likely to report that they had ‘no need’ (‘not 
applicable’). These results may indicate that older patients are less likely to express their 
needs for help, or that their needs are not being adequately captured.  
The study also adds to the literature by clarifying the absolute prevalence of unmet needs 
for older patients across the cancer trajectory. More than half of all older patients had 
unmet needs at one month (56%), and this figure had increased to 65% by three months. 
While expressing relatively fewer unmet needs than their younger counterparts, older 
patients may have less capacity to cope with any level of unmet need due to poorer health 
and less social support. 
In Study 2, age differences in item non-response were explored in quality of life (QOL) 
assessments that had been completed at baseline, one month and three months after 
hospital discharge. As in previous research for other patient groups, older age was 
associated with non-response to a number of ‘sensitive’ questionnaire items (e.g. sex life, 
diarrhoea), as well as greater levels of missing data overall. This study was unique in further 
examining the effects of this missing data on QOL estimates. QOL in one domain was 
significantly overestimated when the suggested ‘simple mean imputation’ method was 
used to manage missing data, and item non-response was associated with poorer QOL 
overall. Where studies exclude patients with missing data, the QOL of older cancer patients 
may be inadequately or inaccurately represented.  
7.1.2. Local context 
In Chapter 3, linked population-based administrative and clinical data was used to 
determine whether patient age alone remains a predictor of adjuvant therapy receipt for 
colorectal cancer in NSW. Other local factors that may hinder or facilitate adjuvant therapy 
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use were also identified. While previous state-based estimates of adjuvant treatment 
receipt have relied on resource-intensive clinician surveys, routinely collected clinical 
registry data was used for the first time in this study to monitor patterns of care. 
The analysis revealed that increasing age remains an independent predictor of non-receipt 
of chemotherapy for lymph node-positive colon cancer and radiotherapy for high-risk rectal 
cancer. However, the overall levels of chemotherapy and radiotherapy use represent a 
considerable increase on treatment rates from a previous NSW study conducted in 2000, 
consistent with international trends. The current study accounted for both comorbidities 
and physical status (ASA score), which is rare in population-based health inequality studies. 
Determining the sources of variation in treatment through the use of three-level data 
modelling to account for the clustering of patients by surgeon and the clustering of 
surgeons within hospitals was another unique contribution of the study. Though much of 
the variation in adjuvant therapy receipt was found to be due to patient characteristics, the 
hospital where surgery was performed accounted for a considerable proportion of 
treatment variation. Other predictors of treatment receipt in this study, such as discussion 
of the case at a multidisciplinary meeting, indicate further opportunities to improve care.  
7.1.3. The surgeon 
Surgeons act as important gatekeepers to the care of patients after their cancer surgery. 
Chapter 4 outlined the findings of a self-administered survey of Australian and New 
Zealand colorectal surgeons. The study aimed to identify factors affecting surgeons’ 
decisions to refer older patients with colorectal cancer for adjuvant therapy by 
investigating surgeon knowledge, opinions, and self-reported practice across a range of 
scenarios. 
Colorectal surgeons were significantly less likely to refer older patients with node-positive 
colon cancer for adjuvant chemotherapy than younger patients, based on chronological age 
alone. While previous physician surveys have tended to focus on patient age and 
comorbidity, this study found that other factors such as distance to treatment and social 
 217 
support had considerable effects on surgeons’ recommendations for referral of older 
patients. Lack of consensus among surgeons about the treatment of older patients was 
another major feature of the survey. Both knowledge and opinions about current research 
evidence and adjuvant therapy receipt were strongly associated with referral 
recommendations. In particular, older surgeons were less likely to report views that were 
consistent with national guidelines and less likely to hold similar opinions toward older and 
younger patients. Overall, 39% of colorectal surgeons indicated that there is an upper age 
limit after which chemotherapy is no longer worthwhile. These findings indicate that 
variation in surgeon opinions and practices may contribute to differences in the treatment 
of older patients. 
7.1.4. The patient 
It has been reported that older cancer patients are more likely to refuse recommended 
adjuvant therapy than younger patients. In Chapter 5, patient-based barriers to adjuvant 
chemotherapy use were investigated through a self-administered survey of patients who 
had undergone colorectal cancer surgery within the previous 24 months. The survey aimed 
to identify factors that distinguish the decision-making processes of older patients from 
younger patients, including preferences for information and involvement in treatment 
decisions. 
Previous research in this area has tended to focus on the balance of toxicity and survival 
benefits, or the strength of preferences for adjuvant therapy, or has not specifically 
investigated age differences in barriers. This survey found that a range of factors were 
uniquely important to older patients’ treatment decision making. Fear of dying, health 
status, age, quality of life, and understanding treatment procedures and effects were more 
important to older patients than younger patients in deciding whether to accept 
chemotherapy. While older patients preferred less information and less involvement in 
treatment decisions, the majority of the older group did want detailed information about 
chemotherapy and some level of involvement in decision making. A novel finding of this  
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study was that patients who preferred less information and involvement still rated many 
factors as important in their decision making, including understanding treatment 
procedures and their effects. The results imply that treatment decisions for older patients 
may be more complex because of the impact of emotional motivators such as fear and 
perceptions about ageing, their greater health concerns, and conflicts between their need 
for understanding and their preferences for information.  
This study also revealed that surgeons’ and patients’ perceived barriers to adjuvant 
chemotherapy use may differ. Practical barriers such as distance to treatment were 
important to the colorectal surgeons surveyed in Chapter 4, but were not important to the 
older patients in this study.  
7.1.5. A risk model 
A mortality risk prediction model was presented in Chapter 6 that could be used to identify 
older patients who will not benefit from adjuvant chemotherapy. Physicians may use 
chronological age as a proxy for survival, though this is not a reliable way to estimate an 
individual patient’s prognosis. Previous risk models for chemotherapy in older patients 
have been developed to predict treatment toxicity only. Where risk models have focused 
on survival, they are not specifically designed for older patients, or are only based on small 
single-centre samples. 
Age was not a significant predictor of one-year mortality after excluding those who died 
within 30 days and accounting for other age-related factors. Instead, a range of factors 
including patient comorbidities, hospital admission factors, and other markers of health or 
frailty were used to build a model that predicted mortality risk with greater discrimination 
than age alone. This model was unique in being developed on a large population-based 
dataset, while also incorporating markers important to the assessment of older patients 
such as reduced mobility and malnutrition. The model may be useful in shifting the 
emphasis in chemotherapy decision making from chronological age alone to the 
identification of those of any age who may live to benefit from these resources. 
 219 
7.2. Practical implications of findings 
7.2.1. For future research 
PROs such as quality of life and supportive care needs are increasingly being seen as central 
to cancer treatment decision making.1 In Chapter 5, older patients rated QOL as more 
important to their decision making than younger patients, consistent with previous 
literature.2 However, recent research suggests that many oncologists do not feel 
comfortable using PRO data to inform clinical practice and their discussions with patients.3 
One cause may be a lack of methodological rigour in analysis and reporting.4 Findings from 
Chapter 2 highlight the need for transparency of reporting of PROs for older patients 
particularly. Without noting the reasons why older patients are less likely to report unmet 
needs, clinicians may assume that older patients are simply more likely to have their needs 
‘met’. Where missing data or methods for handling missing data are not reported in QOL 
studies,5 clinicians cannot determine whether accurate conclusions have been drawn about 
the QOL of those at greater risk of non-response.  
A focus on relative age differences in many studies may also affect perceptions of older 
patients’ needs, well-being, and treatment preferences. While older patients expressed 
relatively fewer unmet needs than younger patients in Chapter 2, over half reported unmet 
needs at both one and three months after surgery. Reporting solely that older patients 
have fewer unmet needs or better QOL may create the impression that their needs and 
well-being are being adequately addressed. Similarly, studies that report older patients 
prefer less treatment information and involvement in decision making should also 
document whether, as in Chapter 5, the majority of older patients actually would prefer to 
be involved and fully informed. 
Much of the literature approaches issues in cancer and ageing from a disease-based 
perspective, with a particular emphasis on comorbidity. Consideration of comorbidity is 
certainly essential, in that chronic conditions can increase the risks of treatment and  
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decrease the potential for benefit.6 However, greater understanding of the reasons for age 
differences in adjuvant therapy receipt likely requires a more ‘holistic’ approach, including 
consideration of psychological, social ageing, and lifespan aspects. In Chapters 4 and 5, the 
multifactorial nature of physicians’ and patients’ decision making was highlighted. 
Perceptions about the importance of social support, QOL, logistical barriers, and cognitive 
or affective factors appear to inform how both patients and physicians balance the 
potential risks and benefits of treatment. An individual’s personal experiences and their 
own age will influence their views about ageing and disease, as well their beliefs about 
whether and for whom treatment is worthwhile. A number of surgeons specifically 
commented that all patients should be equally considered for treatment. However, 20% of 
surgeons reported that younger patients should have preference over older patients given 
the limited resources of the Australian health system. The rationality of patients’ decision 
making at such a highly stressful time has also been questioned.7 Older patients may be 
more vulnerable to forgoing worthwhile treatment because of a fear that cancer is a death 
sentence, or differences in their preferences for risk taking and certainty.8 More research is 
therefore required to understand how these psychosocial factors underlie decision-making 
processes and preferences for both physicians and patients. 
A ‘holistic’ approach also appears to be important in examining how variation in practice 
occurs within the health care system. Variation was a hallmark of surgeon opinions and 
practice recommendations for older patients in Chapter 4. However, a multilevel modelling 
approach using a population-based dataset in Chapter 3 indicated that the hospital of 
surgery was a far greater source of variation in treatment receipt than the surgeon, 
suggesting that these clinicians may actually hold similar preferences against the referral of 
older patients. The effects of the hospital and clinician are generally neither entirely 
independent nor synonymous.9 Highly-trained clinicians may be attracted to hospitals 
where there is greater access to a range of specialist colleagues, a factor that is associated 
with adjuvant treatment receipt.10 Further exploration of these complex interactions and 
patient care pathways is needed, and are important considerations for future research that 
aims to determine sources of treatment variation. 
 221 
Understanding the reasons for differential treatment of older patients requires good 
quality data. Chapter 3 demonstrated that linkage of existing health datasets is a promising 
way to monitor at-risk patient groups in NSW. With greater coverage and access to data 
collected in the private sector, these resources could provide a timelier and more cost-
effective way of conducting patterns of care studies in NSW. Routine recording of factors 
such as patient refusal of treatment, or greater completeness of important health 
measures such as performance status or ASA physical status, would allow greater insight 
into the causes and magnitude of health inequalities. However, increasing the use of 
existing data in research is also feasible. In Chapter 6, a number of health measures were 
able to be extracted from hospital data and used to build a risk model that accurately 
predicts mortality for older colon cancer patients. While further validation of these 
variables and greater collection of physical performance measures is required, the results 
also indicated that potential proxy health measures, such as previous emergency 
admissions, could be useful in the interim. 
7.2.2. For clinical practice 
The concept of unmet needs appears to have originated in the gerontology literature.11 It 
has evolved from an objective assessment of existing support for any functional deficits to 
increasingly focus on patient-perceived needs.11 However, relying on patient-reported 
assessments may actually be detrimental to the outcomes of older patients. The results of 
Chapter 2 support previous findings that older patients are less likely to report their health 
needs. This could result from a number of factors including stoic attitudes towards 
coping,12 lower expectations of care,13 or being less willing to disclose ‘sensitive’ health 
issues, as in Chapter 2. When coupled with a tendency for physicians to be less 
communicative with older patients and to underestimate their needs,14,15 older adults may 
be less likely to receive the care that would enable them to better cope with their cancer 
and cancer treatment, including adjuvant therapy. Increasing physicians’ awareness of their 
communication behaviours and their use of specific communication techniques could 
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facilitate older patients to express their concerns.16 Involving family or caregivers can also 
provide critical information, though the patient should always have the final word.17  
More explicit and individualised assessment of patient preferences may also be necessary 
to ensure older patients are fully informed and supported throughout the decision-making 
process. In Chapter 5, a range of factors were important to older patients’ treatment 
decisions, and there was considerable variability in patient preferences for information and 
involvement in decision making. Without formal assessment, physicians might assume that 
travelling for treatment is an important factor for older patients (as in Chapter 4), where 
patients themselves may not actually perceive this as a barrier to adjuvant therapy use (as 
in Chapter 5). An additional consideration is the apparent clash between older patients 
wanting less information and involvement in treatment decisions than younger patients, 
but being more likely to rate understanding of treatment as an important factor. Decision 
aids can be useful for all patients, including those who seek to understand the reasoning 
behind doctor’s recommendations without wanting to make treatment decisions 
themselves.18 Nonetheless, the majority of older patients in Chapter 5 did want to be fully 
informed and involved in their treatment decisions. Greater tailoring of information and 
awareness of the factors that individual patients perceive as important may help to 
improve patient satisfaction with decision making and ultimately patient outcomes. 
The weight of the evidence suggests that non-receipt of adjuvant therapy rests 
predominantly in the hands of physicians. Physician recommendation and trust in the 
physician were rated highly by patients in Chapter 5, as in previous research.19 The vast 
majority of older patients are willing to accept chemotherapy if it is offered.20,21 In a 
patterns of care study conducted in NSW in 2000, the proportion of patients with node-
positive colon cancer refusing referral for adjuvant chemotherapy was 8.5%.22 Too often, 
older patients report that adjuvant therapy was not discussed.23,24 Variation in surgeon 
opinions and knowledge in Chapter 4 suggests that the individual surgeon a patient sees 
may determine whether they are referred for adjuvant therapy. The variation between  
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hospitals in rates of adjuvant therapy receipt in Chapter 3, and rates of one-year mortality 
in Chapter 6, demonstrate that the care a patient receives can depend on the hospital they 
attend for surgery. 
However, variation also indicates that there is potential for improvements in care and 
outcomes. Multidisciplinary team meetings, a predictor of adjuvant therapy receipt in 
Chapter 3, can be effective in decreasing variation in management and survival.25,26 
Certainly, surgeons who work closely with oncologists have been found to have higher 
oncology consultation rates, which is a crucial factor in adjuvant therapy receipt.27 The 
involvement of other disciplines such as the geriatrician and general practitioner are often 
advocated as part of shared care models or clinical care pathways for older patients.28,29 
Decreases in unmet need over time were less apparent for older patients in Chapter 2, 
suggesting a more prolonged assault of surgery and a need for greater ongoing monitoring, 
possibly through general practitioners in primary care. Other factors associated with 
adjuvant therapy use in Chapter 3, such as having a current partner, and the high 
importance that older patients placed on maintaining independence in Chapter 4, further 
indicate that greater social support and access to care may be necessary to facilitate 
adjuvant therapy use.  
Chen and colleagues suggest that underutilisation of treatment for older cancer patients 
may be reduced if physicians had better tools to select patients who would benefit from 
and tolerate treatment.30 It is now widely legislated that chronological age must not be 
used as a proxy for the proper assessment of individual need.31 Indeed, age was not an 
accurate way of determining who will live to benefit from health resources in Chapter 6. 
Clinicians’ estimates of life expectancy can be imprecise.32 Risk stratification through the 
use of a simplified tool, such as that proposed in Chapter 6, may be a useful way to 
supplement physician judgements in the absence of the considerable resources that may 
be needed to complete the ‘gold standard’ comprehensive geriatric assessment for all 
patients.33 Such tools can also be useful for identifying patients who may benefit from  
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prehabilitation strategies to optimise their health before starting treatment.34 In Chapter 6, 
the mortality risk model that was developed indicated that factors such as malnutrition, 
length of stay, and emergency resection are potential targets for improving the outcomes 
of older patients. 
7.3. Limitations 
7.3.1. Adjusting for confounders 
Determining whether age alone is a predictor of care or outcomes requires that factors 
associated with age, such as comorbidity and functional status, are both collected and used 
in analyses. The incorporation of health markers in clinical trials and population-based 
databases has been identified as a major gap in geriatric oncology research.35 In Chapter 3, 
measures of both comorbidity and ASA physical status were able to be extracted from 
existing hospital data collections to examine age differences in adjuvant therapy receipt. A 
number of other health markers were able to be utilised to develop a mortality risk model 
for node-positive colon cancer patients in Chapter 6. However, it is likely that comorbidities 
and health markers are underascertained in the health datasets used for both of these 
studies. 
There is also no gold standard approach to measuring comorbidity in cancer.36 The use of a 
summary score may miss the impact of specific comorbidities, or the potential 
multiplicative effect of two or more chronic conditions in combination.37 A standard 
validated summary score (Charlson index) was used in Chapter 3, while individual 
comorbidities were used in Chapter 6 to develop a more user-friendly risk model. Physical 
function is perhaps of greater importance for treatment decision making in older patients, 
and will not be adequately captured by a single physical status score. Indexes that predict 
physical function could therefore have greater usefulness for this population.38 Increasing 
the completeness and collection of health status measures is vital for ensuring that the rich 
information provided by population-based datasets can be better utilised to generate 
evidence for underresearched groups such as older cancer patients. 
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Another major challenge when comparing older and younger populations is separating the 
effects of age, cohort and period.39 That is, determining whether observed age differences 
are intrinsically due to the process of ageing, or can be attributed to the time in which a 
cohort grew up in, or are living in at present. These factors cannot be separated in the 
studies conducted as part of this thesis, as they are all cross-sectional (or short-term 
longitudinal) in nature. Older patients and physicians may have views about treatment and 
the medical encounter stemming from the poorer medical outcomes of the past, or from 
previous paternalistic models of care. Concerns about functional suitability for treatment 
could also be the result of cohort attitudes about the effect of functional dependence on 
family, or about present-day technology that is available to facilitate independence. As the 
baby boomer generation approaches old age, barriers and facilitators of treatment will 
likely change in response to the growing demand for services, views on how to allocate 
resources, and the high expectations of this generation for their health, longevity, and 
care.40 Ongoing monitoring of vulnerable groups is therefore necessary. 
Social desirability bias in self-report questionnaires can confound results.41 The potential 
for older patients to underreport their symptoms was discussed in Chapter 2. Physicians 
have also been found to overestimate their adherence to treatment guidelines.42 The 
finding that surgeon age was a predictor of survey responses in Chapter 4 could be biased if 
younger surgeons were more likely to inaccurately portray themselves as treating older and 
younger patients similarly. Nonetheless, considerable differences remained in referral 
recommendations for older and younger patients in this survey. 
7.3.2. Internal and external validity 
While the surgeon survey in Chapter 4 achieved a good response rate (70%) and had a 
relatively large sample size (n=102), the studies of patients’ needs and QOL in Chapter 2 
and the patient survey in Chapter 5 consisted of relatively small samples (n<70) recruited 
from a single tertiary referral hospital. There is the potential that these studies were 
underpowered to detect age differences in unmet needs, missing data, or factors of  
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importance for patients’ decision making. The patients recruited for these smaller studies 
were broadly representative of CRC patients in terms of sex, cancer stage, and country of 
birth, however the median age of both of these populations was 4-5 years lower than 
would be expected. These factors may affect the generalisability of the findings, 
particularly for the older age groups. In the patient survey of barriers to chemotherapy use, 
none of the participants had refused adjuvant therapy. Insights into actual barriers could 
therefore not be deduced. While the findings of these small studies should be treated with 
caution, it is encouraging that the results are largely consistent with previous findings and a 
priori hypotheses. 
The trade-off between the cost and quality of data is an ongoing issue in monitoring the 
quality of care at a population level.43 Issues in the coverage and completeness of the 
ClinCR dataset used to determine rates of adjuvant therapy uptake were extensively 
discussed in Chapter 3. However, the findings of Chapter 3 are likely to have high validity in 
the Australian context, as one third of the country’s population resides in NSW. Developing 
cancer-specific geriatric tools is frequently cited as a priority area for improving the care 
and outcomes of older patients.44,45 The use of local data to develop a risk model that 
included markers of frailty and health status in Chapter 6 may increase the clinical 
credibility and therefore the usefulness of this model, though it requires further 
development and testing. 
7.3.3. Specific research gaps 
This thesis did not explore the potential for the impact of the oncologist on the treatment 
of older patients. While surgeons have previously been found to act as important 
gatekeepers in the receipt of adjuvant therapy, oncologists also appear to hold preferences 
against the treatment of older patients46 and are less likely to recommend adjuvant 
therapy even in the absence of comorbidity.47 In Chapter 3, the hospital variation in 
adjuvant therapy receipt that was present after accounting for surgeons could point to 
differing practices of oncologists, or breakdowns in the care pathway. An important  
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consideration for research examining surgeon treatment patterns in isolation is that 
surgeons generally happen to fall before oncologists in the treatment pathway. That is, the 
surgeon may select out those who the oncologist would deem unfit for adjuvant therapy 
anyway. Where hospital variation in adjuvant therapy receipt is large, a system-based 
approach to intervention may therefore be necessary. 
This thesis also focused primarily on issues in adjuvant chemotherapy for colon cancer, 
rather than adjuvant or neoadjuvant radiotherapy for rectal cancer. While having similar 
aims in terms of prevention of recurrence and survival, these treatments differ significantly 
in their effects on the body and in surgical issues dictated by the tumour location. Overall 
rates of radiotherapy for rectal cancer were lower than rates of chemotherapy for colon 
cancer in Chapter 3, consistent with previous research. However, age differences in 
radiotherapy receipt were less significant. This finding was reflected in Chapter 4 where 
there was greater consensus between surgeons that age alone should not be a barrier to 
radiotherapy use. Greater exploration of the decision-making issues unique to radiotherapy 
in rectal cancer is needed, including the smaller potential benefits resulting from improved 
surgery techniques, additional local concerns around out-of-pocket costs and travel,48 and 
the investment needed in new facilities to keep pace with the demand for services.49 
7.4. Future directions and priorities 
Though cancer and ageing would appear to be obvious bedfellows, geriatric oncology is a 
relatively new field. The first programs dedicated to geriatric oncology only appeared in the 
mid 1990s,50 and the first Australian program was created less than five years ago.51 With 
the realisation that this group is rapidly becoming the vast majority of cancer patients, 
issues in geriatric oncology have been receiving increasing attention.52 Treatment 
guidelines for adjuvant therapy in colorectal cancer have existed since 1990.53 However, 
older cancer patients present a unique set of challenges for physicians, not least of which is 
their notorious under-examination in all aspects of health research. 
 228 
What is needed to increase the evidence-based care of older colorectal cancer patients? 
The lack of consensus among surgeons in Chapter 4 suggests that more research is needed 
both to predict the benefits and risks of treatment for older patients, and to determine 
how information from emerging evidence can best be used to assist physicians’ treatment 
decisions. Both of these are needed in tandem; more high-quality and specialised geriatric 
trials will not be of benefit unless this research can be translated into practice. Evidence is 
sparse on the best ways to affect change in physician treatment practices. Routine 
monitoring of performance and peer-comparison feedback is one potential avenue.54 It is 
also promising to note that rates of guideline-recommended treatment are already on the 
rise, suggesting that further improvements are possible. 
Recent trends towards personalised medicine based on an individual’s genetic profile will 
certainly be of benefit for older cancer patients. Strides in identifying biomarkers that 
predict physiological age may help to shift the emphasis in treatment decision making from 
arbitrary age cut-offs to better predictors of treatment complications and life expectancy. 
In the meantime, the care and outcomes of older patients may be improved by routine 
assessment to identify fitness and vulnerability, greater use of tools to help patients and 
physicians balance the benefits and risks of treatment, investment in geriatrics training and 
service infrastructure, and more rigorous and valid PRO research. Additional informed 
debate is also required around the social and economic considerations in ageing and 
cancer, as no assessment tool on its own will be able to change attitudes about the value of 
treating cancer in older patients. 
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